Longevity Glossary

17α-Estradiol is a stereoisomer of the dominant estrogen 17β-estradiol with much weaker feminizing activity. In the NIA Interventions Testing Program, it consistently extended median lifespan in male mice, possibly via hypothalamic and metabolic effects. Mechanism is incompletely understood and human longevity data do not exist; it is not approved or established as a human anti-aging therapy.

Adeno-associated virus (AAV) gene therapy uses recombinant AAV capsids to deliver a transgene cassette — typically a promoter, coding sequence, and poly-A signal — to target tissues. Different serotypes (AAV9 for CNS/muscle, AAV8 for liver, AAV2 for retina) have distinct tissue tropisms determined by capsid-surface receptor interactions, and the ~4.7 kb packaging limit constrains which genes can be delivered as a single construct. Pre-existing NAb titres and T-cell responses to capsid proteins are the principal immunogenicity barriers, and in some trials have required plasmapheresis or high-dose immunosuppression to avoid clearance or hepatotoxicity. In longevity-relevant preclinical work, AAV vectors have been used to deliver Klotho, TERT, follistatin, and FGF21 transgenes in rodents, yielding functional improvements; no anti-aging AAV product has received regulatory approval, and all human longevity applications remain investigational or compassionate-use.

Acarbose is an alpha-glucosidase inhibitor approved for type 2 diabetes mellitus. By blocking intestinal carbohydrate breakdown, it blunts postprandial glucose and insulin spikes and shifts substrate to colonic fermentation. In the NIA Interventions Testing Program, acarbose extended median lifespan in male mice and modestly in females, an effect attributed to glycemic smoothing and microbiome shifts. Off-label longevity use in humans is investigational; gastrointestinal side effects (flatulence, diarrhea) limit tolerability.

The ACE insertion/deletion (I/D) polymorphism (rs4646994) involves a 287-bp Alu repeat in intron 16 of the angiotensin-converting enzyme gene; the D allele is associated with approximately 1.5–2 times the serum ACE activity of the II genotype, influencing the renin-angiotensin-aldosterone system and thereby blood pressure regulation and cardiovascular tone. Early studies reported associations between the D allele and myocardial infarction risk, and between the I allele and elite endurance performance, though many of these findings have not replicated consistently in larger studies or meta-analyses. In the context of longevity, associations have been reported in several centenarian cohorts but the direction and magnitude are inconsistent across populations. The ACE I/D locus is best understood as a modest modulator of ACE enzyme levels with population-specific effects, rather than a robust longevity locus.

Actigraphy uses a wrist-worn accelerometer to infer sleep-wake states from movement patterns over days to weeks, providing an ambulatory and low-burden alternative to polysomnography for longitudinal sleep assessment. Validated algorithms translate raw activity counts into estimates of total sleep time, sleep efficiency, sleep-onset latency, and waking after sleep onset. It is recommended by the American Academy of Sleep Medicine for evaluating insomnia, circadian rhythm disorders, and treatment response in naturalistic settings. Actigraphy systematically overestimates total sleep time and sleep efficiency relative to PSG, particularly in patients with insomnia, and cannot reliably stage sleep.

Adenosine is a purine nucleoside that accumulates in the brain during wakefulness as a byproduct of neuronal energy metabolism and acts on A1 and A2A receptors to promote sleepiness and suppress arousal, serving as the primary molecular mediator of homeostatic sleep pressure. Its levels are highest after prolonged waking and decline during sleep. Caffeine exerts its alerting effects principally by competitively blocking adenosine receptors without depleting adenosine itself, which is why the sleepiness rebound after caffeine clearance is pronounced. Beyond sleep regulation, adenosine is involved in cerebrovascular autoregulation and has been implicated in the glymphatic clearance process that intensifies during slow-wave sleep.

Adiponectin is a 30-kDa adipokine secreted predominantly by white adipocytes, with lower expression in brown adipose tissue and trace expression in other tissues such as placenta and cardiac muscle, and is unique among adipokines in being inversely related to fat mass: levels fall with obesity and visceral adiposity and rise with weight loss, caloric restriction, and aerobic exercise. It circulates as trimers, hexamers, and high-molecular-weight multimers; the high-MW form is considered the most biologically active. Adiponectin signals through AdipoR1 and AdipoR2 receptors to activate AMPK and PPAR-α, improving insulin sensitivity, promoting fatty acid oxidation, suppressing hepatic glucose output, and exerting anti-inflammatory and atheroprotective effects. Low adiponectin is an independent predictor of type 2 diabetes, metabolic syndrome, and cardiovascular disease, and is associated with accelerated biological aging; high levels are observed in centenarians and their offspring.

Adult stem cells, or somatic stem cells, are undifferentiated cells residing in specific tissue niches that maintain and repair the tissue throughout life. Examples include hematopoietic, mesenchymal, intestinal, and neural stem cells. They are typically multipotent, generating the cell types of their tissue of origin. Their decline with age underlies stem cell exhaustion, making their preservation and rejuvenation a primary goal of longevity and regenerative medicine.

Advanced glycation end-products are stable, often crosslinked compounds formed when sugars react with proteins, lipids, or DNA over time. They accumulate in long-lived tissues such as skin, cartilage, and arterial walls, where they impair elasticity and function. AGEs activate the RAGE receptor, triggering inflammation and oxidative stress. Their build-up is linked to diabetes complications, atherosclerosis, kidney disease, and skin ageing.

Aerobic capacity is the maximum rate of oxygen uptake the body can sustain to produce ATP via oxidative metabolism during prolonged exercise. Per the Fick principle (VO2 = Q × (a-v)O2), it is governed by oxygen delivery (cardiac output, hemoglobin, capillary supply) and muscle extraction (mitochondrial function), and is most often quantified as VO2max. Higher aerobic capacity supports endurance, faster recovery, and metabolic resilience, and tracks closely with healthspan and reduced cardiovascular and all-cause mortality.

Akkermansia muciniphila is a Gram-negative mucin-degrading bacterium that colonises the intestinal mucus layer and is typically present at <1 % to a few percent of the healthy gut microbiota, with substantial inter-individual variability. By continuously digesting mucin glycoproteins it stimulates host renewal of the mucus layer, thereby reinforcing the physical barrier between luminal contents and the epithelium. Lower abundance is associated with obesity, insulin resistance and inflammatory bowel disease in multiple cross-sectional cohorts, though causation is not established. Depommier et al. (Nat Med 2019) demonstrated in a randomised trial that pasteurised — not live — A. muciniphila improved insulin sensitivity, reduced insulinaemia and attenuated body weight gain in overweight adults relative to placebo; the pasteurised form consistently outperformed the live preparation in murine models as well, with the outer membrane protein Amuc_1100 (identified in mechanistic work by Plovier et al., Nat Med 2017) as a key mediator signalling through TLR2. The bacterium is now available as a novel food supplement in the EU, but clinical evidence remains limited to early-phase trials.

Albumin is the most abundant plasma protein, synthesized exclusively by the liver, and maintains colloid osmotic pressure while transporting hormones, fatty acids, calcium, bilirubin, and many drugs. Serum levels reflect hepatic synthetic capacity, nutritional status, inflammation, and renal or gastrointestinal losses. Lower albumin is a robust marker of biological aging and is consistently associated with sarcopenia, frailty, longer hospital stays, and higher all-cause mortality, which is why it features in many composite aging indices.

The albumin/globulin ratio (A/G ratio) is calculated from total protein and albumin measurements as albumin divided by (total protein minus albumin), with the globulin fraction encompassing immunoglobulins, complement proteins, acute-phase reactants, and transport proteins. In healthy adults the A/G ratio typically ranges from ~1.1 to 2.5; a lower ratio can result from reduced albumin (malnutrition, liver disease, nephrotic syndrome) or from elevated globulins (chronic inflammation, multiple myeloma, liver cirrhosis, autoimmune conditions), and an inverted ratio (<1.0) warrants investigation. Higher A/G ratio in population studies is associated with better nutritional status and is inversely correlated with systemic inflammation; lower values are independently associated with greater frailty, shorter telomere length, higher all-cause mortality, and accelerated biological aging in several large cohort analyses. As a composite reflecting both hepatic synthetic function and the inflammatory immune response, the A/G ratio can add interpretive context to albumin and globulin assessed in isolation.

Alkaline phosphatase (ALP) is a hydrolase enzyme that cleaves phosphate groups at alkaline pH and is measured in serum as a composite of isoforms originating primarily from the liver, bone, intestine, and placenta. Elevated ALP most commonly reflects hepatobiliary disease — cholestasis in particular — or accelerated bone turnover as seen in Paget's disease, bone metastases, and hyperparathyroidism; concurrent elevation of GGT (and/or 5'-nucleotidase) alongside ALP points to a hepatic rather than osseous origin, since these enzymes are not produced by osteoblasts. Low ALP can indicate hypophosphatasia, zinc or magnesium deficiency, or hypothyroidism. In longevity contexts, persistently elevated ALP has been associated with higher all-cause and cardiovascular mortality in epidemiological cohorts, independent of liver disease status.

Allostatic load is the cumulative physiological cost of adapting to chronic stressors, representing wear and tear on regulatory systems that maintain homeostasis through continuous adjustment—a process termed allostasis. The concept was developed by Bruce McEwen and Eliot Stellar in 1993 and operationalised in epidemiology as a composite score across neuroendocrine (e.g. cortisol, DHEA-S), cardiovascular, metabolic, and immune biomarkers. Higher allostatic load predicts all-cause mortality, cardiovascular disease, cognitive decline, and accelerated biological ageing, and mediates socioeconomic disparities in health. In longevity research, it provides a framework for understanding how cumulative psychosocial and environmental stress translates into measurable organ-system dysregulation.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are intracellular enzymes released into blood when hepatocytes are injured. ALT is relatively liver-specific, while AST also originates from muscle, heart, and red blood cells. Elevated values most often reflect metabolic-associated steatotic liver disease, alcohol use, viral hepatitis, or drug toxicity, and the AST/ALT ratio helps distinguish causes. Persistently raised liver enzymes are associated with cardiometabolic risk and higher all-cause mortality.

AMPK (AMP-activated protein kinase) is a cellular energy sensor activated when AMP and/or ADP relative to ATP rise, signaling low energy availability. Once active, it stimulates catabolic pathways like fatty acid oxidation and autophagy while inhibiting anabolic processes such as mTORC1-driven protein synthesis. AMPK activation mimics aspects of caloric restriction, and age-related changes in AMPK signaling can contribute to impaired metabolic regulation. Metformin and exercise are well-known indirect AMPK activators.

Amyloid-β (Aβ) is a family of peptides of 36–43 amino acids cleaved from the amyloid precursor protein (APP) by β- and γ-secretase; the 42-residue form (Aβ42) is especially prone to misfolding and aggregation into soluble oligomers and insoluble amyloid plaques. Aβ42 plaques are a defining histopathological feature of Alzheimer's disease, detectable by PET imaging or CSF assay years before clinical symptoms. The amyloid cascade hypothesis proposes Aβ accumulation as an upstream initiator of Alzheimer's pathology, but whether plaques themselves are the primary toxic species or an epiphenomenon remains debated — soluble oligomers rather than fibrillar plaques are now widely regarded as the most neurotoxic form. Anti-amyloid monoclonal antibodies lecanemab (FDA approval 2023, EMA approval 2025) and donanemab (FDA approval 2024) have completed phase-3 trials and received regulatory approval, showing modest but statistically significant slowing of cognitive decline with substantial plaque clearance, lending qualified support to the cascade hypothesis. Aducanumab (Aduhelm) received accelerated FDA approval in 2021 but was withdrawn by Biogen in January 2024 due to commercial failure; it never received EMA approval.

The anaerobic threshold (AT) is the exercise intensity above which aerobic metabolism can no longer meet ATP demand and lactate begins to accumulate at a rate exceeding clearance; it corresponds approximately to the second lactate threshold (LT2) and lies near, but is not identical to, the maximal lactate steady state (MLSS), typically 75–85% of VO2max in fit individuals. The term is mechanistically imprecise — lactate accumulation reflects an imbalance between production and clearance rather than an onset of anaerobic metabolism per se — and some authors prefer 'lactate threshold 2' or 'respiratory compensation point'. Sustained exercise at AT drives robust mitochondrial and cardiovascular adaptations; performance at or near AT is a strong predictor of endurance capacity and correlates with cardiovascular risk reduction.

Antagonistic pleiotropy, formulated by evolutionary biologist George C. Williams in 1957, holds that genes selected for benefits early in life can cause harm later, after reproduction has occurred. Because selection pressure weakens with age, such alleles persist despite late-life costs. The hypothesis is a foundational explanation for why aging evolved and remains a leading evolutionary framework alongside mutation accumulation and disposable soma theory.

Apolipoprotein B (ApoB) is the structural protein of atherogenic lipoproteins, including LDL, VLDL, IDL, and Lp(a). Because ApoB-100 is typically present as approximately one molecule per atherogenic particle, plasma ApoB serves as a clinical proxy for atherogenic particle number. Multivariable Mendelian randomization (e.g., Richardson et al.) prioritizes ApoB and particle burden as the causal lipid driver of coronary artery disease, making ApoB a more accurate predictor of cardiovascular events and mortality than LDL cholesterol alone. Lower ApoB is associated with reduced atherosclerotic disease. Per the Sniderman/NLA framework, low-risk targets are typically <80 mg/dL, with high-risk thresholds <60 mg/dL.

Apolipoprotein E (APOE) is a lipid-transport protein encoded by the APOE gene, which segregates into three alleles — ε2, ε3, and ε4 — producing six possible genotypes. The ε4 allele is the strongest common genetic risk factor for late-onset Alzheimer's disease, conferring roughly 3-fold higher risk per allele in heterozygous carriers, while homozygous ε4/ε4 carriers face approximately 10–15-fold elevated risk (Farrer 1997 meta-analysis); a 2024 study (Fortea et al., Nature Medicine) proposed reclassifying this genotype as a near-deterministic genetic form of late-onset Alzheimer's, though this remains under debate. Conversely, ε2 appears modestly protective against Alzheimer's and is associated with lower LDL levels. Because APOE genotype is fixed at birth and has large, well-replicated effect sizes, it is uniquely informative for stratifying lifetime dementia and cardiovascular risk, though penetrance is incomplete and lifestyle factors can modify the trajectory.

The APOE ε4 allele encodes apolipoprotein E isoform E4, which differs from the ε3 isoform at residue 112 (cysteine→arginine), altering lipoprotein binding preferences and reducing efficient clearance of triglyceride-rich remnants and LDL from circulation. In the brain, E4 impairs amyloid-β clearance via the blood-brain barrier and through astrocytic and microglial processing, promotes tau pathology, and potentiates neuroinflammation via microglial activation — effects partly independent of amyloid. The allele confers dose-dependent Alzheimer's disease risk: one ε4 copy increases risk approximately 3–4-fold, two copies approximately 8–12-fold in European populations, with risk magnitudes varying across ancestries. Despite its disease associations, the ε4 allele has been maintained at roughly 14% average global allele frequency (with substantial regional variation, ~5% in East Asia to >30% in some African populations), likely reflecting ancient trade-offs involving immune function, fertility, and early cognitive performance.

Apoptosis is a tightly regulated form of programmed cell death in which cells are dismantled in an orderly fashion via caspase activation, typically without triggering inflammation as it is non-lytic and anti-inflammatory relative to necrosis or pyroptosis. It eliminates damaged, infected, or surplus cells and is essential for development, tissue homeostasis, and tumor suppression. Tissue- and context-specific changes in apoptosis with age contribute to impaired clearance of damaged or senescent cells in some tissues and to atrophy and neurodegeneration in others.

Low-dose aspirin (typically 75–100 mg daily) is an irreversible COX-1 inhibitor that suppresses platelet thromboxane A2, reducing platelet aggregation. It is approved for secondary prevention of myocardial infarction and ischemic stroke, where benefit clearly outweighs bleeding risk. The ASPREE trial in healthy older adults showed no cardiovascular benefit, increased major bleeding, and an early signal of increased all-cause mortality (largely cancer-driven and attenuated in ASPREE-XT extended follow-up). Current guidelines discourage routine primary prevention; the USPSTF 2022 recommends individualized decision-making in adults 40–59 with at least 10 percent 10-year CVD risk and recommends against initiation in adults aged 60 or older. Cancer-prevention signals remain investigational.

The AST/ALT ratio, also called the De Ritis ratio after Fernando De Ritis who first described its diagnostic utility in the 1950s, is calculated as aspartate aminotransferase (AST) divided by alanine aminotransferase (ALT). In hepatocellular injury, ALT tends to rise more than AST because it is more liver-specific, yielding a ratio below 1.0; in alcoholic liver disease the ratio typically exceeds 2.0, partly because alcohol-related mitochondrial damage preferentially depletes intracellular pyridoxal phosphate needed for ALT synthesis and because AST release from damaged mitochondria predominates. A ratio above 1.0 in the setting of elevated transaminases also raises suspicion for cirrhosis, where regenerative nodules lose cytosolic ALT preferentially. Beyond liver disease, an elevated AST/ALT ratio in individuals with normal or near-normal absolute enzyme values may reflect non-hepatic AST contributions from skeletal or cardiac muscle. In population-level longevity research, a ratio persistently above ~1.0 in the absence of acute illness or vigorous exercise is associated with higher cardiometabolic risk and all-cause mortality, and should prompt investigation for alcoholic liver injury, steatohepatitis, or underlying cirrhosis rather than being dismissed as unremarkable.

Astaxanthin is a ketocarotenoid pigment produced predominantly by the microalga Haematococcus pluvialis and accumulated through the food chain in crustaceans, salmon, and trout, accounting for their characteristic pink-red coloration. Its molecular structure — a polyene chain with carbonyl and hydroxyl groups on both ionone rings — enables it to span the full width of the lipid bilayer and scavenge singlet oxygen and free radicals more potently than many other carotenoids, including β-carotene. Unlike certain antioxidants, it does not act as a pro-oxidant at high concentrations under physiological conditions. Proposed mechanisms relevant to longevity include Nrf2 activation, NF-κB inhibition, mitochondrial protection, and modulation of inflammatory cytokines. Rodent studies show improvements in oxidative stress, immune parameters, and some cardiovascular markers; human RCTs are small and generally short-term, reporting modest effects on lipid oxidation biomarkers, skin aging, exercise-induced muscle damage, and inflammation. Synthetic astaxanthin (dominant in aquaculture) and natural algal-derived forms differ in esterification and stereochemistry, which may affect bioavailability. Evidence for direct human longevity benefit remains preliminary.

ATM (ataxia-telangiectasia mutated) encodes a serine/threonine protein kinase that is the master activator of the DNA damage response to double-strand breaks; upon activation it phosphorylates hundreds of substrates including H2AX, CHK2, p53, and BRCA1 to coordinate cell-cycle arrest, DNA repair, and apoptosis. Biallelic loss-of-function mutations cause ataxia-telangiectasia, a recessive syndrome characterized by cerebellar neurodegeneration, immunodeficiency, radiation sensitivity, and a cancer risk exceeding 30%. Heterozygous ATM carriers (~1% of the population) have intermediate cancer risk — particularly for breast and colorectal cancer — and recent data suggest moderately elevated cardiovascular disease risk, placing ATM among the clinically actionable cancer-predisposition genes. In longevity biology, compromised ATM function exemplifies how defects in the DNA damage response accelerate hallmarks of aging including genomic instability and inflammation.

The autonomic nervous system (ANS) regulates involuntary bodily functions including heart rate, blood pressure, digestion, and respiration. It is traditionally divided into sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) divisions, with the enteric nervous system commonly recognized as a semi-autonomous third division regulating the gastrointestinal tract. In longevity science, ANS function is assessed via HRV, baroreflex sensitivity, and heart rate recovery, since dysautonomia and chronic sympathetic dominance are implicated in cardiovascular disease and accelerated biological aging.

Autophagy is a conserved lysosomal degradation pathway in which cells engulf damaged organelles, misfolded proteins, and other cytoplasmic material in double-membrane vesicles called autophagosomes for recycling (a process most precisely describing macroautophagy, the dominant subtype). By clearing dysfunctional components and recycling amino acids during nutrient stress, it maintains cellular homeostasis. Declining autophagic flux is widely observed with age, though the magnitude is tissue- and context-dependent, and its induction by fasting, exercise, and rapamycin is considered one of the major proposed longevity mechanisms.

B-cell senescence encompasses age-related changes in B-cell development, composition, and function that collectively impair humoral immunity. A hallmark is the accumulation of age-associated B cells (ABCs) — a population characterised by expression of T-bet, FcRL5 and CD11c and typically CD21lo/CD27- — which expand preferentially in aging and autoimmune contexts and are poor participants in germinal centre reactions. Germinal centre responses, which are necessary for somatic hypermutation and affinity maturation of antibodies, decline in magnitude and quality with age, resulting in lower-affinity, less class-switched antibody repertoires. These changes contribute to reduced vaccine efficacy and an increased propensity for auto-reactive and low-affinity antibody production in older adults.

The Bacteroidetes/Firmicutes ratio was prominently proposed in the mid-2000s as a functional biomarker of gut microbiome health, based on observations in obese mice and small human cohorts that obesity was associated with a relative reduction in Bacteroidetes and expansion of Firmicutes, and that weight loss reversed this pattern. The mechanistic hypothesis was that a high-Firmicutes microbiome extracts more energy from the same diet, thus promoting fat accumulation. However, this simplified narrative has not replicated reliably across diverse human cohorts: large subsequent studies found the ratio to vary substantially with sequencing methodology, diet, geography and cohort composition, and many found no consistent direction of association with obesity or metabolic health. The field has largely deprioritised this ratio as a clinically meaningful metric, recognising that the division of the gut microbiota into two phyla discards the vast functional diversity within each, and that species- or gene-level analyses provide much more informative resolution. It persists in popular science writing and supplement marketing, where it is frequently overstated.

Baroreflex sensitivity (BRS) quantifies the magnitude of the heart rate response to acute changes in arterial blood pressure, expressed as milliseconds of RR-interval change per mmHg of pressure change. Arterial baroreceptors in the carotid sinus and aortic arch tonically modulate vagal and sympathetic outflow to buffer blood pressure fluctuations; a higher BRS indicates a more responsive and efficient reflex arc. BRS declines with age, hypertension, heart failure, and diabetes, and low BRS is an independent predictor of adverse cardiac events and mortality, particularly post-myocardial infarction. It is assessed by pharmacological methods (phenylephrine or nitroprusside bolus), spontaneous sequence analysis, or the modified Oxford technique, and is studied as a cardiovascular aging biomarker responsive to exercise training and weight loss.

BDNF is a growth-factor protein that supports neuronal survival, synapse formation, and — at least in animal models — adult hippocampal neurogenesis (its extent in adult humans remains debated). Levels rise with aerobic exercise and quality sleep; effects of intermittent fasting are well-established in rodents but less clear in humans, and levels fall under chronic stress and depression. In longevity research, lower BDNF is associated with depression and Alzheimer's risk, linking lifestyle to memory and mood regulation.

Beclin-1 (encoded by BECN1) is a core component of the class III phosphatidylinositol 3-kinase (PI3K-III / VPS34) complex that nucleates phagophore membranes at the initiation step of macroautophagy, with its activity regulated by interactions with BCL-2 family proteins, UVRAG, and Rubicon. The broader ATG (AuTophaGy-related) gene family — comprising approximately 40 genes in yeast with conserved mammalian orthologues — encodes the machinery for phagophore elongation (ATG5, ATG12, ATG16L1), membrane lipidation (ATG7, ATG3), and closure (ATG2, ATG9). Beclin-1 is monoallelically deleted in many breast and ovarian cancers, implicating autophagy in tumour suppression, while global decline in Becn1 and other ATG gene expression in ageing tissues is proposed to contribute to the deterioration of autophagic flux observed with age.

Berberine is an isoquinoline alkaloid found in multiple plant genera, including Berberis, Hydrastis canadensis (goldenseal), and Coptis chinensis. It is sold as a dietary supplement in most jurisdictions and is not an approved drug in the EU or US. Berberine inhibits mitochondrial complex I, raising the AMP:ATP ratio and thereby activating AMPK downstream; small trials show modest reductions in fasting glucose, HbA1c, LDL cholesterol, and triglycerides in metabolic syndrome and type 2 diabetes. Marketed informally as natural metformin, evidence quality is limited, product purity varies, and CYP3A4-mediated drug interactions warrant caution. Longevity use is investigational.

Bifidobacterium is a genus of Gram-positive, anaerobic, non-motile, branched-rod bacteria belonging to the phylum Actinobacteria (Actinomycetota); it is among the first colonisers of the neonatal gut, particularly in breastfed infants, where strains such as B. longum subsp. infantis are uniquely equipped to metabolise human milk oligosaccharides (HMOs). Their core metabolic products include acetate and lactate (via the bifid shunt, a fructose-6-phosphate phosphoketolase pathway), acidifying the intestinal environment and suppressing pathogens. Abundance declines markedly after weaning, with a further sharp decline after the seventh decade of life; reduced Bifidobacterium abundance in older adults has been associated with frailty, increased intestinal permeability and heightened systemic inflammation, though causal interpretation remains challenging. Several species — particularly B. longum, B. lactis, B. bifidum and B. breve — are among the most extensively studied and commercially used probiotic organisms, with clinical evidence supporting modest benefits in antibiotic-associated diarrhoea, infant colic, irritable bowel syndrome and rotavirus-associated diarrhoea; effects in healthy adults are generally less pronounced.

Primary bile acids — cholic acid and chenodeoxycholic acid — are synthesised in the liver from cholesterol and conjugated to glycine or taurine before secretion into the small intestine. Gut bacteria transform them via deconjugation, 7α-dehydroxylation, epimerisation and oxidoreduction into a structurally diverse pool of secondary and tertiary bile acids, including deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA) and isoallo-lithocholic acid (isoallo-LCA). These secondary bile acids function as signalling molecules beyond their classical roles in dietary fat emulsification: they activate the nuclear receptor FXR and G-protein-coupled receptor TGR5, modulating glucose homeostasis, lipid metabolism, energy expenditure and innate immune tone. Isoallo-LCA is of particular interest in longevity research because it potently induces the differentiation of immunosuppressive RORγt⁺ regulatory T cells and is enriched in centenarians (Sato et al. 2021). The composition of the secondary bile acid pool is critically dependent on microbiota composition — notably species in Lachnospiraceae and Ruminococcaceae — and is substantially altered in ageing, obesity and inflammatory bowel disease.

Bilirubin is the predominant end-product of haem catabolism, formed when reticuloendothelial cells degrade senescent red blood cells; it circulates as unconjugated (indirect) bilirubin bound to albumin before hepatic uptake, conjugation with glucuronic acid, and biliary excretion. Elevated total bilirubin is classified as pre-hepatic (haemolysis), hepatic (hepatocellular dysfunction), or post-hepatic (biliary obstruction) based on the unconjugated-to-conjugated ratio and accompanying enzymes. Mildly elevated unconjugated bilirubin in isolation — as in Gilbert syndrome — is generally benign and is associated with a more favourable cardiovascular risk profile in observational data, possibly via bilirubin's antioxidant properties as a lipid-soluble radical scavenger. Severely elevated bilirubin is a marker of advanced liver failure and a component of prognostic scores such as MELD.

Biological age is an estimate of how old a person's body appears to be based on physiological and molecular markers, rather than the calendar. It can be derived from blood biomarkers (e.g. PhenoAge), DNA methylation patterns (epigenetic clocks), grip strength, gait speed or organ-specific proteomic signatures. Although widely used in longevity research, no single biological-age measure is yet endorsed by regulators as a clinical endpoint, and validation varies strongly between methods.

Bisphosphonates are synthetic analogues of pyrophosphate that bind avidly to hydroxyapatite in bone mineral and are taken up by osteoclasts during bone resorption, where nitrogen-containing bisphosphonates (alendronate, zoledronate, risedronate) inhibit farnesyl diphosphate synthase in the mevalonate pathway, impairing osteoclast cytoskeletal function and survival. They are approved for osteoporosis, Paget's disease, hypercalcaemia of malignancy, and bone metastases, where they significantly reduce fracture risk and skeletal-related events. Observational and secondary-analysis data suggest broader aging-relevant effects: zoledronate (intravenous, annual) was associated with reduced all-cause mortality in a randomised trial in patients with recent hip fracture (HORIZON Recurrent Fracture Trial; Lyles et al., 2007, NEJM) and in observational cohorts, and bisphosphonate use has been associated with reduced breast, colorectal, and possibly other cancers in several epidemiological studies, though residual confounding cannot be excluded. Geroscience interest centres on possible senolytic-adjacent effects — bisphosphonates deplete osteoclast progenitors and may selectively reduce calcification-associated senescent cell burden — but these mechanisms are hypothetical in humans. Side effects include oesophageal irritation, osteonecrosis of the jaw (rare, mainly with high-dose intravenous use), and atypical femoral fractures with prolonged therapy.

Blue Zones are regions reported to have unusually many centenarians. The popularly cited list (Buettner) includes Okinawa (Japan), Sardinia (Italy), Nicoya (Costa Rica), Ikaria (Greece), and Loma Linda (USA). Shared features include plant-based diets, moderate caloric intake, low-intensity movement, strong social ties, and purpose. Saul Newman has argued that supercentenarian counts may be inflated by age-record errors, pension fraud, and missing birth registries; this methodological critique was recognised when Newman was awarded the 2024 Ig Nobel Prize in Demography for the work, and the demographic robustness of the original Blue Zone identifications is now contested.

Bone mineral density is the amount of mineral — primarily hydroxyapatite — per unit area (g/cm²) or volume of bone tissue, most commonly assessed at the lumbar spine and femoral neck by DEXA. The T-score compares an individual's BMD to the young-adult mean peak reference; WHO criteria define osteopenia (T-score −1.0 to −2.5) and osteoporosis (T-score ≤ −2.5), the latter roughly doubling hip fracture risk per SD reduction. BMD declines with age, accelerating in women post-menopause; resistance and impact-loading exercise, adequate dietary calcium and vitamin D, and estrogen-related hormonal status are the principal modifiable determinants. Hip fracture in older adults carries ~20–30% one-year mortality, making BMD preservation a direct longevity target.

Box breathing is a paced breathing technique using equal-length phases of inhale, hold, exhale, and hold (commonly four seconds each). Slowing respiration well below the typical 12–16 breaths per minute is associated with increased vagal tone and heart-rate variability in slow- and resonance-breathing studies. It is widely taught in military, clinical, and performance settings for acute stress regulation. Direct RCT evidence for box breathing as a distinct protocol is limited; most support is extrapolated from broader paced/slow-breathing research.

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice, marketed for tendon, ligament, and gut healing. Animal studies suggest pro-angiogenic and tissue-repair effects, but human clinical-trial data are very limited, comprising only a small number of pilot studies with no large well-controlled RCTs. It is not approved by the FDA or EMA, has been added to FDA restriction lists, and is prohibited at all times under WADA category S0 (Unapproved Substances), as it has not been approved by any governmental health authority for human therapeutic use.

MRI-based brain age is a biological-age estimate derived from structural or functional brain imaging features—including cortical thickness, white-matter integrity, grey-matter volume and functional connectivity—processed by machine-learning models trained on large neuroimaging cohorts. The gap between predicted brain age and chronological age, termed the brain-age gap or BrainAGE (introduced by Franke et al., 2010), is a biomarker of brain health: a positive gap (brain appearing older) associates with cognitive decline, neurodegeneration, stroke and all-cause mortality, while a negative gap is linked to better cognitive reserve. Accuracy and interpretability vary with imaging protocol, preprocessing pipeline and training cohort demographics.

Brain MRI volumetrics uses structural magnetic resonance imaging to quantify the volume of specific brain regions — most notably the hippocampus, lateral ventricles and total grey- and white-matter — as well as cortical thickness across parcellated regions. Automated analysis pipelines such as FreeSurfer and the GPU-accelerated FastSurfer process T1-weighted images to generate normative deviation scores; larger ventricular volumes and reduced hippocampal or cortical thickness are established markers of accelerated brain ageing, with rates of atrophy increasing substantially after age 60. Cross-sectional population studies such as UK Biobank have mapped trajectories of regional volume loss against age, lifestyle factors and disease risk, enabling the concept of a 'brain age gap' — the difference between estimated brain age and chronological age — as a potential biomarker for neurodegenerative risk and cognitive resilience.

Brown adipose tissue is a thermogenic organ characterized by high mitochondrial density and the expression of uncoupling protein 1 (UCP1), which dissipates the proton gradient across the inner mitochondrial membrane as heat rather than storing it as ATP. In adult humans, metabolically active BAT depots are found primarily in the supraclavicular, paravertebral, and cervical regions and are activated by cold exposure and sympathetic signaling via β3-adrenergic receptors. BAT activity declines with age and increasing adiposity, and lower activity associates with higher BMI, worse insulin sensitivity, and greater cardiometabolic risk in cross-sectional data. Cold exposure, β3-agonists, and candidate compounds such as mirabegron and capsinoids can augment BAT activity, with ongoing investigation into whether sustained augmentation improves metabolic health outcomes in humans.

CA-125 (cancer antigen 125) is a high-molecular-weight mucin-like glycoprotein encoded by MUC16 and expressed on coelomic and Müllerian-derived epithelium; it is shed into the circulation in proportion to epithelial surface disruption. Serum CA-125 above 35 U/mL is used clinically as a tumour marker for epithelial ovarian cancer, particularly for monitoring response to treatment and detecting recurrence, though sensitivity for early-stage disease is limited to approximately 50%. Elevated CA-125 is non-specific: endometriosis, uterine fibroids, pelvic inflammatory disease, pleural effusion, and hepatic cirrhosis can all produce substantial elevations in the absence of malignancy. The multivariate Risk of Ovarian Malignancy Algorithm (ROMA), combining CA-125 with HE4, improves diagnostic specificity and is preferred over CA-125 alone for pre-operative risk stratification.

Caloric restriction is a sustained reduction in energy intake, typically 10–30% below ad libitum, without malnutrition. It activates conserved nutrient-sensing pathways including AMPK and sirtuins while suppressing mTOR and insulin/IGF-1 signaling. In many rodent models it extends lifespan, though effects vary by strain, sex, age at onset, and protocol; non-human primate trials gave divergent results (Wisconsin vs. NIA). In humans, the CALERIE-2 trial (~12% achieved restriction, below the 25% target) improved cardiometabolic markers and reduced inflammation.

A caloric restriction mimetic (CR mimetic) is a compound that reproduces some molecular and physiological effects of caloric restriction — including AMPK activation, mTORC1 inhibition, sirtuin activation, reduced insulin/IGF-1 signalling, enhanced autophagy and favourable shifts in metabolic biomarkers — without requiring a sustained reduction in food intake. The concept was formalised by Ingram and colleagues in 1998. Leading candidates include rapamycin (mTOR inhibitor), metformin (AMPK activator), resveratrol (putative SIRT1 activator), NAD+ precursors (NMN, NR) and acarbose. Evidence for lifespan extension in mice is established for rapamycin and acarbose under ITP conditions; translation to humans remains an open research question, and no CR mimetic has demonstrated robust healthspan extension in a powered randomised human trial.

Cardiorespiratory fitness (CRF) is the ability of the circulatory and respiratory systems to deliver oxygen to working muscles during sustained activity, most often quantified by VO2max. It integrates lung function, cardiac output, vascular health, and muscle oxidative capacity. Some large cohort studies (e.g., Mandsager et al. 2018) suggest low CRF can carry mortality risk comparable to or greater than coronary artery disease, smoking, or diabetes, making CRF a powerful modifiable longevity predictor.

Carotid intima-media thickness (CIMT) is the B-mode ultrasound measurement of the combined thickness of the intima and media layers of the common carotid artery wall, serving as a surrogate marker for subclinical atherosclerosis and vascular ageing. CIMT increases progressively with age and is elevated in the presence of traditional cardiovascular risk factors; population-based studies established associations with incident myocardial infarction, stroke and all-cause mortality, and it was incorporated into risk calculators in the early 2000s. However, subsequent meta-analyses (Lorenz et al., Lancet 2012) showed that CIMT progression did not improve prediction of clinical events beyond traditional risk factors, leading major cardiology guidelines to downgrade its routine clinical use. CIMT remains widely used in cardiovascular research as an outcome measure for intervention trials and in observational studies of accelerated vascular ageing.

Cathepsins are a family of lysosomal proteases — predominantly cysteine proteases (cathepsins B, C, H, K, L, S, V, X/Z) but also aspartyl (cathepsins D, E) and serine types (cathepsins A, G) — that collectively execute the terminal degradation of proteins delivered by autophagy, endocytosis, and phagocytosis in the acidic lysosomal lumen. Beyond lysosomal digestion, cathepsins can be secreted to remodel the extracellular matrix (cathepsin K is the primary bone collagenase), and cytosolic leakage of cathepsins — particularly cathepsin B — can trigger the NLRP3 inflammasome and initiate apoptosis, a pathway termed lysosomal membrane permeabilisation. Cathepsin activity declines with ageing in part due to impaired lysosomal acidification and altered cystatin inhibitor balance, impairing protein quality control and contributing to accumulation of undegraded material in long-lived post-mitotic cells such as neurons.

CausAge is an epigenetic-age clock introduced by Ying, Gladyshev and colleagues (preprint 2022; Nature Aging 2024) that attempts to address a fundamental limitation of correlation-trained clocks: standard elastic-net or regression clocks select CpG sites associated with age without distinguishing whether the methylation change causes, results from, or merely co-varies with the ageing process. CausAge applies Mendelian-randomization-informed causal inference to identify CpGs whose methylation change is more likely upstream of biological ageing, and separately derives DamAge (damage-associated accelerated ageing) and AdaptAge (adaptive response) sub-clocks. The framework suggests that clock CpGs are heterogeneous in their causal role and that mortality-associated acceleration may be driven primarily by damage-linked sites rather than adaptive ones.

The CD4/CD8 ratio is the proportion of CD4+ helper T cells to CD8+ cytotoxic T cells in peripheral blood, with a healthy reference range typically cited as approximately 1.5–2.5. In young, immunocompetent adults, CD4+ cells predominate and coordinate adaptive responses, whereas CD8+ cells patrol for infected or transformed cells. With age — particularly in CMV-seropositive individuals — oligoclonal CD8+ expansions accumulate, compressing the ratio and sometimes inverting it below 1.0, a pattern associated with frailty, poor vaccine responses, and increased all-cause mortality in elderly cohorts and in studies of HIV-positive individuals. An inverted CD4/CD8 ratio is increasingly used as a component of immune-risk profiling in the context of immunosenescence.

Cellular reprogramming is the experimental conversion of one cell type into another, most often a differentiated somatic cell into a pluripotent stem cell, by forcing expression of specific transcription factors known as OSKM (Oct4, Sox2, Klf4, and c-Myc). The process resets the epigenome, including DNA methylation and histone marks; however, it is partial or cyclic reprogramming — rather than full iPSC induction — that is being explored as a route to rejuvenation, since complete reprogramming erases cell identity. It underpins iPSC technology and is being examined as a strategy for organ regeneration and systemic rejuvenation.

Cellular senescence is a stable cell-cycle arrest triggered by stressors such as DNA damage, telomere dysfunction, oncogene activation or oxidative stress. Senescent cells remain metabolically active and typically secrete a pro-inflammatory mixture of cytokines, chemokines and proteases known as the SASP. While senescence initially suppresses tumour formation and aids wound healing, the accumulation of senescent cells with age contributes to tissue dysfunction and age-related disease.

A centenarian is a person who has reached the age of 100 years or more. Centenarians are a key research population in longevity science because they typically delay or escape major age-related diseases. Studies such as the New England Centenarian Study and Japan's Okinawa Centenarian Study examine genetic, lifestyle, and environmental factors associated with exceptional human lifespan and healthspan.

Several studies of extreme longevity — notably the Italian group led by Biagi and Franceschi analysing semi-supercentenarians (105–109 years) and Sato and colleagues in Japanese centenarians — have identified microbiota features that distinguish long-lived individuals from healthy younger or elderly controls. Consistent observations include maintenance of relatively high alpha diversity into extreme old age, enrichment of Christensenellaceae and Akkermansia muciniphila, and a distinctive secondary bile acid profile characterised by elevated concentrations of isoallo-lithocholic acid (isoallo-LCA) produced by Odoribacteraceae family members, which potently induces regulatory T cells and may attenuate systemic inflammation. Whether these signatures are causal contributors to longevity, passenger effects of specific diets or genetics in long-lived populations, or results of survivor bias — those who reach 100+ have presumably already escaped the diseases that kill others earlier — cannot be determined from cross-sectional data. The findings are intriguing and point toward bile-acid–microbiota crosstalk and immune regulation as longevity-associated pathways, but should not yet be interpreted as actionable targets for the general population.

Cerebral small vessel disease (CSVD) encompasses a spectrum of pathological changes affecting the perforating arteries, arterioles, capillaries and venules of the brain, resulting in a characteristic constellation of neuroimaging findings: white matter hyperintensities, lacunar infarcts, enlarged perivascular spaces, microbleeds and cortical superficial siderosis. Hypertension is the dominant modifiable risk factor; additional contributors include diabetes, dyslipidaemia, smoking and genetic variants such as NOTCH3 mutations in CADASIL. CSVD accounts for approximately 25% of all strokes and is the most common cause of vascular cognitive impairment, with cumulative lesion burden correlating with executive dysfunction, gait disturbance, depression and progression to vascular dementia. Currently there is no disease-modifying pharmacotherapy specific to CSVD; blood pressure control remains the most robustly evidence-based intervention for slowing lesion accrual.

Cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl esters from HDL for triglycerides in VLDL and LDL, effectively lowering HDL-cholesterol. The I405V variant (rs5882) in the CETP gene reduces CETP activity and is enriched in Ashkenazi Jewish centenarians and their offspring relative to controls in the Einstein Aging Study (Barzilai et al., 2003), accompanying notably high HDL and large HDL particle size. Large HDL particles are more effective in reverse cholesterol transport and are associated with reduced cardiovascular and cognitive disease risk. The variant illustrates how a naturally occurring loss-of-function polymorphism can phenocopy the cardiovascular benefit sought by pharmacological CETP inhibitors, several of which failed in trials despite HDL elevation — suggesting particle quality over quantity matters.

The cGAS-STING pathway is an innate immune sensing mechanism in which cyclic GMP-AMP synthase (cGAS) detects cytosolic double-stranded DNA — a signal of viral infection, nuclear damage or mitochondrial DNA leakage — and synthesises the second messenger cGAMP, which activates the endoplasmic-reticulum adaptor protein STING (stimulator of interferon genes). STING then drives transcription of type-I interferons and pro-inflammatory NF-κB target genes, generating a potent immune response. In the context of ageing, the pathway is aberrantly activated by micronuclei, cytoplasmic chromatin fragments from ruptured senescent-cell nuclear envelopes, and leaked mitochondrial DNA, making cGAS-STING a key amplifier of inflammaging and the SASP; pharmacological STING inhibitors are under early investigation as potential modulators of age-related inflammation.

Chromatin is the complex of DNA, histones, and associated proteins that packages the genome inside the nucleus. Its basic unit, the nucleosome, can be tightly compacted as heterochromatin or loosely arranged as euchromatin, controlling which genes are accessible for transcription. Chromatin organisation safeguards genomic stability and cellular identity. Loss of heterochromatin and disorganised chromatin architecture are recognised hallmarks of ageing and contribute to cellular dysfunction.

Chronological age is the time elapsed since a person's birth, usually measured in years. It is the standard reference variable in demography, medicine and epidemiology and remains one of the strongest single predictors of mortality and many age-associated conditions. Unlike biological age, chronological age does not capture variation in physiological decline between individuals; two people of the same chronological age may differ markedly in functional capacity, disease risk and remaining healthspan, and depending on cohort and endpoint other measures can match or exceed its predictive value.

Chronotype is the individual disposition toward earlier or later sleep-wake timing, commonly described as morning, intermediate, or evening type. It is shaped by genetics, age, light exposure, and social schedules. Chronotype influences cognitive peak times, athletic performance, and cardiometabolic risk, and a mismatch with imposed work or school hours, known as social jetlag, has been linked to obesity, mood disorders, and impaired metabolic health.

The circadian rhythm is the body's roughly 24-hour internal cycle that coordinates sleep-wake timing, hormone release, body temperature, and metabolism. It is governed by the suprachiasmatic nucleus in the hypothalamus and entrained primarily by light exposure. Stable circadian alignment supports cardiometabolic health, immune function, and cognitive performance, while chronic disruption is linked to obesity, type 2 diabetes, and accelerated biological aging.

Clonal hematopoiesis of indeterminate potential (CHIP) refers to the somatic expansion of a hematopoietic stem cell clone carrying a driver mutation — most commonly in DNMT3A, TET2, ASXL1, or JAK2 — in the blood of individuals without overt haematologic malignancy. The prevalence rises sharply with age, reaching roughly 10–20% in people over 70. Landmark analyses by Jaiswal and colleagues (2017) demonstrated that CHIP carriers have approximately double the risk of cardiovascular events, a finding attributed partly to pro-inflammatory macrophage programming by TET2-mutant clones. Because CHIP alters the epigenetic and transcriptional landscape of blood cells, it confounds DNA-methylation-based biological age clocks and other blood-based aging biomarkers, representing an important caveat in their interpretation.

Cytomegalovirus is a ubiquitous beta-herpesvirus that establishes lifelong latency after primary infection, with seroprevalence ranging from roughly 40–70% in high-income populations, with rates rising substantially in older age groups, to over 90% in parts of Africa, Asia, and South America. Because CMV is never fully cleared, the immune system sustains a large, chronically activated CD8+ T-cell response against viral antigens, a process called memory inflation. Over decades, these oligoclonal CMV-specific CD8+ expansions progressively occupy a growing fraction of the total T-cell repertoire, displacing naive cells and narrowing immunological breadth — a phenomenon linked to poor vaccine responses, frailty, and all-cause mortality in older adults. CMV seropositivity is considered one of the strongest extrinsic drivers of immunosenescence and is now incorporated into immune-age profiling approaches such as the immune risk profile.

Coenzyme Q10 (ubiquinone) is a lipid-soluble molecule essential for mitochondrial electron transport and ATP production, and an intracellular antioxidant. Endogenous levels decline with age and with statin use. Clinical evidence is strongest in heart failure: in the Q-SYMBIO trial (300 mg/day), CoQ10 reduced all-cause mortality and major cardiovascular events in chronic heart failure patients; however, replication has been inconsistent and most other trials have been smaller. Effects on blood pressure and statin-related muscle symptoms are modest; longevity benefits in healthy adults are not established.

Cognitive reserve, developed and formalised by Yaakov Stern building on earlier brain-reserve work (Katzman and colleagues, late 1980s), refers to the brain's functional adaptability — built through education, complex work, multilingualism, and lifelong learning. It is distinguished from brain reserve, the structural or biological capacity often operationalised via measures of brain integrity and size. Higher cognitive reserve is associated with better cognitive outcomes for a given level of pathology. In longevity science, it is a central modifiable target of brain-health interventions, helping postpone dementia symptoms.

Cold exposure is the deliberate use of cold air, water, or ice (cold showers, ice baths, cryotherapy) as a hormetic stressor. Acute cold triggers noradrenaline release and peripheral vasoconstriction and, if sufficiently intense, shivering thermogenesis; some protocols are non-shivering by design. It may activate brown adipose tissue, though BAT activation in humans varies substantially with the exposure protocol and detection method. Reported effects include improved cold tolerance and subjective alertness; evidence for metabolic, immune, and longevity benefits in humans remains limited and mixed.

Cold thermogenesis is the body's heat-producing response to cold, comprising shivering thermogenesis in skeletal muscle and non-shivering thermogenesis driven by UCP1-dependent activation of brown and other thermogenic ('beige') adipose depots. Repeated cold stimulation can increase tracer-based glucose uptake by thermogenic adipose tissue in small imaging studies, though this reflects local activity rather than necessarily systemic metabolic improvement. Whether these effects translate into durable, clinically meaningful improvements in body composition or metabolic health remains under investigation.

The complement system is a network of more than 30 plasma and membrane-bound proteins that constitute an effector arm of innate immunity, activated through three converging pathways — classical (antibody-dependent), lectin, and alternative — all leading to cleavage of C3 and C5 and ultimately the formation of the membrane attack complex (C5b-9). Core functions include opsonisation of pathogens for phagocytosis, direct lysis of gram-negative bacteria and enveloped viruses, recruitment of inflammatory cells via anaphylatoxins C3a and C5a, and clearance of apoptotic debris. With aging, complement dysregulation — including diminished activation capacity alongside paradoxical chronic low-level activation — has been implicated in age-related macular degeneration (AMD), where variants in complement factor H (CFH) substantially modify genetic risk, and in neuroinflammation, where complement-mediated synaptic pruning may become pathologically excessive in conditions such as Alzheimer's disease.

Compression of morbidity is a concept introduced by James Fries in 1980 describing a scenario in which the onset of chronic disease and disability is postponed faster than the increase in lifespan, so that severe illness is concentrated into a shorter period at the end of life. It is a guiding goal of geroscience and healthspan-oriented medicine. Empirical evidence is mixed: in some populations morbidity has compressed, in others it has expanded as lifespan rose.

A continuous glucose monitor (CGM) is a wearable sensor, typically inserted into subcutaneous tissue, that measures interstitial glucose every few minutes, typically about 7 to 14 days for transcutaneous sensors (system-dependent), and up to a year for implantable devices such as Eversense 365. It generates trend data on fasting, postprandial, and nocturnal glucose, time-in-range, and glycemic variability. CGMs are increasingly used in non-diabetic adults to personalize nutrition and inform longevity-oriented lifestyle adjustments.

The coronary artery calcium (CAC) score is a non-contrast cardiac CT measurement reported as an Agatston score that quantifies calcified atherosclerotic plaque as a marker of total atherosclerotic burden; non-calcified (soft) plaque is not detected. A higher CAC score is strongly associated with future myocardial infarction, cardiovascular events, and all-cause mortality, and primary-prevention guidelines (2018 ACC/AHA, 2021 ESC) recommend CAC for risk reclassification in intermediate-risk adults. A score of zero indicates very low short-term event risk but does not fully exclude atherosclerosis, particularly in younger adults or those with elevated Lp(a) or familial hypercholesterolemia. Standard Agatston categories are: 0 (very low), 1–99 (mild), 100–399 (moderate), and ≥400 (severe).

Coronary CT angiography (CCTA) uses multi-detector computed tomography with intravenous iodinated contrast to produce three-dimensional images of the coronary arteries, enabling assessment of both luminal stenosis and plaque composition — including non-calcified, low-attenuation (lipid-rich) plaques that are not visible on unenhanced calcium scoring. In the SCOT-HEART randomised trial (n=4,146), CCTA-guided management reduced the composite of coronary heart disease death or non-fatal myocardial infarction by 41% over five years compared with standard care, partly through reclassification of risk and initiation of preventive therapy. Modern CCTA delivers effective radiation doses of approximately 1–5 mSv with iterative reconstruction, substantially lower than earlier protocols; CT-derived fractional flow reserve (CT-FFR) extends the examination to haemodynamic significance assessment without invasive catheterisation. CCTA differs from coronary artery calcium (CAC) scoring: CAC quantifies calcified plaque burden only, while CCTA reveals the full atherosclerotic plaque landscape including non-calcified disease.

The cortisol awakening response (CAR) is a sharp rise in salivary cortisol of roughly 50 percent on average (commonly reported in the range of about 38 to 75 percent) from the awakening sample to a peak about 30 to 45 minutes after waking. It reflects healthy hypothalamic-pituitary-adrenal axis activation, mobilising energy and focus for the day. A blunted or exaggerated CAR is associated with chronic stress, burnout, depression, sleep disorders, and adverse cardiometabolic outcomes, making it a useful marker in longevity and stress research.

Creatine is a guanidino compound synthesized endogenously in liver and kidney from arginine, glycine, and methionine, and obtained exogenously from red meat, fish, and supplements. As phosphocreatine, it rapidly regenerates ATP from ADP via the creatine kinase reaction during high-intensity efforts, buffering energy supply in muscle and brain. Creatine monohydrate supplementation (3–5 g/day after an optional loading phase) is one of the most extensively validated ergogenic aids, consistently increasing lean mass and strength in resistance-trained adults across meta-analyses. Emerging evidence in older adults indicates additional benefits on muscle preservation and fall prevention, with some RCTs and meta-analyses also suggesting modest cognitive effects — particularly relevant because older adults have lower dietary creatine intake and endogenous synthesis declines. Safety at habitual supplementation doses is well established in healthy adults, though those with pre-existing kidney disease should consult a physician.

Creatine kinase (CK) is an enzyme that catalyses the reversible transfer of a phosphate group from phosphocreatine to ADP, regenerating ATP in tissues with high and fluctuating energy demands, principally skeletal muscle, cardiac muscle, and brain. Serum CK is released when these tissues are damaged, with isoenzyme fractionation — CK-MM (skeletal), CK-MB (cardiac), CK-BB (brain) — guiding organ-level attribution; markedly elevated CK-MB or troponin-confirmed CK-MB fraction remains a diagnostic criterion for myocardial infarction in some protocols. Transient CK elevations after unaccustomed strenuous exercise are expected and benign, whereas persistent elevation suggests myopathy, rhabdomyolysis, or statin-induced muscle toxicity. In sarcopenia research, resting CK and its trajectory are explored as indirect indices of muscle membrane integrity.

Creatinine is a breakdown product of muscle creatine, produced at a relatively constant rate and cleared predominantly by glomerular filtration with a small contribution from tubular secretion, making serum creatinine a core marker of renal function. Because absolute values depend on muscle mass, age, sex, dietary meat intake, and creatine supplementation, laboratories report estimated glomerular filtration rate (eGFR) using the 2021 race-free CKD-EPI equation as current standard. Lower eGFR indicates reduced filtration capacity and is robustly associated with cardiovascular events, frailty, and mortality.

Critical power (CP) is a theoretically derived aerobic metabolic ceiling: the highest sustainable power output (or running speed, as critical velocity) below which a finite work capacity W' can be repeatedly reconstituted, and above which W' is depleted to exhaustion. Mathematically, CP and W' are estimated from the hyperbolic relationship between exercise power and time-to-exhaustion across several all-out efforts. CP closely approximates the maximal lactate steady state and the respiratory compensation point, demarcating the heavy-intensity from the severe-intensity exercise domain. CP declines with age and predicts endurance performance and cardiovascular risk; training interventions that shift CP upward increase the sustainable exercise ceiling.

CRON is a structured form of caloric restriction in which energy intake is reduced by roughly 20–30% while micronutrient density (vitamins, minerals, essential fatty acids, protein quality) is deliberately maximized. The approach was developed by Roy Walford (with Lisa Walford, and later Brian M. Delaney as a popularizer and CR Society co-founder), with The Anti-Aging Plan (1994) by Roy and Lisa Walford as a key reference. The aim is to capture metabolic benefits—improved insulin sensitivity, lower inflammation, favorable lipids—without inducing nutrient deficiencies.

Cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease are proteins measured in lumbar puncture samples that reflect core brain pathologies: Aβ42 (and the Aβ42/40 ratio) decreases in CSF as amyloid is sequestered into plaques, while phospho-tau 181 and 217 (p-tau181, p-tau217) and total tau (t-tau) increase with neurofibrillary tangle pathology and neurodegeneration. Together they operationalise the A/T/N (amyloid/tau/neurodegeneration) biomarker framework endorsed by the 2024 Alzheimer's Association diagnostic criteria, enabling biological rather than purely clinical diagnosis. CSF biomarkers show strong concordance with amyloid and tau PET and can detect Alzheimer's pathology 15–20 years before symptomatic onset; their main limitation is the invasiveness of lumbar puncture. Plasma-based equivalents (especially p-tau217) are rapidly maturing and approaching CSF-level diagnostic accuracy.

Curcumin is the principal polyphenol in turmeric (Curcuma longa) and modulates NF-kB, Nrf2, and other inflammatory and oxidative pathways. Standard curcumin has very low oral bioavailability; supplements typically use piperine, phospholipid, or nanoparticle formulations. Meta-analyses suggest modest reductions in inflammatory markers, joint pain, and lipid measures, but effects vary by formulation and study quality. Evidence for direct longevity benefits in humans is limited.

Cystatin C is a small (13 kDa) cysteine protease inhibitor produced at a constant rate by all nucleated cells, freely filtered by the glomerulus, and almost entirely reabsorbed and catabolized by the proximal tubule, making it a sensitive endogenous filtration marker. Unlike creatinine, its serum concentration is minimally influenced by muscle mass, sex, or dietary protein, though it rises with higher body fat, thyroid dysfunction, and corticosteroid use, which should be considered in interpretation. The 2021 CKD-EPI cystatin C and creatinine-cystatin C equations provide more accurate eGFR estimates in populations where creatinine is confounded by muscle mass extremes. Elevated cystatin C is a robust predictor of cardiovascular events, cognitive decline, and all-cause mortality, and epidemiological analyses suggest it may track true renal aging more faithfully than creatinine-derived eGFR.

HOMA-β (Homeostatic Model Assessment of Beta-cell function) is a fasting-state surrogate for pancreatic β-cell insulin-secretory capacity, calculated as (20 × fasting insulin in µU/mL) / (fasting glucose in mmol/L − 3.5). It reflects predominantly basal insulin secretion and correlates modestly with more demanding assessments such as the disposition index from intravenous glucose tolerance tests, though it cannot capture dynamic glucose-stimulated secretion. β-cell mass and secretory function decline progressively with age and are accelerated by insulin resistance, glucolipotoxicity, and chronic low-grade inflammation. Monitoring HOMA-β alongside HOMA-IR provides a paired view of both demand and supply within the glucose-regulation axis, relevant to prediabetes risk stratification and longevity-oriented metabolic assessment.

D+Q is one of the most studied senolytic combinations: dasatinib (a tyrosine-kinase-inhibitor cancer drug) plus quercetin (a flavonoid), given intermittently and designed to selectively eliminate or reduce senescent-cell burden. Preclinical studies show improvements in physical function and tissue health in aged mice. Human data are limited to small pilot trials in IPF, diabetic kidney disease, and frailty, which have shown reductions in senescence markers; efficacy as an anti-aging therapy remains unproven and use is off-label.

Deep sleep, or slow-wave sleep (N3), is the stage characterised by high-amplitude delta waves on EEG and the highest arousal threshold. It dominates the first third of the night and drives growth hormone release, cardiovascular recovery, immune regulation, and glymphatic clearance of metabolic waste. Deep sleep declines with age, and lower amounts are associated with poorer memory and increased risk of neurodegenerative disease.

The default mode network (DMN) is a set of anatomically connected cortical and subcortical regions — including the medial prefrontal cortex, posterior cingulate cortex, precuneus and angular gyri — that are co-activated at rest and deactivate during externally directed tasks, a pattern first described systematically by Raichle and colleagues in 2001. The DMN supports self-referential thought, episodic memory retrieval, mental simulation and social cognition. In normal aging, DMN connectivity and task-related deactivation weaken, correlating with poorer episodic memory and reduced cognitive flexibility. In Alzheimer's disease, the DMN shows disproportionate amyloid-β deposition and atrophy in its core hubs, consistent with its high baseline metabolic activity and tight coupling to the interstitial fluid dynamics that clear Aβ during sleep.

Denosumab is a fully human IgG2 monoclonal antibody that binds and neutralizes RANKL (receptor activator of nuclear factor-κB ligand), the cytokine required for osteoclast differentiation, activation, and survival; by blocking the RANK–RANKL axis it profoundly suppresses bone resorption. It is FDA-approved for osteoporosis in postmenopausal women and men at high fracture risk (Prolia, 60 mg SC every 6 months), prevention of skeletal-related events in bone metastases (Xgeva, higher dose), and giant cell tumour of bone. Unlike bisphosphonates, RANKL inhibition also affects immune cells and tumour microenvironments because RANKL is expressed on osteoblasts, activated T cells, and stromal cells beyond bone; this has prompted research into oncological and immunological applications. Observational data suggest possible cardiovascular and all-cause mortality reductions in denosumab-treated osteoporosis patients beyond fracture prevention, paralleling findings with bisphosphonates, but confounding and frailty-bias complicate interpretation. A critical safety feature is rebound bone loss if therapy is discontinued without transitioning to a bisphosphonate, as osteoclast activity surges; rare osteonecrosis of the jaw and atypical femoral fractures are also reported.

Dual-energy X-ray absorptiometry (DEXA) measures body composition and bone mineral density by directing two X-ray beams at different energy levels through tissue and quantifying differential attenuation; it partitions the body into lean mass, fat mass, and bone mineral content at regional and whole-body levels with high precision and low radiation (~1–5 µSv on modern scanners; up to ~10 µSv on older devices). DEXA-derived appendicular lean mass index (ALMI = lean mass in kg of arms + legs / height in m²) is used in EWGSOP2 sarcopenia criteria and visceral adipose tissue (VAT) estimates are increasingly available on modern scanners. Serial DEXA measurements quantify muscle and fat changes from training, diet, and aging interventions; the method's main limitations include hydration sensitivity for lean-mass estimates and scanner-model variability.

Dehydroepiandrosterone sulfate (DHEA-S) is the sulfated, long-circulating form of DHEA, secreted by the adrenal cortex (zona reticularis) and serving as a precursor to androgens and estrogens in peripheral tissues. Although it has minor diurnal variation, serum levels are far more stable than DHEA itself, making DHEA-S the preferred clinical marker of adrenal androgen output. It peaks in early adulthood and declines steeply with age (adrenopause); lower values are observationally associated with frailty, reduced bone density, and impaired immune function, though DHEA supplementation trials have largely been null for hard outcomes.

The disposable soma theory, proposed by Thomas Kirkwood in 1977, posits that organisms allocate finite metabolic resources between somatic maintenance and reproduction. Because natural selection favors reproductive success, the body invests only enough in repair to survive likely environmental hazards, leaving residual damage that accumulates as aging. The theory remains influential in evolutionary biogerontology and underlies modern thinking on caloric restriction and trade-offs.

DNA damage refers to chemical or structural alterations of the genome, including base modifications, single- and double-strand breaks, and crosslinks. It arises from reactive oxygen species, ionising radiation, UV light, and replication stress. Cells respond through DNA damage repair pathways; when overwhelmed, damage triggers senescence, apoptosis, or mutations. Genomic instability driven by accumulated DNA damage is a recognised hallmark of ageing and a cancer driver.

DNA methylation is an epigenetic modification in which methyl groups are added to cytosine bases, predominantly at CpG sites, by DNA methyltransferases. It regulates gene expression, X-inactivation, and genome stability without altering the underlying sequence. Methylation patterns shift predictably with age, forming the basis of epigenetic clocks such as Horvath's. Aberrant methylation contributes to cancer, immune dysfunction, and the broader epigenetic drift seen in ageing.

The DNAm Skin & Blood clock, published by Horvath and colleagues in 2018, is an epigenetic age estimator based on 391 CpG sites selected from methylation arrays applied to skin fibroblasts and blood samples. It was developed partly to overcome the observation that the original 2013 Horvath clock systematically underestimated age in keratinocytes and fibroblasts, tissues central to studies of in-vitro reprogramming and rejuvenation. Because it was trained on a tissue type directly accessible in longevity intervention studies, it is frequently used as a readout in partial reprogramming experiments alongside the multi-tissue Horvath clock.

DunedinPACE (Pace of Aging Calculated from the Epigenome) is an epigenetic clock published in 2022 by Belsky and colleagues that estimates the rate of biological ageing rather than a static age. It was trained in the Dunedin 1972-1973 birth cohort on longitudinal change across 19 organ-system biomarkers and translated into a DNA-methylation score using 173 CpGs. The score is calibrated so that 1 represents the cohort-mean pace of one year of biological aging per chronological year; values above 1 indicate faster-than-average ageing. DunedinPACE shows good test-retest reliability and predicts morbidity and mortality.

Dynapenia is the age-related loss of muscle strength and power that occurs independently of muscle mass loss. The term was coined by Clark and Manini (2008) to distinguish age-related strength loss from sarcopenia, which historically centred on muscle mass. It reflects neurological decline — fewer motor units, slower firing rates, reduced central drive — rather than just atrophy. Because strength predicts mortality more strongly than mass, dynapenia is now considered a distinct geriatric risk factor; power-focused training is the primary countermeasure.

Dysbiosis describes a shift in the composition, diversity or metabolic output of the microbiota away from a configuration associated with host health, though it is an operational rather than precisely defined term because no single healthy reference community exists. It is characterised by loss of beneficial taxa such as short-chain fatty acid–producing Firmicutes, expansion of potentially pathobiontic species, reduced alpha-diversity, or altered functional capacity — changes associated with inflammatory bowel disease, metabolic syndrome, type 2 diabetes and colorectal cancer, among others. Causal directionality is difficult to establish in human studies, since most evidence is associative and dysbiosis may be both a driver of and a consequence of host inflammation. As a hallmark of ageing recognised in the 2023 update by López-Otín and colleagues, age-associated dysbiosis is increasingly considered a contributor to inflammaging and frailty.

Eccentric training emphasizes the lengthening phase of a muscle contraction, such as the lowering portion of a squat or curl. Muscles produce greater force eccentrically than concentrically, generating high mechanical tension with relatively low metabolic cost. This makes eccentric work effective for building strength, hypertrophy, and tendon stiffness, and it is widely used in tendinopathy rehabilitation. Older adults tolerate it well, though delayed-onset muscle soreness is common.

EGCG is the most abundant catechin in green tea and a polyphenol with antioxidant, anti-inflammatory, and AMPK-modulating activity. Observational data link green tea consumption to lower cardiovascular and all-cause mortality. Trials of EGCG supplements show small effects on lipids, blood pressure, and body weight. High-dose extracts (typically above 800 mg EGCG/day) have been associated with liver enzyme elevations and hepatotoxicity; the European Food Safety Authority (EFSA) has identified this threshold as a safety concern and the EU has imposed limits on EGCG in food supplements. Direct evidence for human longevity from isolated EGCG remains limited.

Elastin is the extracellular matrix protein that confers recoil and elastic compliance to tissues under cyclical mechanical stress, particularly arterial walls, lungs, and skin; it is deposited almost exclusively during foetal and early postnatal development, and its half-life is estimated to exceed 70 years in humans, making post-synthetic preservation critical. With ageing, elastin fibres undergo progressive fragmentation driven by serine proteases (neutrophil elastase), cathepsins (cathepsin K, L), and matrix metalloproteinases (MMP-2, MMP-9, MMP-12), accompanied by loss of the microfibrillar scaffold of fibrillin-1 required for elastin assembly and repair. Accumulated elastin-derived peptides act as bioactive fragments that engage the elastin-binding protein (EBP) receptor to promote inflammation and MMP secretion, creating a pro-degradative feedback loop implicated in pulmonary emphysema, aortic aneurysm formation, and cutaneous ageing.

Endocrine-disrupting chemicals (EDCs) are exogenous substances that interfere with hormone synthesis, transport, receptor binding or metabolism; bisphenol A (BPA) and its structural analogues (BPS, BPF) act primarily as agonists or antagonists at oestrogen receptors (ERα, ERβ) and also interact with androgen and thyroid hormone pathways, while phthalates — plasticisers used widely in food packaging, medical devices and personal-care products — reduce androgen biosynthesis by inhibiting steroidogenic enzymes. Epidemiological associations include earlier puberty onset, reduced sperm quality, polycystic ovary syndrome, type 2 diabetes and obesity, though establishing causality in observational data is complicated by ubiquitous co-exposure and the non-monotonic dose-response curves characteristic of many EDCs. The EU banned BPA from polycarbonate baby bottles in 2011 and adopted a comprehensive ban on intentional BPA use in food-contact materials in December 2024 (Regulation (EU) 2024/3190), with phased transition periods, and applies a group tolerable daily intake for phthalates, but regulatory thresholds remain contested; cumulative mixture risk assessment is not yet standard practice in most jurisdictions.

Epigenetic age is a biological-age estimate derived from DNA-methylation patterns at selected CpG sites, computed by algorithms known as epigenetic clocks (e.g. Horvath, Hannum, PhenoAge, GrimAge, DunedinPACE). The difference between epigenetic and chronological age, called epigenetic age acceleration, is associated with mortality, cardiovascular disease and cancer in research cohorts. Validation depends on the specific clock; first-generation clocks track chronological age, while mortality-trained clocks better predict health outcomes. Commercial consumer tests vary in reliability.

Epigenetic alterations are age-related changes in DNA methylation patterns, histone modifications, chromatin architecture and non-coding RNA expression that occur without changes to the underlying DNA sequence. With age, the epigenome typically shows global hypomethylation alongside focal hypermethylation, loss of heterochromatin and altered transcription. These shifts underpin epigenetic clocks: first-generation chronological-age estimators such as the Horvath clock, and second-generation clocks like PhenoAge and GrimAge that predict mortality and disease risk above and beyond chronological age.

EPOC is the elevated oxygen uptake that persists after exercise ends, as the body restores ATP and creatine phosphate, clears lactate, refills oxygen stores, and returns hormones and temperature to baseline. The effect is largest after high-intensity or resistance work and modestly increases total energy expenditure. Although often called the afterburn, EPOC is best understood as a physiological recovery process rather than a primary fat-loss mechanism.

Endoplasmic reticulum (ER) stress arises when the capacity of the ER to fold, modify, and quality-control secretory and membrane proteins is exceeded by the demand — triggered by misfolded protein accumulation, calcium depletion, lipid bilayer disequilibrium, or viral infection. Three ER-resident sensors — IRE1alpha, PERK, and ATF6 — detect luminal stress and activate the unfolded protein response (UPR) to restore ER homeostasis by attenuating global translation, upregulating chaperones, and expanding the ER. Chronic, unresolved ER stress, which increases with ageing due to diminished chaperone capacity and accumulated misfolded proteins, shifts UPR signalling toward pro-apoptotic and pro-inflammatory outputs, contributing to beta-cell loss in type 2 diabetes, neurodegeneration, and atherosclerosis.

Estradiol (E2) is the most biologically active estrogen, produced mainly in the ovaries before menopause and in smaller amounts via aromatization of androgens in adipose tissue, brain, bone, liver, breast, and other peripheral tissues. It supports endothelial function, bone turnover, reproductive tissues, and may support cognition. After menopause, levels drop sharply and remaining production occurs via peripheral aromatization, contributing to accelerated bone loss, vasomotor symptoms, and a multifactorial rise in cardiometabolic risk. In men, modest estradiol from aromatization is important for bone health.

Exosomes are extracellular vesicles of 30–150 nm diameter that originate from the endosomal multivesicular body pathway and carry a cargo of proteins, lipids, mRNAs, miRNAs, and other non-coding RNAs that can modulate gene expression and cell behaviour in recipient cells. In aging research, exosomes derived from young plasma or from mesenchymal stem cells (MSC-EVs) have shown rejuvenating effects in rodent models — improving cardiac function, cognitive performance, and tissue regeneration — and are proposed as a cell-free alternative to plasma transfusion or stem cell therapy with potentially lower immunogenic risk. Regulatory classification is contested: the FDA considers most exosome products as biologics subject to IND application for clinical use, and in 2019 issued a safety alert warning that exosome products marketed for anti-aging, orthopedic, or hair loss indications outside clinical trials have not demonstrated safety or efficacy. The clinical evidence base consists primarily of small pilot studies and case series; controlled randomised trial data in aging are absent. Standardisation of isolation method, cargo characterisation, potency assays, and dosing remains an unresolved challenge across the field, and exosome products sold directly at clinics should be viewed with significant caution.

The extracellular matrix (ECM) is the protein and proteoglycan scaffold that provides structural support and transmits biochemical and mechanical signals to resident cells; with age, it undergoes progressive stiffening, fragmentation, and compositional remodelling driven by accumulated crosslinks, glycation end-products, reduced matrix turnover, and dysregulated matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) balance. ECM stiffening alters integrin-mediated mechanosignalling, promotes pro-fibrotic TGF-beta pathways, and has been shown to reinforce the SASP of senescent cells in a feed-forward loop. These changes impair tissue repair, compromise stem cell niches, and contribute to pathologies including cardiac fibrosis, osteoarthritis, and age-related pulmonary decline, making ECM integrity an emerging target for longevity-focused interventions.

Extracellular vesicles (EVs) are membrane-bound particles released by virtually all cell types and conventionally classified into exosomes (30–150 nm, endosomal origin via multivesicular bodies), microvesicles (100–1000 nm, direct plasma membrane budding), and apoptotic bodies (>1000 nm); MISEV2018/2023 guidelines recommend defining EVs operationally by physical properties (e.g., 'small EVs') unless biogenesis is directly demonstrated; they carry bioactive cargo including proteins, lipids, mRNA, microRNA, and DNA that can reprogram recipient cells upon uptake. EVs serve as key mediators of intercellular communication and are upregulated by senescent cells as part of the SASP, with aged plasma showing a distinct EV proteome and miRNA content that can accelerate senescence and inflammation when transferred to younger organisms in parabiosis-inspired experiments. Concurrently, EVs derived from young or stem cell sources are investigated as candidate therapeutic agents in regenerative medicine, with studies reporting improvements in muscle, cardiac, and cognitive function in aged rodent models, though mechanisms of selectivity and in vivo dosing remain areas of active investigation.

F2-isoprostanes are a family of prostaglandin F2α-like compounds formed non-enzymatically by free radical-mediated peroxidation of arachidonic acid esterified in phospholipids; they are released into plasma and excreted in urine, where 8-iso-PGF2α (iPF2α-III) is the most widely measured species. Because their production depends on the rate of in vivo lipid peroxidation and is independent of dietary fatty acid intake at typical measurement conditions, urinary F2-isoprostanes are regarded as the most reliable in vivo biomarker of systemic oxidative stress. Elevated levels are consistently found in cigarette smokers, obese individuals, diabetics, and patients with cardiovascular disease or neurodegenerative disorders; values decrease with antioxidant-rich diets, caloric restriction, and exercise. In epidemiological studies, higher F2-isoprostane levels predict incident cardiovascular events and are associated with accelerated biological aging.

Faecal microbiota transplant (FMT) is the transfer of processed stool from a healthy donor into the gastrointestinal tract of a recipient, with the aim of reconstituting a disrupted microbial community. Its only firmly established clinical indication is recurrent Clostridioides difficile infection (CDI), where it achieves cure rates of approximately 85–90 % and has superior efficacy to antibiotics alone, and it is now guideline-recommended for this purpose in most Western health systems. For all other indications — inflammatory bowel disease, metabolic syndrome, autism spectrum disorder, neurological conditions and ageing-related outcomes — the evidence base is investigational and results from randomised trials have been mixed, with some showing modest effects and others showing no benefit. Delivery methods include colonoscopy, nasogastric or nasoduodenal tube, enema and encapsulated freeze-dried preparations; donor screening is critical and complex, requiring testing for a broad panel of pathogens, and several serious adverse events including transmission of multi-drug-resistant organisms have been reported. The 'longevity' framing of FMT — informed by mouse studies showing life-extension after transfer from young donors — remains speculative in humans.

Fasting glucose is the plasma blood-sugar concentration after at least eight hours without caloric intake. It reflects baseline glucose homeostasis driven by hepatic glucose output, β-cell insulin secretion, peripheral insulin sensitivity, and counter-regulatory hormones such as glucagon, with renal glucose handling as a further contributor. Persistently elevated values indicate impaired fasting glucose, prediabetes, or type 2 diabetes, and Mendelian randomization supports a causal effect of higher fasting glucose on coronary disease. Even within the upper-normal range, rising fasting glucose tracks with increased risk, so stable lower-normal values are generally favorable.

Fasting insulin measures circulating insulin after an overnight fast and reflects β-cell output, hepatic insulin clearance, and peripheral insulin sensitivity together. Elevated fasting insulin is one of the earliest signs of insulin resistance and often appears before fasting glucose or HbA1c rise, consistent with the natural history seen in cohorts such as Whitehall II and IRAS. Hyperinsulinemia is associated with metabolic syndrome, type 2 diabetes, and a higher risk of cardiovascular disease and all-cause mortality. Lower fasting insulin generally indicates better insulin sensitivity and metabolic flexibility.

The fasting-mimicking diet is a 5-day low-calorie, low-protein, plant-based regimen developed by Valter Longo's group that reproduces metabolic effects of water-only fasting—reduced IGF-1, glucose, and insulin; elevated ketones—while still providing some food. Pivotal trials used 3 cycles spaced one month apart and reported improvements in cardiometabolic risk markers and abdominal adiposity. Suggested benefits on biological age estimates rest on secondary analyses (Brandhorst et al. 2024, Nature Communications) and should be considered preliminary.

Ferritin is a ubiquitous intracellular iron-storage protein that releases a small fraction into circulation; serum ferritin is therefore the most widely used biomarker for assessing total body iron stores. Low ferritin (typically <30 µg/L, or <15 µg/L in some guidelines) indicates depleted iron stores preceding overt iron-deficiency anemia and is associated with fatigue, reduced exercise capacity, impaired cognitive function, and hair loss even before hemoglobin falls. Conversely, elevated ferritin is a potent positive acute-phase reactant that rises substantially with inflammation, infection, liver disease, obesity, and metabolic syndrome, complicating interpretation; persistently elevated values without these confounders may reflect hereditary hemochromatosis or secondary iron overload, which accelerates oxidative stress, hepatic fibrosis, and cardiomyopathy. Optimal ferritin for health is debated; many longevity-oriented practitioners target approximately 70–120 µg/L, with caution warranted at both extremes.

Ferroptosis is a form of regulated cell death driven by iron-dependent accumulation of lipid peroxides to lethal levels, distinguishing it mechanistically from apoptosis, necroptosis and pyroptosis. The key regulatory node is glutathione peroxidase 4 (GPX4), which uses the antioxidant glutathione to reduce phospholipid hydroperoxides; when GPX4 activity is insufficient — due to glutathione depletion, GPX4 inhibition or excess labile iron — unreduced lipid peroxides propagate chain reactions that disrupt membrane integrity. Ferroptosis has been implicated in neurodegeneration, ischaemia-reperfusion injury and cancer cell death, and its relevance to tissue ageing is an active area of research, particularly in the context of declining GPX4 expression and iron accumulation observed with age.

FGF21 (fibroblast growth factor 21) is an endocrine member of the FGF superfamily secreted primarily by the liver in response to fasting, dietary protein restriction, and mitochondrial stress, acting on target tissues through FGFR1c/β-Klotho co-receptor complexes. It promotes fatty acid oxidation, ketogenesis, and insulin sensitisation, and suppresses growth hormone/IGF-1 axis activity. Transgenic mice overexpressing FGF21 live roughly 36% longer on median (Zhang 2012, with sex-specific mean-lifespan extensions of ~30% in males and ~40% in females) with improvements in metabolic health and adiposity, while elevated circulating FGF21 in humans is paradoxically associated with metabolic disease and frailty, likely reflecting compensatory induction in states of metabolic stress rather than a direct pro-ageing role. Pharmacological FGF21 analogues are in clinical development for metabolic liver disease.

FibroScan (vibration-controlled transient elastography, VCTE) measures liver stiffness in kilopascals (kPa) by propagating a low-frequency shear wave through hepatic tissue and tracking its velocity via ultrasound, with stiffer tissue reflecting more advanced fibrosis. Validated cut-offs range from approximately 7–8 kPa for significant fibrosis (F2) to >12–14 kPa for cirrhosis, though values are influenced by inflammation, congestion, food intake and BMI. In metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) — now the commonest cause of chronic liver disease globally — VCTE is endorsed as a non-invasive alternative to biopsy for fibrosis staging and longitudinal monitoring, avoiding both sampling error and procedural risk. The controlled attenuation parameter (CAP), measured simultaneously on modern devices, quantifies hepatic steatosis in dB/m and enables a single-visit assessment of both fat content and fibrosis stage.

Fibrosis is the pathological excess deposition of extracellular matrix — predominantly fibrillar collagens type I and III — by activated myofibroblasts in response to chronic injury, inflammation, or senescent-cell SASP signalling, replacing normal parenchymal cells with a stiff, poorly vascularised scar. TGF-beta1 is the dominant pro-fibrotic cytokine, signalling through SMAD2/3 to transcriptionally activate collagen synthesis, suppress MMPs, and drive fibroblast-to-myofibroblast differentiation; IL-11, PDGF, and connective tissue growth factor (CTGF/CCN2) cooperate in a context-dependent manner. Age markedly increases fibrotic susceptibility because impaired senescent cell clearance sustains TGF-beta and SASP output, macrophage polarisation shifts toward pro-fibrotic M2 phenotypes, and regenerative responses become dysregulated, making liver cirrhosis, idiopathic pulmonary fibrosis, and cardiac fibrosis major determinants of age-related organ failure.

Fisetin is a flavonoid found in strawberries, apples, and persimmons. In aged mice, Yousefzadeh et al. (2018, EBioMedicine) reported reduced senescent cell burden and extended median lifespan using a late-life intermittent dosing protocol; the paper also documented reduced age-associated tissue dysfunction. Independent replication remains limited. Mechanisms include induction of apoptosis in senescent cells and modulation of inflammatory pathways, making it a candidate dietary senolytic under investigation. Human trials are ongoing, and clinical evidence in people remains preliminary.

Flow, described by psychologist Mihaly Csikszentmihalyi, is a state of deep absorption in a challenging activity matched to one's skill, accompanied by reduced self-awareness and altered time perception. It is a popular wellbeing concept whose subjective experience is well-documented, while neural correlates remain debated. For longevity it is relevant because regular flow correlates with life satisfaction, sustained engagement, and the kind of meaningful activity that supports cognitive aging.

FOXO transcription factors (Forkhead box O) are downstream effectors of the insulin/IGF-1 pathway that regulate genes governing stress resistance, DNA repair, autophagy, and antioxidant defense. When insulin/IGF-1 signaling is low, FOXO enters the nucleus and activates protective transcriptional programs. FOXO3 variants are among the most reproducibly associated genetic markers of human exceptional longevity, observed across centenarian cohorts in multiple ethnicities.

FOXO3 encodes a forkhead-box transcription factor that integrates signals from the insulin/IGF-1 and AMPK pathways to regulate stress resistance, autophagy, apoptosis, and antioxidant gene expression. A cluster of intronic single-nucleotide polymorphisms — most prominently rs2802292 — was first associated with exceptional longevity in Hawaiian men of Japanese ancestry (Willcox et al., 2008) and has since been replicated across multiple independent cohorts in Europe, East Asia, and Ashkenazi populations. The protective allele is thought to promote nuclear retention of FOXO3, enhancing expression of downstream targets including GADD45, SOD2, and autophagy regulators. Because FOXO3 sits at the convergence of multiple conserved longevity pathways, it remains one of the most consistently replicated genetic associations with human lifespan.

Frailty is a clinical state of increased vulnerability to stressors resulting from accumulated deficits across multiple physiological systems, leading to diminished reserve and resilience. Two complementary operationalisations dominate the literature: the phenotypic frailty model of Fried and colleagues (2001, Cardiovascular Health Study), which defines frailty by at least three of five criteria (unintentional weight loss, exhaustion, low grip strength, slow walking speed, low physical activity); and the Frailty Index of Mitnitski and Rockwood, which counts the proportion of health deficits present across 30–70 items (symptoms, signs, diagnoses, laboratory values). Both predict adverse outcomes—falls, hospitalisation, disability, and mortality—independently of chronological age, and frailty prevalence rises sharply after age 80. In geroscience, it is a key functional outcome for evaluating senolytic, senostatic, and other geroprotective interventions.

The free radical theory of aging, proposed by Denham Harman in 1956, originally attributed aging to cumulative cellular damage from oxygen-derived free radicals, drawing on rate-of-living and oxygen-toxicity reasoning. Harman's 1972 update, the mitochondrial free radical theory of aging (MFRTA), specifically implicated mitochondrial ROS and mtDNA as the central drivers. While oxidative damage is undeniably involved, large antioxidant trials largely failed, and the theory is now considered partial. Modern frameworks integrate it with mitochondrial dysfunction and redox signaling.

Free radicals are atoms or molecules carrying one or more unpaired electrons, which makes them highly reactive. They arise from normal metabolism, immune activity, and external sources such as UV radiation, pollution, and tobacco smoke. By stealing electrons from neighbouring molecules, free radicals damage membranes, enzymes, and DNA. The free-radical theory of ageing posits that this cumulative damage contributes to functional decline and age-related disease; though historically influential, the theory is now considered an incomplete account of ageing, as supplemental antioxidants have not reliably extended lifespan in animal trials or human RCTs, and reactive oxygen species are increasingly recognised as signalling molecules as well as damaging agents.

Free T3 (fT3) and free T4 (fT4) are the unbound, biologically active fractions of triiodothyronine and thyroxine. T4 is the main thyroid secretion product and is deiodinated peripherally to the more potent T3, which acts on nuclear receptors to regulate metabolism, thermogenesis, and cardiovascular function. Measuring free fractions avoids interference from binding-protein changes and helps distinguish primary thyroid disease, central hypothyroidism, and non-thyroidal illness when interpreted alongside TSH.

Gait speed — typically assessed over a 4- or 6-metre walk at comfortable pace — is one of the most robust and inexpensive functional biomarkers of systemic aging, integrating muscular strength, balance, cardiorespiratory capacity, and neurological integrity into a single measurement. A large meta-analysis (Studenski et al., JAMA 2011, over 34,000 participants) showed that each 0.1 m/s increase in gait speed was associated with a 12% lower mortality hazard, and gait speed was as informative about survival as age, sex or body-mass index. Slow gait (typically <0.8 m/s) predicts incident dementia, frailty, falls, hospitalisation and mortality independently of leg strength alone, reflecting the broad integrative demands of coordinated locomotion on the central and peripheral nervous system. In clinical geroscience, gait speed is included in the Short Physical Performance Battery (SPPB) and serves as both a diagnostic marker of physical frailty and a sensitive, modifiable outcome for exercise and nutritional interventions.

GDF11 (growth differentiation factor 11) is a TGF-β superfamily ligand that plays an established role in axial patterning and organogenesis during embryonic development by signalling through activin type II receptors and SMAD2/3 transcription factors. Its role in adult ageing attracted intense interest following 2013–2014 parabiosis studies that reported circulating GDF11 levels decline with age and that supplementation reversed features of cardiac hypertrophy and muscle and brain ageing in mice; however, subsequent work raised significant questions about assay specificity, with some studies finding GDF11 levels actually increase with age, and others failing to replicate the rejuvenating effects. The current consensus is that GDF11's role as a systemic pro-youthful factor in adult mammals remains unresolved and contested, pending studies with validated, isoform-specific assays.

GDF15 (growth differentiation factor 15), also known as MIC-1, is a divergent TGF-β superfamily member that is expressed at low levels under homeostatic conditions but is strongly induced by mitochondrial stress, DNA damage, inflammation, and diverse cellular stressors. It signals through a dedicated receptor complex comprising GFRAL and RET in the hindbrain to suppress appetite and reduce body weight, a mechanism relevant to cancer cachexia and the metabolic effects of drugs such as metformin, which robustly elevates GDF15. Circulating GDF15 rises with age and is associated with markers of frailty, cardiovascular disease, and all-cause mortality; it is increasingly studied as a biomarker of mitochondrial stress and biological age, though its net role — detrimental stress signal or adaptive mediator — depends heavily on context.

Gene therapy delivers genetic material to add, silence, or edit genes — typically via AAV vectors for stable transgene expression and lipid nanoparticles for transient nucleic-acid delivery (e.g., mRNA, gene-editing components). Longevity targets include telomerase (TERT), follistatin, Klotho, and partial reprogramming via OSK (the three Yamanaka factors Oct4, Sox2 and Klf4 — omitting c-Myc to reduce oncogenicity). Rodent data are strong for some constructs, but human applications remain pre-clinical or run as small offshore or patient-paid programs outside FDA-regulated frameworks (BioViva, Libella). Risks include immunogenicity, oncogenicity, and off-target editing; no anti-aging gene therapy is approved.

Genomic instability is the progressive accumulation of damage to nuclear and mitochondrial DNA, including point mutations, chromosomal rearrangements, copy-number changes and retrotransposon activation. It arises from endogenous sources such as replication errors and reactive oxygen species as well as exogenous insults like UV light and toxins, and is exacerbated by declining DNA-repair capacity. As one of the primary hallmarks of ageing, it drives clonal expansion, cancer risk and tissue dysfunction.

Gerontology is the scientific study of aging across biological, psychological, and social dimensions. Established as a formal discipline in the early 20th century, with Ilya Mechnikov coining the term in 1903, it encompasses biogerontology, social gerontology, and geriatric medicine. It remains the broader umbrella field within which geroscience focuses specifically on molecular and cellular mechanisms relevant to disease prevention.

Geroscience is an interdisciplinary field that investigates the biological mechanisms of aging and their causal links to chronic disease. Coined around 2007 by researchers at the Buck Institute and formalized by the NIH-led Geroscience Interest Group, it rests on the premise that targeting aging itself can simultaneously delay multiple age-related conditions. It now underpins translational efforts like the TAME trial.

Gamma-glutamyl transferase (GGT) is a membrane-bound enzyme that transfers gamma-glutamyl groups and supports glutathione recycling, with highest activity in liver, biliary epithelium, and kidney. Serum GGT rises with cholestasis, alcohol intake, hepatic steatosis, and many enzyme-inducing drugs, making it a sensitive but unspecific liver marker. Beyond hepatology, higher GGT within the reference range is independently associated with insulin resistance, cardiovascular disease, and increased all-cause mortality, marking oxidative stress.

GLP-1 receptor agonists (e.g. liraglutide, semaglutide, dulaglutide) mimic the incretin hormone glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Approved indications include type 2 diabetes and obesity; large trials demonstrate reduced cardiovascular events, now-approved kidney-disease risk reduction in type 2 diabetes with chronic kidney disease (semaglutide, FDA January 2025, FLOW trial), and investigational heart-failure symptom improvements in HFpEF. Longevity-relevant effects include weight loss, improved glycemia, and possible neuroinflammatory dampening. Off-label use purely for healthspan extension in metabolically healthy adults remains investigational.

Glucagon is a 29-amino-acid peptide hormone secreted by pancreatic alpha-cells in response to hypoglycemia, prolonged fasting, and amino acid ingestion, and suppressed by glucose and insulin. It acts on hepatic glucagon receptors to stimulate glycogenolysis and gluconeogenesis, raising blood glucose, and promotes hepatic ketogenesis during fasting. It is classically viewed as the counter-regulatory hormone to insulin, and the glucagon-to-insulin ratio is an important determinant of hepatic fuel partitioning. In type 2 diabetes, glucagon secretion is paradoxically elevated postprandially and resistant to glucose-mediated suppression, contributing to hyperglycemia; GLP-1 receptor agonists partly correct this by potentiating insulin and suppressing inappropriate glucagon release. Newer dual and triple agonists targeting glucagon, GLP-1, and GIP receptors are in clinical development for obesity and metabolic disease.

Glucose variability quantifies the magnitude and frequency of blood glucose fluctuations over hours and days, typically expressed as standard deviation, coefficient of variation, or mean amplitude of glycemic excursions (MAGE). High variability is implicated in oxidative stress, endothelial dysfunction, and diabetic complications independent of mean glucose. In non-diabetic adults, lower variability correlates with better metabolic health, and continuous glucose monitoring increasingly tracks it as a longevity-relevant biomarker.

Glutathione (GSH) is the most abundant intracellular low-molecular-weight thiol, synthesised in two ATP-dependent steps from glutamate, cysteine, and glycine by glutamate-cysteine ligase (GCL) and glutathione synthetase. It serves as a substrate for glutathione peroxidases (GPx) that neutralise hydrogen peroxide and lipid hydroperoxides, is conjugated to electrophilic toxins by glutathione S-transferases, and maintains the thiol-redox status of proteins. Total GSH declines with ageing in most tissues, due in part to reduced biosynthesis and increased oxidative load, and low GSH:GSSG (oxidised glutathione) ratios are associated with accelerated cellular senescence and disease risk; N-acetylcysteine and glycine supplementation are being evaluated as strategies to restore GSH levels in older adults.

GlycA is a composite nuclear magnetic resonance (NMR) spectroscopy signal arising predominantly from N-acetyl methyl groups on acute-phase glycoproteins — primarily α1-acid glycoprotein, α1-antitrypsin, haptoglobin, α1-antichymotrypsin, and transferrin — and reflects the integrated concentration and glycosylation state of these inflammatory proteins. Because it integrates across multiple acute-phase reactants simultaneously, GlycA has lower within-person variability than hs-CRP and may better capture chronic low-grade systemic inflammation rather than acute fluctuations. Population studies associate higher GlycA with incident cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, cancer, and all-cause mortality, with some evidence that it predicts these outcomes independently of and complementary to hs-CRP. GlycA is currently a research-grade marker not routinely available in clinical laboratories and is most often reported as part of NMR lipoprotein panels.

GlycanAge is a biological-age estimate derived from the N-glycan composition of immunoglobulin G (IgG), measured in blood plasma by high-throughput capillary electrophoresis or ultra-performance liquid chromatography. IgG glycosylation shifts predictably with age—specifically, a decline in galactosylation and sialylation alongside a rise in bisecting GlcNAc accompanies the shift toward a more pro-inflammatory IgG glycome—and these patterns also respond to lifestyle interventions and chronic disease. Because glycans regulate IgG effector function and inflammaging, the measure captures an immunologically relevant dimension of ageing not directly accessible to DNA-methylation clocks; however, reference populations and clinical thresholds are still under active investigation.

Glycation is the non-enzymatic attachment of sugars such as glucose or fructose to proteins, lipids, or nucleic acids. Through the Maillard reaction it generates unstable Schiff bases, then Amadori products, and ultimately advanced glycation end-products. Glycation stiffens collagen, impairs enzyme activity, and disrupts cell signalling. Driven primarily by hyperglycaemia and elevated glycaemic load, it accelerates skin ageing, vascular stiffening, and diabetic complications.

Glycine is the smallest and simplest amino acid, non-essential under normal conditions but conditionally essential in aging, pregnancy, and disease states where demand may exceed endogenous synthesis from serine and threonine. It is the most abundant amino acid in collagen and a structural backbone of glutathione (as the third residue of the γ-Glu-Cys-Gly tripeptide), explaining its role as a rate-limiting substrate for glutathione synthesis in older adults whose glycine levels are typically low. Glycine also acts as an inhibitory neurotransmitter in the spinal cord and brainstem, modulates NMDA receptor activity, and participates in one-carbon metabolism, bile acid conjugation, and creatine synthesis. Dietary sources include gelatin, skin, bones, and connective tissue; modern lean-meat-focused diets provide relatively little. Animal studies show lifespan extension by glycine supplementation in mice (ITP, Miller 2019); evidence from C. elegans is indirect, arising mainly from methionine restriction and one-carbon metabolism studies rather than direct glycine trials. In humans, glycine deficiency in older adults is increasingly recognized, and small pilot trials (particularly in the context of GlyNAC, n≈8 each) suggest restoration of glutathione levels and improvements in multiple aging-related biomarkers.

The glymphatic system, described by Iliff, Nedergaard and colleagues in 2012, is the brain's waste-clearance pathway, in which cerebrospinal fluid flows along perivascular spaces, exchanges with interstitial fluid, and removes metabolic byproducts such as beta-amyloid and tau. Activity increases substantially during sleep (and under anaesthesia in animal models), when the interstitial space expands by roughly 60 percent (Xie et al., 2013). Impaired glymphatic clearance is implicated in Alzheimer's disease and other neurodegenerative conditions, making sleep a key intervention point for brain longevity.

GlyNAC is the combined oral supplementation of glycine and N-acetylcysteine (NAC), designed to replenish both precursors of the tripeptide glutathione (γ-Glu-Cys-Gly), which declines progressively with age. The combination addresses the limiting precursors simultaneously — cysteine (via NAC) and glycine — rather than the gamma-glutamylcysteine step, which is typically less rate-limiting in older adults. Pioneered by Rajagopal Sekhar and colleagues at Baylor College of Medicine, a series of randomized, double-blind pilot trials in older adults (GlyNAC trials, published 2021–2024) using 16–24 weeks of supplementation documented restoration of erythrocyte glutathione to levels seen in young adults and improved multiple aging-associated deficits including mitochondrial fuel oxidation, oxidative stress, inflammation, endothelial dysfunction, insulin resistance, genomic damage, muscle strength, and gait speed. Evidence remains limited to short-duration trials with small samples; longer-term RCTs with clinical outcome endpoints are lacking. GlyNAC is commercially available as a dietary supplement and has no approved indication.

Gompertz law, formulated by the British actuary Benjamin Gompertz in 1825, describes the empirical observation that human mortality risk increases exponentially with adult age: specifically, the force of mortality (hazard rate) approximately doubles every 8 years in most high-income populations. Mathematically, the instantaneous mortality rate is expressed as μ(t) = a·e^(bt), where a is the baseline mortality rate and b is the age-dependent acceleration. The law holds across most of adult life in humans and many other species, but mortality deceleration or plateaus observed at very old ages suggest it is not universal beyond the oldest cohorts. Gompertz dynamics are central to actuarial science, epidemiology, and the theoretical biology of ageing.

GrimAge is a second-generation epigenetic clock introduced by Lu et al. (2019, with Steve Horvath as senior author). Instead of predicting chronological age, it is trained on time-to-death and combines DNA-methylation surrogates for seven plasma proteins (e.g. PAI-1, GDF-15) and DNAm-based smoking pack-years. In multiple cohorts GrimAge and the updated GrimAge2 (2022) outperform earlier clocks at predicting all-cause mortality, cardiovascular disease and cancer. It is widely used in research; clinical use as a diagnostic endpoint remains investigational.

Grip strength is the maximal force generated when squeezing a dynamometer and serves as a low-cost proxy for whole-body muscular function. In the 17-country PURE cohort (Leong et al., Lancet 2015; ~140,000 adults), each 5 kg decrement in grip strength predicted roughly a 16% increase in all-cause mortality, outperforming systolic blood pressure as a mortality predictor. It correlates with neuromuscular health, nutritional status, and recovery capacity, making it one of the most validated biomarkers of biological aging.

The gut microbiota comprises approximately 38 trillion bacteria — plus archaea, fungi, viruses and other microorganisms — that colonise the human gastrointestinal tract, with the highest density in the colon. Collectively they encode a gene catalogue roughly 150-fold larger than the human genome and perform functions the host cannot accomplish alone, including fermentation of dietary fibre into short-chain fatty acids, synthesis of certain B vitamins and vitamin K2, modulation of bile acid chemistry, and calibration of mucosal immunity. Compositional and functional differences between individuals are large — shaped by birth mode, infant feeding, diet, geography, antibiotics and age — and these inter-individual differences complicate the search for universal 'optimal' compositions. The term 'microbiome' technically encompasses both the organisms and their collective genetic material, but the two words are widely used interchangeably in the clinical literature.

The gut-brain axis is the bidirectional communication network linking the enteric nervous system, vagus nerve, hypothalamic-pituitary-adrenal (HPA) axis, immune signalling and blood-borne microbial metabolites between the gastrointestinal tract and the central nervous system. The gut microbiota participates in this network by producing neuroactive compounds — including serotonin precursors (roughly 90 % of the body's peripheral serotonin is synthesised in enterochromaffin cells, stimulated partly by microbial metabolites), gamma-aminobutyric acid (GABA), short-chain fatty acids and secondary bile acids — that can reach the brain directly or modulate afferent vagal signalling. Animal studies have provided compelling evidence that germ-free or antibiotic-treated mice show altered stress responses, anxiety-like behaviour and neuroinflammation that can be partly reversed by specific microbiota reconstitution or probiotic treatment. Human evidence is more limited: proof-of-concept trials with specific psychobiotics have shown modest anxiolytic or antidepressant-like signals in some cohorts, but effect sizes are small and replication has been inconsistent, meaning clinical translation remains premature.

A genome-wide association study (GWAS) is an agnostic scan of common single-nucleotide polymorphisms (SNPs, typically minor allele frequency >1–5%) across the genome to identify loci statistically associated with a trait or disease, using a stringent significance threshold of p<5×10⁻⁸ to control for multiple testing of ~1 million tag SNPs in linkage disequilibrium (LD) with surrounding variants. GWAS operates on the common-disease/common-variant hypothesis and is optimized for polygenic traits; most discovered variants have modest individual effect sizes (OR 1.05–1.3), requiring very large sample sizes (tens to hundreds of thousands) to detect reliably. In longevity, GWAS findings are relatively sparse: the APOE locus (particularly ε2 protection and ε4 risk) is by far the strongest and most replicated hit for exceptional longevity; other candidates including FOXO3, TOMM40/APOC1, and CDKN2B-AS1 are supported by some studies but lack universal replication. The modest GWAS yield for longevity likely reflects its heterogeneous, polygenic, and late-acting genetic architecture.

The Hallmarks of Aging are a set of interconnected biological processes proposed by López-Otín and colleagues to describe the molecular and cellular drivers of ageing. The 2023 update lists twelve hallmarks, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled macroautophagy, chronic inflammation and dysbiosis. They serve as the dominant framework for longevity research and intervention design.

The Hannum clock is a blood-based epigenetic age estimator published by Gregory Hannum and colleagues in 2013. It uses DNA methylation levels at 71 CpG sites, derived from whole-blood samples of 656 individuals, to predict chronological age with a cross-validated correlation of ~0.96. Unlike the Horvath clock, which is multi-tissue, the Hannum clock was trained and validated specifically in blood, making it less generalisable to other tissues. It remains widely cited but has been largely superseded for mortality prediction by second-generation clocks trained on health outcomes.

The Hayflick limit is the maximum number of times a normal human somatic cell can divide in culture, typically 40 to 60 times, before entering replicative senescence. Discovered by Leonard Hayflick in 1961, the limit is mechanistically explained by progressive telomere shortening with each division. It established that aging has a cell-intrinsic component and remains a foundational concept linking cellular replication, telomere biology, and organismal aging.

A hazard ratio is the ratio of the instantaneous event rate in one group to that in a reference group at any given moment during follow-up, derived from a Cox proportional-hazards regression model. An HR of 0.75 means the treated group experiences the event at 75% of the rate of controls throughout follow-up, not that overall risk is reduced by 25% at a fixed time point — a common misreading. The proportional-hazards assumption requires that this ratio remain constant over time; violations (e.g., time-varying drug effects) must be tested, and when present, time-restricted or parametric models are more appropriate. In longevity and survival studies the HR is the dominant effect measure, but its magnitude depends on baseline hazard and follow-up length, limiting direct comparisons across trials.

HbA1c (glycated hemoglobin) reflects the proportion of hemoglobin stably bound to glucose, providing an integrated estimate of average blood glucose over approximately the prior 2 to 3 months, with the most recent ~30 days contributing roughly half of the signal per published kinetic models. It is the primary biomarker for diagnosing and monitoring type 2 diabetes (threshold 6.5%) and prediabetes (5.7 to 6.4%). HbA1c is influenced by erythrocyte lifespan, anemia, and hemoglobin variants.

HDL cholesterol (high-density lipoprotein cholesterol) measures the cholesterol carried by HDL particles, which transport cholesterol from tissues back to the liver in reverse cholesterol transport. Population studies historically associated higher HDL-C with lower cardiovascular risk, but Mendelian randomization and HDL-raising drug trials show the relationship is non-causal and U-shaped: very high HDL-C is also linked to increased mortality. HDL functionality matters more than its concentration alone.

Healthspan is the period of life spent in good health, free from serious chronic disease and major functional impairment. It is conceptually distinct from lifespan, which counts total years lived. In longevity research healthspan is increasingly preferred as an outcome because the goal is to compress the years of frailty and disease at the end of life. Operational definitions vary and may use disease-free survival, disability indices or composite biomarker scores.

Heart rate variability is the beat-to-beat fluctuation in time between successive heartbeats, measured in milliseconds. Within a healthy sinus rhythm, higher values typically reflect stronger vagal modulation and cardiovascular adaptability, but pathologically high beat-to-beat variability (e.g. atrial fibrillation or frequent ectopic beats) does not indicate good autonomic health and must be excluded before interpretation. Declining HRV trends are associated with aging, chronic stress, and elevated all-cause mortality risk.

Heat shock proteins (HSPs) are a family of highly conserved molecular chaperones, named for their induction by heat but active under many forms of stress. They assist protein folding, prevent aggregation, attempt to refold denatured proteins when possible, and route irreparable ones for degradation. HSPs such as HSP70 and HSP90 are central to proteostasis, and HSP induction by exercise and heat exposure (including sauna) is studied as one contributing mechanism among many for their health effects.

The heat shock response is a conserved cellular program triggered by elevated temperature and other proteotoxic stressors. Heat shock factor 1 (HSF1) activates transcription of heat shock proteins (HSPs) such as HSP70 and HSP90, which act as chaperones to refold or degrade damaged proteins. This pathway supports proteostasis and is hypothesised to mediate hormetic benefits of sauna and exercise; direct human longevity evidence remains preliminary.

Lead, cadmium and inorganic mercury are the heavy metals most consistently associated with chronic low-level human exposure and adverse health outcomes in epidemiological research. Lead enters via ageing drinking-water infrastructure and legacy paint; cadmium accumulates through cigarette smoke, contaminated soil and certain foods; methylmercury is concentrated in large predatory fish through bioaccumulation. Mechanistically, these metals displace essential ions, inhibit enzymatic activity, generate reactive oxygen species and alter DNA methylation patterns — epigenetic effects linked to accelerated biological ageing. NHANES blood-lead studies have reported a continuous dose-response relationship between blood lead levels and all-cause and cardiovascular mortality even at concentrations previously considered safe, contributing to successive downward revisions of reference values.

Haematopoietic stem cells (HSCs) are rare, multipotent progenitors residing primarily in the bone marrow that sustain lifelong blood cell production through asymmetric self-renewal divisions and hierarchical differentiation into all lymphoid and myeloid lineages. With ageing, the HSC pool expands numerically but deteriorates functionally: aged HSCs show myeloid-biased output at the expense of lymphopoiesis, reduced engraftment efficiency, increased DNA damage, altered epigenetic landscapes, and mitochondrial dysfunction. Clonal haematopoiesis — the age-associated expansion of HSC clones carrying somatic mutations in epigenetic regulators such as DNMT3A, TET2, and ASXL1 — is present in more than 10% of individuals over 65 with conventional sequencing depth (and substantially more on deep sequencing) and confers elevated risk of haematological malignancy, cardiovascular disease, and all-cause mortality, establishing HSC ageing as a direct contributor to systemic health decline.

Hepatic insulin resistance describes the selective failure of the liver to suppress gluconeogenesis and glycogenolysis in response to postprandial insulin, while lipogenesis may paradoxically remain insulin-responsive — a dissociation termed selective hepatic insulin resistance. The result is excessive fasting and postprandial hepatic glucose output, driving compensatory hyperinsulinemia that further promotes de novo lipogenesis and hypertriglyceridemia. Primary drivers include intrahepatic lipid accumulation from excess free fatty acid influx, fructose metabolism, and impaired mitochondrial fat oxidation, converging on serine phosphorylation of the insulin receptor substrate (IRS-1/IRS-2). Hepatic insulin resistance is an early and mechanistically central feature of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, and epidemiologically associates with elevated cardiometabolic and all-cause mortality risk.

Heritability of lifespan is the proportion of variance in age at death attributable to additive genetic differences among individuals in a defined population. Classic twin-study estimates placed narrow-sense heritability at roughly 20–30% (Herskind et al. 1996); large-scale genomic analyses and a 2018 study in Genetics (Ruby et al.) using genealogical databases suggested even lower heritability once marital assortment is properly accounted for, with some estimates falling below 10% for lifespan itself. More recent analyses (Shenhar et al. 2026, Science) that better account for confounding factors place the intrinsic heritability of human life span at approximately 50%, suggesting earlier estimates may have been deflated by failure to separate intrinsic from extrinsic mortality. Even at the higher end, modifiable factors — lifestyle, environment, stochastic events — account for a substantial portion of variance. Specific genetic variants such as APOE ε4 and FOXO3A show replicated associations with mortality risk and exceptional longevity respectively, even if their individual effect sizes are modest.

Heterochromatin is the condensed, transcriptionally repressed fraction of chromatin marked by histone modifications such as H3K9me2/3 and H3K27me3, and maintained by factors including HP1 proteins, the polycomb repressive complexes and DNA methylation; it silences repetitive elements, maintains genome stability and enforces cell-type-specific gene expression patterns. With age, heterochromatin — particularly constitutive heterochromatin at pericentromeric and telomeric regions — undergoes progressive loss and spatial reorganisation, a process associated with de-repression of retrotransposons, ectopic gene expression and genomic instability. Lamin A dysfunction, HDAC sirtuin decline and the epigenetic drift captured by DNA methylation clocks all converge mechanistically on heterochromatin erosion, making it a proposed upstream driver linking multiple hallmarks of ageing.

Heterochronic parabiosis (HCP) is an experimental surgical technique in which the circulatory systems of a young and an old animal are joined by anastomosis of subcutaneous vasculature, exposing each partner continuously to the other's blood. Classic studies by Clive McCay in the 1950s and a revival by Irina and Michael Conboy (2005, Nature), Amy Wagers, Saul Villeda, and colleagues in the 2000s–2010s showed that old mice conjoined with young partners exhibit improvements in muscle regeneration, neurogenesis, cardiac hypertrophy, and liver function, while young mice show partial deterioration. Two competing mechanistic hypotheses emerged: the young-factors model, proposing that circulating rejuvenating factors in young blood are responsible — highlighted by controversy over GDF11, which was initially championed and then disputed as a beneficial rejuvenation factor — and the dilution model, proposed by Irina Conboy and colleagues, arguing that dilution of pro-aging factors (TGF-β, β2-microglobulin) accumulated in old blood is the dominant mechanism, a view supported by experiments using young saline-albumin exchange rather than young blood specifically. Human translation efforts include Alkahest (spin-out from Villeda's group), which has fractionated plasma into defined protein fractions (GRF6019) for Alzheimer's and Parkinson's trials, and small commercial young-plasma infusion services that preceded regulatory scrutiny; the FDA issued a safety alert in 2019 warning against unproven commercial young-plasma infusions. No plasma-based therapy for aging is currently approved by the FDA or EMA.

Frequency-domain HRV analysis decomposes the beat-to-beat interval spectrum into bands: high frequency (HF, 0.15–0.4 Hz) primarily reflects respiratory sinus arrhythmia driven by vagal modulation, while low frequency (LF, 0.04–0.15 Hz) has mixed sympathetic and vagal contributions, with the precise sympathetic share dependent on respiratory rate and posture. The LF/HF ratio (with HF/LF being the reciprocal form) was historically used as an index of sympathovagal balance, but this interpretation is contested; current HRV Task Force guidance and subsequent work note that LF is not a pure sympathetic marker and that the ratio has limited physiological specificity. HF power and RMSSD remain the more validated short-term vagal indices, while LF power and the ratio are best treated as supplementary spectral descriptors rather than reliable autonomic balance readouts.

HIF-1α (hypoxia-inducible factor 1α) is the oxygen-regulated subunit of the HIF-1 heterodimeric transcription factor that drives the cellular and systemic transcriptional response to low oxygen (hypoxia). Under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylase domain enzymes (PHDs), recognised by the VHL E3 ubiquitin ligase, and rapidly proteasomally degraded; hypoxia inhibits PHD activity, allowing HIF-1α to accumulate, heterodimerize with HIF-1β (ARNT), and activate hypoxia response element (HRE)-driven genes for anaerobic glycolysis (GLUT1, LDHA), angiogenesis (VEGF), and erythropoiesis (EPO). In ageing, HIF-1α plays a contextually dual role: in C. elegans, both loss-of-function and gain-of-function HIF-1 mutations can extend lifespan depending on conditions such as temperature and oxygen tension, reflecting a context-dependent dual role; in mammals appropriate HIF-1α activity is required for hypoxic adaptation and ischemic preconditioning, and its dysregulation contributes to tumor progression, pulmonary hypertension, and potentially to age-related metabolic decline.

High-sensitivity troponin (hs-Tn) assays measure the cardiac isoforms troponin I (hs-TnI) or troponin T (hs-TnT) at concentrations about 10-fold lower than conventional assays, with analytical coefficient of variation ≤10% at the 99th-percentile reference limit. This sensitivity enables detection of the small troponin leaks that occur with myocardial injury from acute MI, myocarditis, takotsubo syndrome, and demand ischemia, as well as low-grade chronic cardiomyocyte injury. Beyond acute chest-pain rule-out, chronically elevated hs-Tn in the population predicts incident heart failure, atrial fibrillation, and cardiovascular and all-cause mortality independently of established risk factors, making it an emerging biomarker of subclinical cardiac aging and injury. Values must always be interpreted in clinical context, as non-cardiac causes (e.g., renal failure, sepsis, pulmonary embolism) can also elevate troponin.

HIIT alternates short bouts of near-maximal effort with periods of low-intensity recovery, typically over 10–30 minutes total. The high-intensity intervals stress cardiac output and mitochondrial function, driving rapid gains in VO2max, insulin sensitivity, and stroke volume. Compared with steady-state cardio, HIIT delivers similar or greater cardiorespiratory adaptations in less time, making it a time-efficient longevity intervention when balanced with lower-intensity aerobic work.

The Hippo pathway is a conserved kinase cascade — centred on MST1/2 and LATS1/2 kinases — that controls organ size, tissue homeostasis, and stem cell activity by phosphorylating and thereby inactivating the transcriptional co-activators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif). When Hippo signalling is active, phosphorylated YAP/TAZ are sequestered in the cytoplasm or degraded; when the pathway is off, YAP/TAZ translocate to the nucleus, associate with TEAD transcription factors, and drive pro-proliferative and anti-apoptotic gene programmes. Mechanical cues, cell density, extracellular matrix stiffness, and G-protein-coupled receptor signals converge on the pathway. In ageing, increased tissue stiffness and altered mechanical environments can dysregulate YAP/TAZ, contributing to impaired regeneration and fibrosis; YAP/TAZ are also implicated in the SASP and senescence-bypass phenotypes.

Hippocampal volume measures the size of the brain region central to memory consolidation and spatial navigation. Atrophy rates vary by cohort and method: meta-analyses report roughly 0.5–1.4 percent per year in cognitively normal controls, accelerating to about 3.5–4 percent per year in Alzheimer's disease. MRI-derived volume serves as an early biomarker of cognitive aging. Aerobic exercise has been shown to preserve or even enlarge it (Erickson et al. 2011, PNAS), while separate lines of evidence link sleep quality and chronic stress to hippocampal structure.

Histone modifications are reversible chemical changes to histone proteins around which DNA is wound, including acetylation, methylation, phosphorylation, and ubiquitination. They reshape chromatin structure and recruit regulatory complexes, thereby controlling gene transcription, DNA repair, and replication. The combined pattern is often called the histone code. Age-related shifts in histone marks contribute to epigenetic drift, loss of cellular identity, and dysregulated stress and longevity pathways.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a fasting blood index calculated as (fasting insulin in µU/mL × fasting glucose in mmol/L) / 22.5, or equivalently (fasting insulin in µU/mL × fasting glucose in mg/dL) / 405. It estimates whole-body insulin resistance from fasting measures, predominantly reflecting hepatic insulin action, as a low-cost surrogate for clamp methods. Cutoffs are population- and assay-dependent, with no universal threshold; values are commonly cited around 2 to 2.9 in adults.

Homocysteine is a sulfur-containing amino acid produced during methionine metabolism and cleared via remethylation or transsulfuration pathways that depend on folate, vitamin B12, and vitamin B6. Elevated plasma homocysteine reflects impaired one-carbon metabolism and is associated with vascular endothelial dysfunction, atherosclerosis, and stroke; cognitive decline and dementia are observationally associated, but causality is uncertain. Major randomized trials of B-vitamin lowering (HOPE-2, NORVIT, VISP, SEARCH, VITATOPS) have not consistently reduced cardiovascular events overall, though some meta-analyses suggest a small reduction in stroke risk. Homocysteine is therefore interpreted as a risk and metabolic-health marker.

Hormesis is a biphasic dose-response phenomenon in which a low or moderate dose of a stressor produces a beneficial adaptive effect, while higher doses are harmful. Mild stressors such as heat, cold, exercise, fasting, or certain phytochemicals can involve activation of defence and adaptive pathways such as Nrf2, heat-shock proteins and AMPK in some settings, with the precise response depending on dose, tissue and context. In longevity research, hormesis is one mechanistic framework, alongside others, for why intermittent stress can extend healthspan in model organisms.

Menopausal HRT replaces estrogen, typically combined with a progestogen in women with a uterus, to relieve vasomotor symptoms, protect bone, and treat genitourinary symptoms. Per WHI re-analyses and the timing hypothesis, the benefit-risk profile is more favorable when initiated within roughly ten years of menopause or before age 60. VTE risk is greater with oral estrogen than with transdermal preparations, and breast cancer risk is greater with combined estrogen+progestogen than estrogen-alone, rising with duration. It is symptom- and risk-directed therapy, not a proven life-extension intervention.

The Horvath clock is a multi-tissue epigenetic age estimator published by Steve Horvath in 2013. It uses DNA methylation levels at 353 CpG sites to predict chronological age across more than 50 tissues and cell types with a median error of about 3.6 years. It is the most-cited epigenetic clock and well validated as a predictor of chronological age, but its association with mortality and disease is weaker than that of later, mortality-trained clocks such as GrimAge.

High-sensitivity C-reactive protein (hs-CRP) is a liver-produced acute-phase protein, induced primarily by IL-6, and measured with an assay sensitive enough to detect low-grade systemic inflammation. Outside acute infection, persistently elevated hs-CRP signals chronic inflammation linked to atherosclerosis, insulin resistance, and metabolic syndrome. hs-CRP is a downstream marker of IL-6–driven inflammation; Mendelian randomization does not support CRP itself as causal for coronary heart disease, while trials targeting upstream inflammation (e.g., CANTOS with canakinumab) reduce cardiovascular events. It remains a useful marker of inflammatory burden associated with cardiovascular and mortality risk.

Hyperbaric oxygen therapy delivers 100% oxygen at pressures typically of 2.0–2.4 atmospheres absolute (with the clinical threshold for HBOT generally defined as at least 1.4 ATA) inside a pressurised chamber, dramatically increasing dissolved oxygen in plasma. It is an established treatment for decompression sickness, carbon monoxide poisoning, and selected non-healing wounds. Off-label longevity uses (telomere length, cognition, anti-ageing) rely on small trials with methodological limits; current evidence does not support routine use for healthy ageing.

Hypoxia training exposes the body to reduced oxygen, either continuously (altitude, hypoxic tents) or intermittently (cycles of low and normal oxygen). Reported adaptations include stabilisation of hypoxia-inducible factor (HIF), and the practice may increase EPO/erythropoiesis and has been associated with mitochondrial adaptations, though magnitude depends strongly on hypoxic dose, duration, and individual factors. Used by endurance athletes and studied for cardiometabolic and cognitive applications, the evidence is heterogeneous, and intermittent hypoxia carries risks particularly in obstructive sleep apnea or certain cardiovascular conditions.

iAge is an inflammatory-age metric introduced by Sayed and colleagues (2021, Stanford) that uses a deep-learning model trained on a panel of 50 circulating cytokines and chemokines from 1,001 healthy individuals across the decade-long Stanford 1000 Immunomes Project. The model compresses the immunome profile into a single inflammatory-age score that predicts cardiovascular risk, multimorbidity, and all-cause mortality independently of chronological age. CXCL9—a chemokine associated with T-cell recruitment and endothelial dysfunction—was identified as the single most informative driver. The clock highlights the immune system as a distinct, targetable dimension of biological ageing.

Insulin-like growth factor 1 (IGF-1) is produced mainly in the liver under growth hormone stimulation and mediates many anabolic GH effects on muscle, bone, and other tissues. As a biomarker it serves as a stable surrogate for GH activity and reflects nutritional status and protein intake. Higher levels in adulthood are linked to greater cancer risk; very low levels are observationally associated with frailty and reduced lean mass, though this association may partly reflect underlying disease or malnutrition rather than a direct causal longevity detriment. The net relationship between IGF-1 and longevity in humans is complex and not simply U-shaped.

IGF-1 signaling refers to the cascade triggered when insulin-like growth factor 1 binds the IGF-1 receptor, activating parallel PI3K/AKT and MAPK/ERK branches that promote cell growth, proliferation, and protein synthesis while suppressing FOXO-driven stress resistance. IGF-1 can also engage insulin/IGF-1R hybrid receptors at lower affinity. Reduced IGF-1 signaling extends lifespan in worms, flies, and mice, and lower circulating IGF-1 is observed in some long-lived human cohorts. The trade-off between growth/repair benefits and longevity costs remains actively debated.

Ikigai is a Japanese concept loosely translated as a sense of purpose or reason for being, encompassing everyday sources of meaning — relationships, routines, small pleasures — as described by Japanese scholars such as Mieko Kamiya. The popular four-circle Venn diagram (what you love / are good at / can be paid for / what the world needs) is not Japanese in origin: it was created by blogger Marc Winn in 2014 by relabeling Andrés Zuzunaga's unrelated 2011 Spanish purpose diagram, and has no documented connection to Okinawa. The underlying construct of life purpose has been linked in observational studies (e.g., Sone et al. 2008, Ohsaki Study) to lower cardiovascular mortality.

Interleukin-10 is a pleiotropic anti-inflammatory cytokine produced primarily by macrophages, T regulatory cells, and B cells that restrains pro-inflammatory signalling by inhibiting the synthesis of cytokines including IL-6, TNF-α, and IL-12 in myeloid cells, partly through suppression of NF-κB and STAT1. In healthy immune homeostasis, IL-10 acts as a critical brake on inflammation, preventing immunopathology during infection and autoimmunity; IL-10 acts antagonistically to pro-inflammatory cytokines such as IL-6 and TNF-α. With aging, the balance between IL-10 and pro-inflammatory cytokines is dysregulated in a context-dependent manner, with some studies reporting impaired IL-10 induction in older individuals while others observe elevated levels, suggesting that the relationship is tissue- and stimulus-specific rather than uniformly declining.

Interleukin-6 (IL-6) is a pleiotropic cytokine produced by immune cells, adipocytes, endothelial cells, and senescent cells that signals through the membrane-bound IL-6 receptor (classical signalling) or through soluble IL-6 receptor trans-signalling, with distinct tissue effects. Acutely, IL-6 is a key inducer of the hepatic acute-phase response — driving CRP, fibrinogen, and serum amyloid A synthesis — and plays an essential role in host defence; after vigorous exercise, skeletal muscle transiently secretes high amounts, reflecting a myokine function. Chronically elevated circulating IL-6, as seen in chronic inflammatory conditions, obesity, and biological aging (inflammaging), is an independent predictor of all-cause and cardiovascular mortality across multiple large prospective cohorts, with prognostic value that remains significant after adjusting for CRP. In longevity research, IL-6 is a central biomarker of inflammaging and a mechanistic target under investigation, given that IL-6 elevation drives downstream pathways linked to sarcopenia, cognitive decline, frailty, and cancer progression.

Immunosenescence is the age-related remodelling of the immune system characterised by a decline in naive lymphocyte output from the thymus and bone marrow, clonal expansion of antigen-experienced memory and effector cells, and a shift in cytokine balance toward a pro-inflammatory baseline. The result is a paradox of concurrent immunodeficiency — reduced capacity to respond to novel pathogens and vaccines — alongside chronic low-grade inflammation (inflammaging). Contributing factors include thymic involution, CMV-driven memory inflation, and accumulating senescent immune cells that secrete SASP components. These changes are associated with increased susceptibility to infections, reduced vaccine efficacy, and higher incidence of autoimmunity and malignancy in older adults.

Inflammaging describes the chronic, low-grade, sterile inflammation that develops with age in the absence of overt infection. It is characterised by often elevated baseline levels of pro-inflammatory mediators such as IL-6, TNF-alpha and CRP, driven by senescent cells, accumulated cellular debris, gut dysbiosis and immune dysregulation. Inflammaging is a recognised hallmark of ageing and, in many studies, an independent risk factor associated with increased risk of cardiovascular disease, neurodegeneration, frailty, sarcopenia and overall mortality.

Insulin resistance is a state in which target tissues respond poorly to insulin, prompting the pancreas to secrete more to maintain glucose homeostasis. Driven by visceral adiposity, ectopic fat in liver and muscle, chronic inflammation, and inactivity, it underlies prediabetes, type 2 diabetes, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Insulin resistance is also associated with accelerated cardiovascular aging, cognitive decline, and shortened healthspan.

Insulin sensitivity describes how effectively cells, especially in muscle, liver, and adipose tissue, respond to insulin to take up glucose and suppress hepatic glucose output. Higher sensitivity allows lower circulating insulin to maintain normoglycemia, reducing strain on pancreatic beta cells. It is improved by physical activity, sleep, low visceral fat, and dietary fiber. Robust insulin sensitivity is a hallmark of metabolic health and longevity-relevant resilience.

The insulin/IGF-1 pathway (often abbreviated IIS) is a conserved nutrient-sensing network in which insulin and IGF-1 bind tyrosine kinase receptors to activate PI3K, AKT, and mTOR while inhibiting FOXO. It coordinates glucose uptake, growth, and anabolic metabolism with nutrient availability. Loss-of-function mutations along this pathway dramatically extend lifespan in C. elegans (daf-2), Drosophila, and mice, establishing IIS as a foundational longevity pathway across the animal kingdom.

The integrated stress response (ISR) is a conserved eukaryotic signalling programme that converges on phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α) by any of four stress-sensing kinases — HRI (haem deficiency), PKR (double-stranded RNA), PERK (ER unfolded proteins) and GCN2 (uncharged tRNAs / amino acid deprivation). eIF2α phosphorylation globally suppresses cap-dependent translation while selectively enhancing translation of stress-response mRNAs containing upstream open reading frames, most notably ATF4, which orchestrates transcriptional adaptation to the specific stress. The ISR supports short-term adaptation but, when chronically active — as seen in neurodegenerative disease, obesity and ageing — impairs synaptic plasticity, memory, and protein synthesis capacity in post-mitotic tissues; small-molecule ISR inhibitors such as ISRIB, which antagonise the inhibitory effect of phospho-eIF2α on eIF2B thereby restoring translation capacity, show efficacy in preclinical models of neurodegeneration and cognitive decline.

Intermittent fasting is an umbrella term for eating patterns that alternate normal intake with extended fasting windows, including 16:8 time-restricted eating, alternate-day fasting, and 5:2 protocols. Fasting periods lower insulin and glycogen, trigger lipolysis and ketogenesis, and induce autophagy. Clinical trials show modest improvements in body composition, glycemic control, and blood pressure; meta-analyses suggest results are broadly comparable to matched continuous calorie reduction, though some trials report small advantages for visceral fat or insulin sensitivity.

Ionized calcium (iCa²⁺), also called free calcium, is the biologically active fraction of total serum calcium, comprising approximately 45–50% of the total and not bound to albumin or complexed with anions such as phosphate and citrate. It is maintained within a narrow range (1.15–1.35 mmol/L) by a tightly coupled hormonal axis involving PTH, calcitriol, and calcitonin acting on bone, kidney, and intestine. Ionized calcium measurement is preferred over total calcium in settings where albumin is abnormal — as in critical illness, liver disease, or hypoalbuminaemia — because total calcium corrected by simple albumin formulas can be unreliable. Hypercalcaemia raises suspicion for primary hyperparathyroidism or malignancy, while hypocalcaemia presents with neuromuscular irritability and, if severe, arrhythmia.

Induced pluripotent stem cells (iPSCs) are adult somatic cells reprogrammed into a pluripotent state using factors such as OSKM (Oct4, Sox2, Klf4, c-Myc), capable of differentiating into any cell type of the body. They bypass the ethical concerns of embryonic stem cells and enable patient-specific disease modeling, drug screening, and autologous cell therapies. In aging research, iPSCs reset many epigenetic age markers, though epigenetic resetting is often incomplete and iPSCs can retain partial donor-cell epigenetic memory, providing a powerful platform to study and reverse cellular aging.

Isometric training involves contracting muscles against an immovable resistance without joint movement, as in planks, wall sits, or holding a mid-range squat. It builds tendon stiffness and joint-angle-specific strength while imposing minimal mechanical stress, making it useful in rehabilitation. A 2023 network meta-analysis (Edwards et al., Br J Sports Med) of 270 randomized trials found isometric exercise — particularly wall sits — produced the largest reductions in resting systolic (~8 mmHg) and diastolic (~4 mmHg) blood pressure among studied modalities, including aerobic and dynamic-resistance training.

The JAK-STAT (Janus kinase – signal transducer and activator of transcription) pathway is a rapid, receptor-proximal signalling cascade through which cytokines and growth factors — including interferons, interleukins, and erythropoietin — transmit signals from the cell surface to the nucleus. Ligand binding induces receptor dimerisation and transphosphorylation of associated JAKs (JAK1, JAK2, JAK3, TYK2), which in turn phosphorylate STATs (STAT1–STAT6), enabling their dimerisation, nuclear translocation, and target gene activation. In ageing, elevated tonic JAK-STAT signalling driven by the SASP and inflammaging-associated cytokines (notably IL-6/JAK1/STAT3 and IL-6/JAK2/STAT3 axes) coexists with reduced cytokine-response amplitude, contributing to chronic tissue dysfunction; JAK1/2 inhibitors such as ruxolitinib have been shown to reduce SASP and improve healthspan parameters in aged mice, and clinical trials are underway.

The Kaplan-Meier estimator is a nonparametric method for estimating the survival function S(t) — the probability of surviving beyond a given time t — from censored time-to-event data. At each event time, the estimate is updated as the ratio of subjects remaining at risk minus those who experienced the event, multiplied forward as a product-limit. The resulting step function graphically displays survival over follow-up and allows group comparisons via the log-rank test. Key assumptions include that censoring is non-informative (i.e., subjects who leave the study do not systematically differ in prognosis) and that survival probability is independent across individuals. The median survival — where the curve crosses 50% — is the standard summary statistic; mean survival is rarely used because it requires the curve to reach zero.

The ketogenic diet is a very-low-carbohydrate (typically <50 g/day), high-fat, moderate-protein eating pattern that drives the body into sustained nutritional ketosis. Originally developed to treat refractory pediatric epilepsy, it is now studied for type 2 diabetes, obesity, and neurodegenerative conditions. Mechanisms include lower insulin, improved metabolic flexibility, and ketone-mediated signaling. Long-term effects on lipid profiles, kidney function, and adherence remain under active investigation.

Ketone bodies are three water-soluble molecules—β-hydroxybutyrate, acetoacetate, and acetone—produced in hepatocyte mitochondria from acetyl-CoA derived from fatty acid β-oxidation when carbohydrate availability is low. Beyond serving as efficient ATP fuel for brain and heart, β-hydroxybutyrate is an endogenous signaling molecule that inhibits class I histone deacetylases, dampens NLRP3 inflammasome activity, and may improve mitochondrial efficiency, mechanisms relevant to fasting biology and longevity research.

Ketosis is a metabolic state in which the liver converts fatty acids into ketone bodies—β-hydroxybutyrate, acetoacetate, and acetone—that serve as alternative fuel for brain, heart, and muscle when glucose is scarce. It is induced by fasting, prolonged exercise, or very-low-carbohydrate diets, with blood β-hydroxybutyrate typically rising above the 0.5 mmol/L nutritional-ketosis threshold described by Volek and Phinney. β-hydroxybutyrate also acts as a signaling molecule, inhibiting class I HDACs and modulating inflammation.

Klotho (here referring to alpha-Klotho, distinct from beta-Klotho) is a transmembrane protein, predominantly expressed in the kidney and brain, that also circulates as a soluble hormone after cleavage. It regulates phosphate and vitamin D homeostasis via FGF23 co-receptor function and modulates several signaling pathways including insulin/IGF-1, Wnt, and others. Klotho-deficient mice show accelerated aging phenotypes, while Klotho overexpression extends lifespan. Higher circulating Klotho levels in humans are associated with better cognitive performance and reduced cardiovascular and renal disease risk.

Klotho is a transmembrane protein and co-receptor for FGF23 that declines markedly with age; its soluble circulating form (s-Klotho) suppresses Wnt and TGF-β signalling and has been associated with renal function, cognitive health, and cardiovascular protection in observational studies. In mouse models, transgenic Klotho overexpression has extended lifespan (Kurosu et al., 2005), and AAV-mediated Klotho gene therapy has improved kidney function and rescued cognitive deficits in disease models. In aged rhesus macaques, peripheral injection of recombinant Klotho protein — not gene therapy — enhanced cognition (Castner et al., 2023); AAV-Klotho gene therapy in primates has not yet been published. Human longevity application remains strictly preclinical; BioViva and affiliated researchers have reported self-administered gene therapy experiments in single individuals outside regulated clinical frameworks, but these lack controlled safety or efficacy data and should not be interpreted as evidence of benefit. Risks include disruption of FGF23-phosphate homeostasis, possible ectopic calcification, and the general immunogenicity and off-target concerns of systemic AAV delivery.

The KL-VS haplotype of the klotho gene (six linked variants in complete linkage disequilibrium, two of which produce the amino-acid substitutions F352V and C370S in exon 2) increases serum klotho protein levels and is associated with longevity in heterozygous but not homozygous carriers — a pattern consistent with heterozygote advantage. Heterozygous KL-VS carriers show elevated circulating klotho and, in several studies, improved cognitive function and reduced dementia risk, with functional MRI data suggesting enhanced prefrontal connectivity (Dubal et al., 2014; Yokoyama et al., 2015). The variant also associates with favorable cardiovascular and bone mineral density profiles in some cohorts. Mechanistically, higher serum klotho is thought to enhance FGF23 co-receptor signaling, modulate Wnt and IGF-1 pathways, and exert neuroprotective effects independently of its endocrine roles.

Alpha-ketoglutarate (AKG) is a key intermediate of the tricarboxylic acid (TCA) cycle that also serves as an obligate co-substrate for a large family of dioxygenases — including TET methylcytosine hydroxylases and Jumonji-domain histone demethylases — that regulate the epigenome. Plasma AKG levels decline substantially with age in humans, which has motivated its supplementation in longevity research. In a 2020 mouse study (Asadi Shahmirzadi et al., Cell Metabolism), the calcium salt form (CaAKG) significantly extended median lifespan in female mice (by approximately 17%, with ~20% extension at the 90th percentile) while males showed only a non-significant numerical trend (~10%); frailty was reduced in both sexes, though the trial was conducted in a single cohort rather than through the rigorous multi-site NIA Interventions Testing Program. A small 7-month open-label observational analysis of 42 self-selected users of the commercial formulation Rejuvant (Katcher et al., 2021) reported reductions in biological age as estimated by the TruAge DNA-methylation clock, but the study was industry-funded, single-arm without randomisation, and lacked a pre-registered primary endpoint. CaAKG is marketed as a supplement; no drug approval exists for aging indications, and independent replication in humans is absent.

Lactate threshold is used loosely for two points: LT1 (aerobic threshold, ~2 mmol/L), where blood lactate first rises above baseline, and LT2, the highest intensity sustainable without progressive accumulation. LT2 is often approximated by OBLA, a fixed ~4 mmol/L criterion, or by MLSS, the highest steady-state workload — these correlate but are not identical, and absolute values vary by protocol and individual. Training near these thresholds increases mitochondrial enzymes and lactate clearance, raising sustainable workload.

Lamin A is a type-V intermediate filament protein and major structural component of the nuclear lamina — the meshwork underlying the inner nuclear membrane — that is essential for nuclear shape, chromatin organisation, DNA repair and gene regulation. It is encoded by LMNA and undergoes post-translational farnesylation and processing before its precursor, prelamin A, is cleaved by the endoprotease ZMPSTE24 to yield mature lamin A. Progerin is a truncated, permanently farnesylated isoform produced by a cryptic splice-site mutation in LMNA that causes the premature ageing syndrome Hutchinson-Gilford progeria; progerin accumulates at low levels during normal ageing and disrupts nuclear architecture, the DNA-damage response and heterochromatin, making it a model for studying molecular mechanisms of physiological ageing at the nuclear envelope.

LC3 lipidation is the covalent conjugation of the autophagy protein LC3 (microtubule-associated protein 1 light chain 3) to phosphatidylethanolamine (PE) in the phagophore and autophagosome membrane, converting cytosolic LC3-I to the membrane-anchored LC3-II form. The reaction is executed by a ubiquitin-like cascade involving the E1-like enzyme ATG7, the E2-like enzyme ATG3, and the E3-like ATG5-ATG12-ATG16L1 complex, and is dependent on prior phosphatidylinositol 3-phosphate (PI3P) generation by the Beclin-1/VPS34 complex. LC3-II density on autophagosomal membranes recruits selective autophagy receptors such as p62 and NDP52 and is the most widely used proxy for autophagosome abundance; the ratio of LC3-II to LC3-I, measured by immunoblot in the presence and absence of lysosomal inhibitors, is a standard method for estimating autophagic flux.

LDL cholesterol (low-density lipoprotein cholesterol) reflects the cholesterol carried by LDL particles in the bloodstream. Excess ApoB-containing LDL particles can enter and be retained in the arterial intima, where modification (e.g., oxidation) and inflammation drive atherosclerotic plaque formation. LDL-C is a long-established causal risk factor for atherosclerotic cardiovascular disease, heart attack, and stroke; lifelong genetically lower LDL-C (e.g., PCSK9 loss-of-function variants) reduces ASCVD risk dose-dependently. From a longevity perspective LDL-C is lower-is-better, ideally interpreted alongside ApoB and Lp(a), as LDL-C and ApoB can be discordant. Current reference documents include the 2025 ESC/EAS Focused Update and the 2026 ACC/AHA Dyslipidemia Guidelines.

LDL-P, or LDL particle number, quantifies the total concentration of low-density lipoprotein particles in plasma rather than their cholesterol payload, typically measured by nuclear magnetic resonance (NMR) spectroscopy or ion-mobility analysis. Because each LDL particle carries one apolipoprotein B-100 molecule, LDL-P is conceptually equivalent to (and strongly correlated with) the apoB-bearing atherogenic particle count; both reflect the atherogenic particle burden available for subendothelial retention, though units differ (LDL-P in nmol/L vs apoB in mg/dL) and apoB additionally counts VLDL/IDL/Lp(a) particles. In discordance analyses — where LDL-C and LDL-P diverge, most commonly in the setting of hypertriglyceridaemia, insulin resistance, or low HDL — LDL-P is consistently the stronger predictor of cardiovascular events, supporting the concept that it is particle number rather than cholesterol mass per particle that drives atherosclerosis risk. Reference intervals are typically reported as nmol/L, with higher cardiovascular risk associated with LDL-P above approximately 1,000–1,200 nmol/L.

Leptin is a 16-kDa adipokine secreted by white adipose tissue in proportion to fat mass; it acts on hypothalamic receptors, particularly in the arcuate nucleus, to suppress appetite via melanocortin signaling and stimulate energy expenditure, functioning as the primary long-term adiposity signal. Plasma leptin levels follow a diurnal pattern and are acutely influenced by insulin; sustained fasting or weight loss reduces leptin, while weight gain raises it over days to weeks. Leptin resistance is a state in which the brain responds inadequately to circulating leptin despite normal or elevated levels, perpetuating hyperphagia and reduced energy expenditure; proposed mechanisms include impaired leptin transport across the blood-brain barrier, receptor downregulation, and disruption of JAK2/STAT3 signaling by inflammatory mediators such as SOCS3. Leptin resistance is present in most obese individuals and is associated with insulin resistance, metabolic syndrome, and impaired recovery of weight-loss-induced leptin deficiency.

Lewy bodies are eosinophilic intraneuronal inclusions composed predominantly of aggregated α-synuclein protein, first described by Friedrich Lewy in 1912 and identified as the defining pathological feature of Parkinson's disease, dementia with Lewy bodies (DLB), and Parkinson's disease dementia. α-Synuclein (encoded by SNCA) is a presynaptic protein involved in dopaminergic vesicle trafficking; under conditions that include genetic mutations or multiplications of SNCA, oxidative stress, impaired autophagy and lysosomal dysfunction, it misfolds and self-assembles into oligomers and then amyloid-like fibrils that propagate between neurons in a prion-like fashion consistent with Braak's staging of Parkinson's pathology. Whether α-synuclein aggregation is the primary driver of neurodegeneration or a consequence of upstream cellular failure is debated, though the discovery of SNCA multiplications causing familial Parkinson's and the toxicity of oligomeric species in cellular models favour a causal role. In DLB — the second most common neurodegenerative dementia — Lewy body pathology produces fluctuating cognition, visual hallucinations, REM sleep behaviour disorder and parkinsonism, often in combination with Alzheimer co-pathology.

Lifespan is the total length of time an organism lives, from birth to death, typically expressed in years for humans. In population terms it is summarised by life expectancy at birth or at a given age. Maximum lifespan refers to the longest documented age reached within a species; for humans this is around 122 years. Lifespan is influenced by genetics, environment, behaviour and access to medical care, and is a classic outcome in longevity research.

Artificial light at night (ALAN) — from street lighting, screens and indoor illumination — suppresses melatonin secretion via intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing melanopsin, which are maximally sensitive to short-wavelength (~480 nm) blue light, thereby delaying or blunting the nocturnal melatonin surge and phase-shifting the master circadian clock in the suprachiasmatic nucleus. Chronic circadian misalignment is linked to impaired immune function, metabolic dysregulation, cardiovascular risk and accelerated epigenetic ageing. Epidemiological research by Erren and colleagues, along with multiple large cohort studies, has identified associations between ALAN exposure and elevated incidence of breast and prostate cancer, possibly through melatonin-mediated effects on cell proliferation. Urbanisation trajectories project continued increases in global ALAN intensity, making the biological effects of outdoor and indoor light environment increasingly relevant to public health.

Long interspersed nuclear elements-1 (LINE-1, or L1) are autonomous retrotransposons that comprise roughly 17% of the human genome; they encode the proteins ORF1p and ORF2p, which mediate a copy-and-paste mechanism by which LINE-1 sequences can replicate via an RNA intermediate and insert new copies elsewhere in the genome. In somatic cells, LINE-1 elements are normally silenced through DNA methylation, H3K9me3 heterochromatin and the PIWI-piRNA system, but their repression weakens with age as heterochromatin erodes. Reactivated LINE-1 elements can trigger cGAS-STING innate immune sensing via cytosolic reverse-transcribed DNA, promote genomic instability through new insertions, and contribute to the inflammatory milieu of aged cells; reverse transcriptase inhibitors such as lamivudine have been shown in mouse models to suppress LINE-1-driven inflammation and extend healthspan in some settings.

Lipid peroxidation is an autocatalytic, radical-mediated oxidative degradation of polyunsaturated fatty acids (PUFAs) in cell membranes, lipoproteins, and lipid droplets, initiated when reactive oxygen species (ROS) or other radicals abstract a bis-allylic hydrogen atom from a PUFA chain. The resulting lipid radical reacts with molecular oxygen to form a lipid peroxyl radical, which propagates the chain reaction and yields end-products including malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) — reactive aldehydes that form adducts with proteins and DNA. Elevated lipid peroxidation is implicated in membrane dysfunction, mitochondrial damage, and ferroptosis, a form of regulated cell death driven by uncontrolled phospholipid peroxidation that is increasingly linked to neurodegenerative and cardiovascular ageing pathology.

LMNA encodes the nuclear lamina proteins Lamin A and Lamin C through alternative splicing; the lamins form a filamentous meshwork underlying the inner nuclear membrane that provides mechanical support and organizes peripheral chromatin, influencing gene expression, DNA repair, and nuclear shape. A de novo C→T transition at position 1824 (c.1824C>T; G608G) in exon 11 activates a cryptic splice site, producing a truncated and permanently farnesylated Lamin A isoform called progerin, which causes Hutchinson-Gilford Progeria Syndrome (HGPS) — a devastating childhood progeroid syndrome with accelerated cardiovascular disease and a median survival of approximately 14 years. Importantly, low levels of the same aberrant splice product accumulate in normal aging cells even without the HGPS mutation, and nuclear lamina integrity declines broadly with age, suggesting LMNA biology has relevance beyond the rare syndrome. Lonafarnib (Zokinvy), a farnesyltransferase inhibitor that blocks progerin farnesylation, received FDA approval in November 2020 for HGPS and extends median survival by approximately 2.5 years; additional progerin-targeting approaches are in early investigation.

Loneliness, the subjective feeling of social disconnection, is now recognised as an independent risk factor for cardiovascular disease, dementia, and early mortality. Meta-analyses by Holt-Lunstad and colleagues found that strong social relationships were associated with ~50% greater odds of survival (2010, PLOS Medicine), and that social isolation, loneliness, and living alone independently raise all-cause mortality risk by roughly 26–32% (2015, Perspectives on Psychological Science) — an effect Holt-Lunstad has compared by analogy to the mortality risk of smoking up to 15 cigarettes a day, a framing later cited in the 2023 US Surgeon General's Advisory on the epidemic of loneliness and isolation. It dysregulates inflammation, sleep, and HPA-axis stress responses. In longevity science, addressing loneliness through community, purpose, and relationships is a primary, evidence-based intervention.

Longevity escape velocity describes a hypothetical threshold at which medical advances extend remaining life expectancy by more than one year per calendar year, effectively outrunning aging. Popularized by biogerontologist Aubrey de Grey in the early 2000s, it remains a speculative concept rather than an empirically validated milestone. Mainstream geroscience treats it as an aspirational framing rather than a near-term forecast.

Loss of proteostasis is one of the established hallmarks of aging and describes the age-related decline of the protein quality control network. Chaperones become less efficient, the proteasome and autophagy slow down, and misfolded or aggregation-prone proteins accumulate. The resulting proteotoxicity contributes to neurodegenerative disorders, cardiac amyloidosis, and cellular dysfunction across tissues, making proteostasis enhancers an active longevity research target.

Lipoprotein(a) is an LDL-like particle in which apolipoprotein(a) is covalently linked to apoB-100 via a disulfide bond. Plasma levels are largely (often cited around 70–90%) genetically determined and usually stable across adulthood, although modest changes can occur with menopause, kidney disease, or inflammation. Mendelian randomization at the LPA locus supports a causal role for elevated Lp(a) in myocardial infarction, ischemic stroke, and calcific aortic valve stenosis. Because diet and lifestyle barely influence it, Lp(a) should be measured at least once to stratify lifetime cardiovascular risk. Per EAS 2022 thresholds, rule-in risk levels are >50 mg/dL (>125 nmol/L) and rule-out levels are <30 mg/dL (<75 nmol/L).

Lipopolysaccharide (LPS) is a structural component of the outer membrane of Gram-negative bacteria; when shed by bacteria at cell death or division, it is the most potent ligand for Toll-like receptor 4 (TLR4) and a primary driver of the inflammatory cascade in sepsis. In metabolic endotoxemia — a term coined by Cani and colleagues in a 2007 Diabetes paper — low but chronically elevated circulating LPS levels (2- to 3-fold above fasting baseline) arise from impaired intestinal barrier function and increased chylomicron-mediated translocation of LPS after high-fat feeding. The resulting low-grade TLR4 activation on hepatocytes, adipocytes and macrophages promotes insulin resistance, adipose tissue inflammation and hepatic steatosis in rodent models. The phrase 'leaky gut' is a popular shorthand for increased intestinal permeability, but it is informal and mechanistically imprecise; barrier function is controlled by tight junction proteins (occludin, claudins, ZO-1) whose downregulation, along with reduced mucus layer thickness, is demonstrably altered by certain dietary patterns and dysbiosis. Human evidence for a causal metabolic endotoxemia–disease pathway is supportive but not conclusive, and circulating LPS is technically difficult to measure accurately.

The absolute lymphocyte count (ALC) is the total number of circulating lymphocytes — comprising T cells, B cells, and NK cells — derived from a complete blood count differential. In adults, the normal range is approximately 1.0–4.0 × 10⁹/L. Lymphopenia (ALC <1.0 × 10⁹/L) is a recognized marker of immune deficiency and occurs in HIV infection, autoimmune diseases, lymphoma, following chemotherapy or radiotherapy, and in severe malnutrition. With aging, the absolute count tends to decline and the composition shifts — naïve T cells decrease while memory and effector cells accumulate — a constellation termed immunosenescence. Population studies consistently link lower lymphocyte count with higher all-cause mortality, greater frailty, and increased infection vulnerability, and ALC is a component of several validated biological aging indices. Importantly, lymphopenia was a strong predictor of severe COVID-19, underscoring its broader role as a marker of immune reserve.

The lysosome is a membrane-bound organelle filled with acidic hydrolases that degrade proteins, lipids, nucleic acids, and carbohydrates delivered via endocytosis, phagocytosis, or autophagy. Beyond digestion, it acts as a metabolic and signaling hub that senses nutrients through the mTORC1 pathway. Lysosomal dysfunction underlies storage diseases and contributes to aging by impairing autophagy, clearance of lipofuscin, and overall cellular waste management.

The M1/M2 framework describes macrophage activation states at two functional extremes: M1 (classically activated) macrophages, induced by IFN-γ and LPS, produce pro-inflammatory mediators including TNF-α, IL-6, IL-12, and reactive oxygen species; M2 (alternatively activated) macrophages, induced principally by IL-4 and IL-13 (and deactivated/suppressed by IL-10), promote tissue repair, phagocytosis of debris, and anti-inflammatory resolution. It is important to note that this binary model is a pedagogical simplification — current transcriptomic and proteomic data support a continuum of macrophage states that do not neatly map onto two poles. With aging, tissue macrophages tend toward a dysregulated inflammatory baseline, impairing resolution of acute inflammation and contributing to the chronic sterile inflammation underlying inflammaging.

Serum magnesium reflects the small circulating fraction of total body magnesium, with roughly 99% stored in bone, muscle, and soft tissue, making serum levels an insensitive indicator of intracellular magnesium status. Magnesium is an essential cofactor for hundreds of enzymatic reactions including ATP synthesis, DNA replication and repair, and serves as a physiological calcium channel antagonist involved in neuromuscular transmission and cardiac rhythm. Hypomagnesaemia (typically below 0.75 mmol/L) is associated with cardiac arrhythmias, neuromuscular excitability, insulin resistance, and increased vascular calcification; it is common in type 2 diabetes, chronic alcohol use, and with prolonged use of proton pump inhibitors or loop diuretics. Epidemiological data link lower habitual magnesium intake and lower serum levels with higher all-cause mortality and accelerated biological aging.

MASLD (metabolic dysfunction-associated steatotic liver disease) is the 2023 reclassification of what was previously called non-alcoholic fatty liver disease (NAFLD), agreed by major hepatology societies including EASL, AASLD, and ALEH. The new nomenclature shifts from exclusion-based (excluding alcohol) to inclusion-based criteria: steatosis on imaging or biopsy must co-occur with at least one of five cardiometabolic risk factors (overweight/obesity, prediabetes or T2D, elevated blood pressure, elevated triglycerides, or low HDL), reflecting the metabolic substrate of the disease. Patients who drink above defined alcohol thresholds but also meet cardiometabolic criteria are classified as MetALD. The histological spectrum progresses from simple steatosis through metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) to fibrosis, cirrhosis, and hepatocellular carcinoma. MASLD affects an estimated 25–32% of adults globally and is a leading cause of liver-transplant waitlisting in the United States and several other high-income countries.

Maximum heart rate (HRmax) is the highest beats per minute the heart reaches during all-out exertion. It is largely determined by age and genetics, not fitness, and declines with age. HRmax sets training zones for Zone 2 and HIIT. The classic 220 minus age formula is rough; Tanaka (208 − 0.7 × age) outperforms it, especially in older adults, but direct measurement in a maximal test remains the gold standard.

The Mediterranean diet is an eating pattern emphasizing vegetables, fruits, legumes, whole grains, nuts, olive oil, and fish, with moderate dairy and limited red meat. Rich in monounsaturated fats, fiber, and polyphenols, it is associated with lower systemic inflammation, improved lipid profiles, and better endothelial function. Long-term adherence is associated in cohort studies and the PREDIMED trial (which tested Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts; retracted and republished in 2018) with reduced cardiovascular events, type 2 diabetes risk, and all-cause mortality.

Melatonin is a hormone secreted by the pineal gland in response to darkness, signalling biological night and helping align the circadian system. It facilitates sleep onset, modulates core body temperature, and exerts antioxidant effects. Endogenous melatonin declines with age, and bright evening light suppresses its release. Low-dose exogenous melatonin is used to address jet lag, shift work, and delayed sleep-phase patterns.

Mendelian randomization (MR) uses germline genetic variants — typically single-nucleotide polymorphisms associated with an exposure in a genome-wide association study — as instrumental variables to estimate the causal effect of that exposure on an outcome, exploiting the random allocation of alleles at conception as a natural experiment. The method relies on three core assumptions: the instrument is robustly associated with the exposure (relevance), affects the outcome only through that exposure (exclusion restriction), and is independent of confounders (independence). Violations — through pleiotropy, population stratification, or weak instruments — are major pitfalls; sensitivity analyses including MR-Egger, weighted-median, and CAUSE help detect and partially correct for horizontal pleiotropy. In longevity research, MR has been widely used to test causal links between biomarkers such as LDL-C, CRP, IGF-1, or BMI and lifespan outcomes without requiring decades-long randomized trials.

Mesenchymal stem cells (MSCs) are multipotent stromal progenitors capable of differentiating into osteoblasts, chondrocytes, and adipocytes, and are isolated from bone marrow, adipose tissue, umbilical cord (Wharton's jelly), placenta, and dental pulp, with umbilical cord-derived MSCs increasingly favoured for allogeneic use due to lower immunogenicity and higher proliferative capacity. Despite early assumptions of direct tissue engraftment and replacement, current evidence indicates that transplanted MSCs rarely engraft stably at target tissues; instead, the dominant mechanism of action is paracrine, mediated by secreted cytokines, growth factors, extracellular vesicles (exosomes and microvesicles), and mitochondrial transfer, which modulate local immune responses, reduce fibrosis, support angiogenesis, and dampen senescent cell secretome activity. In age-related and chronic disease contexts, MSC therapies have been investigated in clinical trials for osteoarthritis, graft-versus-host disease, Crohn's disease, heart failure, COPD, and frailty, with graft-versus-host disease being the setting with the most established regulatory acceptance in some jurisdictions. For aging and longevity applications specifically, small trials have reported functional improvements in frailty endpoints, but sample sizes, follow-up durations, and outcome standardization remain insufficient for definitive conclusions. Regulatory status varies by region: the EMA and FDA require approval as advanced-therapy medicinal products (ATMPs) or biologics, and many administered products operate outside approved frameworks. Long-term safety data, including oncogenicity risk from repeated dosing, are not fully established.

Metabolic flexibility is the capacity of cells and the whole organism to switch efficiently between fuel sources—primarily glucose and fatty acids—in response to feeding, fasting, and physical activity. It depends on intact mitochondrial function, insulin sensitivity, and hormonal signaling. Loss of flexibility, marked by impaired fasting fat oxidation and postprandial glucose handling, is a hallmark of insulin resistance, obesity, and aging, and is a key target of fasting and exercise interventions.

Metabolic syndrome is a cluster of interrelated cardiometabolic risk factors that substantially amplify the risk of type 2 diabetes, cardiovascular disease, and premature mortality. The most widely applied diagnostic criteria are those of the International Diabetes Federation (IDF) and the harmonised joint scientific statement (IDF/AHA/NHLBI, 2009), which require the presence of three or more of five components: elevated waist circumference (with ethnicity-specific thresholds), elevated fasting triglycerides (≥150 mg/dL), reduced HDL-cholesterol (<40 mg/dL in men, <50 mg/dL in women), elevated blood pressure (≥130/85 mmHg), and elevated fasting glucose (≥100 mg/dL). Insulin resistance and abdominal adiposity are considered the central drivers. Prevalence exceeds 30% in Western adult populations and rises with age, making metabolic syndrome a key target of lifestyle and pharmacological longevity interventions.

Metformin is a biguanide oral antidiabetic drug, first-line therapy for type 2 diabetes mellitus. It lowers hepatic gluconeogenesis and improves insulin sensitivity, partly via mitochondrial complex I inhibition and indirect AMPK activation. Observational data suggest reduced all-cause mortality and cancer incidence in diabetics, motivating the still-largely-unfunded TAME trial proposal (delayed since 2016, partial ARPA-H involvement announced 2024 but enrollment not yet confirmed). Off-label longevity use remains investigational; benefit in metabolically healthy people is unproven and may even blunt exercise adaptations.

Methylene blue (MB) is a synthetic phenothiazine dye with FDA approval (Provayblue, 2016) for treatment of acquired methemoglobinemia at an initial dose of 1 mg/kg intravenously, with a repeat dose of 1 mg/kg if needed (total up to 2 mg/kg). At low concentrations (nanomolar to low micromolar), it acts as a redox cycler in the mitochondrial electron transport chain, accepting electrons from NADH and donating them to cytochrome c, thereby bypassing dysfunctional complexes I and III and supporting ATP synthesis. In cell culture and rodent models, low-dose MB has reduced mitochondrial reactive oxygen species, improved memory in aged animals, and attenuated neurodegeneration-related pathology. Interest in MB for aging stems partly from a small number of human trials investigating cognitive effects in healthy older adults or early Alzheimer's disease, with mixed and modest results; no aging or longevity indication has been approved, regulatory frameworks for low-dose oral use vary by country, and recommendations for off-label use as a longevity agent are unsupported by RCT evidence.

Microbiome diversity describes the richness and evenness of microbial community composition within a single sample (alpha diversity) or across samples (beta diversity). The Shannon entropy index, which accounts for both species richness and relative abundance, is one of the most widely used alpha-diversity metrics; higher Shannon index values indicate a more complex community in which no single taxon dominates. Higher alpha diversity has been broadly associated with resilience, metabolic health and lower risk of conditions such as inflammatory bowel disease, though the relationship is not universal — some disease states feature increased diversity in anatomically inappropriate communities. Population studies consistently show that alpha diversity declines with age, particularly after the seventh decade, and that this decline correlates with frailty, hospitalisation and reduced survival. Diversity should be interpreted with caution as a standalone health proxy: functional redundancy means that a numerically diverse community can still lack critical pathways, and 16S rRNA sequencing depth and primers substantially affect measured diversity values.

Microglia are the brain's resident innate immune cells, derived from yolk-sac progenitors that colonise the CNS during early embryogenesis and are maintained independently of peripheral monocytes. In their homeostatic state they continuously survey the parenchyma with ramified processes, pruning synapses, clearing apoptotic debris and releasing neurotrophic factors. With age, microglia shift toward a 'primed' or dystrophic state characterised by altered morphology, impaired phagocytosis and heightened inflammatory reactivity to secondary stimuli, contributing to neuroinflammation. In Alzheimer's disease, GWAS hits in genes such as TREM2, CR1 and BIN1 strongly implicate microglial dysfunction in pathogenesis, positioning microglia as both sensors of amyloid and tau pathology and as active modulators of disease progression.

Microplastics are solid plastic particles smaller than 5 mm, encompassing nanoplastics at the sub-micron scale, originating from the fragmentation of larger plastic debris, synthetic textiles, tyre wear and personal-care products. They have been detected in human blood, placental tissue, breast milk and, in a 2024 NEJM study by Marfella and colleagues, within carotid artery atheromas — patients with detectable plaque microplastics had a significantly higher risk of myocardial infarction, stroke and death over a mean follow-up of approximately 34 months. Proposed mechanisms of harm include local inflammatory responses, endocrine disruption via adsorbed chemical additives such as phthalates and bisphenols, and oxidative stress, though dose-response relationships in humans remain poorly characterised. Clinical significance and safe threshold levels have not yet been established, and no validated reduction strategy exists beyond minimising dietary and inhalation exposure.

Defined by Petersen's diagnostic criteria (objective cognitive decline on testing, preserved daily functioning, not meeting dementia threshold), mild cognitive impairment exceeds normal aging without impairing independence. Roughly 10 to 15 percent of people with MCI progress to dementia each year in clinic-based cohorts, with lower rates in community samples. In longevity medicine it is a critical intervention window: lifestyle changes, treatment of vascular risk, sleep optimisation, and hearing correction can stabilise or partially reverse symptoms.

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is a hybrid eating pattern targeting brain health. It emphasizes leafy greens, berries, nuts, whole grains, beans, fish, poultry, and olive oil while limiting red meat, butter, cheese, pastries, and fried food. Observational studies link higher adherence to slower cognitive decline and lower Alzheimer's incidence, though a 2023 randomized trial showed only modest cognitive effects over three years.

Mindfulness is the trained practice of bringing non-judgmental attention to present-moment experience, typically through meditation. Randomised trials show modest but consistent benefits for stress, anxiety, depression, chronic pain, and blood pressure. Some studies have linked long-term mindfulness practice to longer leukocyte telomeres and modestly reduced inflammatory markers, though findings are inconsistent and effect sizes are small. It remains a low-risk adjunct to standard brain-health and cardiometabolic interventions.

Mitochondrial biogenesis is the process by which cells increase mitochondrial mass and capacity by coordinating the expression of nuclear and mitochondrial genes. The transcriptional coactivator PGC-1-alpha is a key nodal regulator, regulated by AMPK and SIRT1 among other signals. Endurance exercise, caloric restriction, and cold exposure are well-established physiological stimuli, and robust biogenesis is associated with muscular endurance, metabolic flexibility, and healthy aging.

Mitochondrial density refers to the number and volume of mitochondria per unit of muscle tissue. Higher density expands oxidative capacity, allowing more fatty acids and pyruvate to be burned aerobically and improving endurance and metabolic flexibility. Aerobic and Zone 2 training stimulate mitochondrial biogenesis via PGC-1α, while age and inactivity reduce it. Maintaining mitochondrial density is considered central to healthy aging and cardiorespiratory fitness.

Mitochondrial DNA (mtDNA) is a circular, double-stranded genome of approximately 16,569 base pairs present in multiple copies per cell that encodes 13 essential subunits of the oxidative phosphorylation complexes, 22 transfer RNAs and 2 ribosomal RNAs required for their mitochondria-local translation. Unlike nuclear DNA, mtDNA is packaged in nucleoids without protective histones, is physically proximate to the electron transport chain — a major ROS source — and relies on a distinct and less-redundant set of repair enzymes, making it more susceptible to oxidative damage. Somatic mtDNA mutations and deletions accumulate with age and are elevated in post-mitotic tissues such as muscle and brain; their functional significance ranges from contributing to mitochondrial dysfunction when heteroplasmy crosses threshold levels to triggering cGAS-STING innate immune activation when cytosolic mtDNA is released during cellular stress.

Mitochondrial dysfunction refers to a decline in mitochondrial efficiency, including reduced ATP output, impaired electron transport chain activity, increased reactive oxygen species, and altered mitochondrial dynamics. It is recognized as a hallmark of aging and is implicated in sarcopenia, type 2 diabetes, neurodegeneration, and cardiovascular disease. Interventions under study include exercise, NAD+ precursors, urolithin A, and senolytics, while extreme antioxidant supplementation has not shown longevity benefit.

Mitochondrial haplogroups are clusters of maternally inherited mitochondrial DNA (mtDNA) haplotypes defined by shared polymorphisms, reflecting ancient migration patterns and geographic lineages. Because mtDNA encodes 13 essential respiratory-chain subunits and 22 tRNAs, haplogroup-defining variants can subtly alter oxidative phosphorylation efficiency, reactive oxygen species production, and mitochondrial morphology. Several studies have reported associations between specific haplogroups and longevity, most notably sub-haplogroups D4a and D5 among Japanese centenarians (Tanaka et al.), and haplogroup J in some European centenarian cohorts; however, replication across populations is inconsistent, sample sizes in the original studies were modest, and population stratification is a persistent confound. Mitochondrial haplogroups therefore represent plausible but not firmly established modulators of aging trajectory.

Mitochondrial respiratory capacity is the maximal rate of oxygen flux through the electron transport chain (ETC) under substrate-saturating, ADP-saturating conditions, distinct from mitochondrial density which reflects organelle abundance. It is most precisely quantified ex vivo by high-resolution respirometry (HRR) in permeabilized muscle fibers: OXPHOS-coupled state-3 respiration measures ATP-linked flux, while FCCP-uncoupled (ETS) respiration reveals the theoretical ceiling of inner-membrane electron transfer capacity. Key determinants include complex I–IV catalytic activity, inner-membrane surface area, and the availability of electron donors (NADH, FADH₂). Reduced ETS capacity with aging — partly reflecting cristae remodeling and complex I dysfunction — correlates with declines in VO2max, insulin sensitivity, and physical function; aerobic training and caloric restriction upregulate ETS capacity even in older adults.

Mitochondrial transplantation involves the direct transfer of intact, metabolically functional mitochondria — isolated from autologous or allogeneic tissue — into ischaemic or otherwise bioenergetically compromised cells or organs to supplement or replace dysfunctional mitochondria. The best-documented clinical context is paediatric cardiac surgery: McCully and colleagues (Boston Children's Hospital) reported in a preliminary 2017 JTCVS communication that autologous mitochondria injected into ischaemia-injured myocardium improved ventricular function in children with postcardiotomy ECMO-dependent cardiogenic shock; a larger 2020 JTCVS case series (n=24) showed 80% successful ECMO separation versus 29% in controls. This application is now in early clinical study (NCT02851758). Mechanistic proposals include import via clathrin-mediated endocytosis, macropinocytosis, and direct membrane fusion, though the dominant uptake pathway and long-term mitochondrial survival in recipient cells remain under investigation. Application to aging is hypothetical: in preclinical models, intravenous mitochondrial infusion has been reported to improve muscle function and cognitive markers in aged rodents, but the route, source tissue, dosing, and safety profile for systemic aging applications are not established, and no approved indication for aging exists.

The mitochondrial unfolded protein response (mtUPR) is a stress-signalling pathway activated when the capacity of mitochondrial chaperones — including HSP60, HSP70 and the AAA+ protease ClpP — is overwhelmed by misfolded or aggregated proteins within the mitochondrial matrix. In Caenorhabditis elegans, mtUPR is mediated by the transcription factor ATFS-1, which under stress traffics to the nucleus rather than being imported into mitochondria; in mammals, the homologous pathway involves ATF5 along with other transcription factors including ATF4 and CHOP. Activation of the mtUPR upregulates mitochondrial chaperones, proteases and metabolic genes to restore organelle homeostasis, and its induction by interventions such as NAD+ precursors and mild mitochondrial stress has been linked to lifespan extension in model organisms, though the translation to mammals is not fully established.

Mitophagy is the selective form of autophagy that targets damaged or depolarized mitochondria for lysosomal degradation, with the PINK1/Parkin pathway being the best-characterized route alongside PINK1/Parkin-independent receptor pathways. By removing dysfunctional mitochondria, it can help limit oxidative stress and support bioenergetic function. Impaired mitophagy is linked to neurodegeneration, sarcopenia, and cardiovascular aging, and compounds such as urolithin A are studied for effects consistent with enhanced mitophagy markers, including in older and middle-aged adults.

The Mini-Mental State Examination (MMSE), introduced by Folstein, Folstein and McHugh in 1975, is a 30-point structured clinical interview assessing orientation, registration, attention/calculation, recall, language and visuoconstructional ability; it can be administered in 5–10 minutes. Scores of 24–30 are typically classified as normal, 18–23 as mild, 10–17 as moderate and below 10 as severe cognitive impairment. The MMSE was historically the dominant dementia screening tool and remains widely used in clinical practice and trials as a tracking measure, but it has well-documented ceiling effects for MCI detection — sensitivity for MCI is low — and scores are substantially affected by education level, language background and sensory impairment. The MoCA has largely superseded it for MCI screening in research settings, while the MMSE retains utility for staging and longitudinal monitoring of established dementia.

The Montreal Cognitive Assessment (MoCA), developed by Ziad Nasreddine and published in 2005, is a 30-point, 10-minute bedside screening tool covering visuospatial/executive function, naming, memory, attention, language, abstraction and orientation. Its sensitivity for detecting mild cognitive impairment (MCI) is substantially higher than the MMSE — approximately 90% in the original validation study (Nasreddine 2005), with a range of 80–100% across populations, versus 18–45% for the MMSE in clinic-based studies — making it the preferred first-line screen for subtle cognitive change. A score of 26 or above is conventionally considered normal, with one point added for fewer than 12 years of education, though this threshold has been debated given that scores are influenced by education, language proficiency and cultural background, requiring local normative data for valid interpretation. The MoCA is a screening instrument, not a diagnostic test; abnormal scores require further neuropsychological assessment.

Mortality doubling time (MDT) is the number of years it takes for age-specific mortality risk to double, derived directly from the Gompertz exponent b as MDT = ln(2)/b. In contemporary high-income populations, the MDT for all-cause mortality is approximately 7–8 years in mid-adulthood, meaning a 50-year-old's annual risk of dying is roughly twice that of a 42–43-year-old. MDT is a compact summary of the rate of actuarial ageing and is used comparatively across species (where it varies from months in short-lived organisms to decades in naked mole-rats and humans) and across population subgroups, enabling detection of interventions that alter ageing rate rather than merely shifting baseline mortality.

The C677T polymorphism (rs1801133) in methylenetetrahydrofolate reductase (MTHFR) encodes a thermolabile enzyme with reduced activity (~70% reduced activity / ~30% residual in TT homozygotes and ~35% reduced / ~65% residual in CT heterozygotes, particularly under low-folate conditions) and causes modest elevation of plasma homocysteine. Elevated homocysteine has been epidemiologically associated with cardiovascular disease and neural tube defects, and the variant is correspondingly associated with those outcomes, though the causal role of homocysteine itself remains debated. The clinical relevance of MTHFR C677T genotyping is contested: major laboratory and genetics societies advise against routine population testing, noting that the association is modest, diet-modifiable, and that homocysteine-lowering B-vitamin supplementation has not consistently reduced cardiovascular events in trials. Despite its limited clinical actionability, it remains one of the most over-ordered genetic tests in functional medicine contexts.

mTOR (mechanistic target of rapamycin) is a serine/threonine kinase that integrates signals from amino acids, growth factors, and cellular energy status to regulate protein synthesis, cell growth, and autophagy. It functions in two complexes, mTORC1 and mTORC2. Chronic mTORC1 hyperactivation accelerates aging phenotypes, while pharmacologic inhibition with rapamycin extends lifespan in multiple model organisms, making mTOR one of the most validated longevity targets.

The mechanistic target of rapamycin (mTOR) kinase assembles into two structurally and functionally distinct multi-protein complexes: mTORC1, defined by its scaffold subunit Raptor, and mTORC2, defined by Rictor. mTORC1 integrates signals from amino acids, insulin, energy status and growth factors to promote anabolic processes — principally ribosome biogenesis via S6K1 and 4E-BP1 phosphorylation — and to suppress autophagy by phosphorylating ULK1; it is acutely sensitive to allosteric inhibition by rapamycin. mTORC2, by contrast, is rapamycin-insensitive under standard conditions, phosphorylates AKT at Ser473 to regulate cell survival and cytoskeletal organisation, and feeds into the PI3K/AKT/FOXO axis. In the context of ageing, chronic mTORC1 hyperactivity is considered a principal driver of anabolic imbalance and suppressed autophagy, while the differential contributions of each complex to lifespan extension — particularly when mTOR is inhibited globally — remain an active area of investigation.

Multimorbidity is defined as the co-occurrence of two or more chronic conditions within the same person, without designating a primary or index disease — a distinction from the related but person-centred concept of comorbidity. Its prevalence rises sharply with age: roughly 50% of adults over 65 in high-income countries live with three or more chronic conditions. Multimorbidity is strongly associated with polypharmacy, functional decline, reduced quality of life, greater healthcare utilisation and higher mortality, and it challenges single-disease clinical guidelines that were developed in trial populations that often excluded it. In geroscience, multimorbidity is both a key outcome of biological aging and a prime motivation for targeting upstream aging processes rather than individual diseases sequentially.

N-acetylcysteine is an acetylated form of the amino acid cysteine, used clinically as a mucolytic and as the standard antidote for paracetamol (acetaminophen) overdose. Its principal mechanism in both clinical and longevity contexts is replenishment of intracellular cysteine, the rate-limiting precursor for glutathione biosynthesis, thereby restoring the capacity of the γ-glutamyl-cysteinyl-glycine (GSH) system to buffer reactive oxygen species, support mitochondrial redox balance, and facilitate phase II detoxification. Oral bioavailability is moderate and variable due to first-pass metabolism; liposomal and sustained-release formulations are under study. Beyond antioxidant support, NAC modulates NF-κB-mediated inflammatory signaling and may attenuate cysteine-related DNA methylation shifts. As a standalone agent, it has been evaluated in chronic obstructive pulmonary disease, psychiatric disorders, and metabolic disease with mixed results. In the longevity context it is most relevant as the cysteine-donating half of the GlyNAC combination.

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a coenzyme central to redox reactions in energy metabolism and a required substrate for sirtuins, PARPs, and CD38. Cellular NAD+ levels decline substantially with age across tissues, impairing mitochondrial function, DNA repair, and sirtuin activity. NAD+ precursors such as NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are studied as supplements aimed at restoring tissue NAD+, with mixed clinical evidence.

NADH is the reduced form of NAD+, generated when NAD+ accepts electrons during glycolysis, the citric acid cycle, and fatty acid oxidation. It delivers electrons to the mitochondrial electron transport chain, driving ATP synthesis. The cellular NAD+/NADH ratio reflects metabolic state and influences sirtuin activity, redox signaling, and substrate selection. A shifted ratio toward NADH, often observed in aging and metabolic disease, is associated with reductive stress and mitochondrial dysfunction.

Naive T cells are antigen-inexperienced lymphocytes that continuously recirculate through secondary lymphoid organs awaiting their cognate antigen; they are generated in the thymus and depend on tonic TCR and IL-7 signals for peripheral survival. Upon antigen encounter and co-stimulation, they clonally expand and differentiate into effector cells and, subsequently, long-lived memory T cells (central, effector, and tissue-resident subtypes) that enable faster, stronger recall responses. With age, the naive compartment contracts due to thymic involution and homeostatic proliferation-driven phenotypic conversion, while the memory compartment expands — particularly oligoclonal CD8+ populations driven by persistent viral antigens such as CMV. This shift narrows the T-cell receptor repertoire and limits the capacity to respond to novel pathogens or vaccines.

NEAT is the energy expended during all daily activity outside of structured exercise — walking, standing, fidgeting, household chores, and posture maintenance. It can vary by up to ~2,000 kilocalories per day between individuals of similar body size and often exceeds the contribution of formal workouts to total energy balance. Higher NEAT is associated with lower visceral adiposity, improved metabolic health, and reduced sedentary-time mortality risk, making it a meaningful longevity lever.

Necroptosis is a form of programmed necrotic cell death that proceeds through a defined molecular pathway involving receptor-interacting protein kinases RIPK1 and RIPK3 and the pseudokinase MLKL; when apoptosis is blocked or overwhelmed, RIPK3-mediated phosphorylation of MLKL drives its oligomerisation and plasma-membrane translocation, causing lytic membrane disruption and the release of damage-associated molecular patterns (DAMPs). Unlike apoptosis, necroptosis is inherently inflammatory due to this DAMP release, and it can be triggered by death-receptor ligands, viral sensors and toll-like receptors. Emerging evidence links necroptosis to age-related pathologies including neurodegeneration, ischaemic injury and inflammatory bowel disease, though its specific contribution to physiological ageing versus acute disease remains under investigation.

Negligible senescence describes organisms that show no measurable functional decline, increase in mortality risk, or loss of reproductive capacity with chronological age. The term was coined by biogerontologist Caleb Finch in his 1990 book 'Longevity, Senescence, and the Genome' to characterize species such as certain rockfish, certain tortoises, and hydra. Naked mole-rats, often cited in this context, exhibit extremely slow but not strictly negligible senescence and became associated with this discussion through later work (e.g., Buffenstein 2008 onward). Negligible senescence is studied as a comparative biology benchmark for understanding why most mammals, including humans, do age.

Neuroplasticity is the brain's lifelong capacity to reorganise its structure and synaptic connections in response to learning, experience, and injury. It underpins memory formation, recovery from stroke, and skill acquisition at any age. For longevity, neuroplasticity is the mechanism by which exercise, novel learning, social engagement, and sleep protect cognitive function and slow age-related decline.

The neutrophil-lymphocyte ratio (NLR) is derived from a standard complete blood count as the absolute neutrophil count divided by the absolute lymphocyte count, with a typical reference range of approximately 0.78–3.53 in healthy adults (Forget 2017). It reflects the balance between the innate (neutrophil-driven) and adaptive (lymphocyte-driven) arms of the immune system: higher NLR indicates relative dominance of innate proinflammatory activity and/or suppression of adaptive immunity. Elevated NLR is associated with worse prognosis in a broad range of cancers, higher incidence of cardiovascular events, chronic kidney disease, and metabolic syndrome, and independently predicts all-cause mortality in large population cohorts. Physiologically, NLR rises sharply during acute stress, infection, or corticosteroid use, but persistently elevated values at rest are a marker of chronic inflammaging and immune senescence, making it a useful, cost-free index derived from routine laboratory data.

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors — comprising RelA, RelB, c-Rel, p50 and p52 subunits — that regulate the expression of hundreds of genes involved in inflammation, immunity, cell survival and proliferation. In the canonical pathway, pro-inflammatory signals such as TNF-α, IL-1β, lipopolysaccharide or reactive oxygen species trigger IκB kinase-mediated degradation of inhibitory IκB proteins, releasing NF-κB dimers to translocate to the nucleus and drive target gene expression. NF-κB activity increases with age in multiple tissues and is considered a principal driver of inflammaging, the SASP and age-related immune dysregulation; its activation is also downstream of the cGAS-STING pathway, linking cytosolic DNA sensing to chronic inflammation.

Nicotinamide (NAM, also called niacinamide) is the amide form of vitamin B3 and a direct precursor in NAD+ biosynthesis via the salvage pathway enzyme NAMPT. It is biochemically distinct from the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR): whereas NR and NMN feed into the salvage pathway before NAM's NAMPT entry point, NAM is the common end-product of NAD+ consumption by sirtuins, PARPs, and CD38, making intracellular NAM accumulation a feedback inhibitor of SIRT1 and other sirtuins at high concentrations. This dual role — both precursor and sirtuin inhibitor — complicates interpretation of supplementation studies and distinguishes it mechanistically from NR/NMN. NAM has established medical uses: topical niacinamide is widely used for acne and skin barrier function, and oral high-dose nicotinamide (500 mg twice daily) reduced actinic keratoses and non-melanoma skin cancer rates in a randomized trial (Chen et al., 2015, NEJM). Its use as a systemic longevity supplement is investigational and the net effect on sirtuin-dependent processes at supplemented doses in humans is not established.

Natural Killer cells are innate lymphoid cells that eliminate virus-infected and malignant cells without prior antigen sensitisation, governed by a balance of activating receptors (NKG2D, NKp46, DNAM-1) and inhibitory receptors that recognise self-MHC class I molecules. NK cells also regulate adaptive immunity through rapid cytokine secretion, particularly IFN-γ. With aging, NK cell numbers in peripheral blood tend to increase but the cells shift toward a terminally differentiated, less proliferative phenotype with reduced cytotoxic capacity per cell and impaired cytokine production. This functional decline contributes to reduced tumour immunosurveillance and poorer control of herpesvirus reactivation in older adults.

The NLRP3 inflammasome is a multiprotein cytosolic complex — composed of the sensor protein NLRP3, the adaptor ASC and pro-caspase-1 — that assembles in response to a broad range of danger signals including ATP, uric acid crystals, cholesterol crystals, saturated fatty acids and mitochondrial ROS. Upon assembly, the complex drives auto-proteolytic caspase-1 activation, which in turn cleaves pro-IL-1β and pro-IL-18 into their mature secreted forms and cleaves gasdermin D to initiate pyroptosis. NLRP3 inflammasome activity increases with age in multiple tissues, contributes to inflammaging and is mechanistically linked to atherosclerosis, type 2 diabetes, gout and Alzheimer's disease; clinical trials are evaluating novel selective small-molecule NLRP3 inhibitors (e.g. MCC950 analogues, inzomelid) and downstream IL-1β antagonists such as canakinumab, as well as colchicine — which suppresses NLRP3-driven inflammation indirectly via microtubule disruption rather than selective NLRP3 blockade — in several of these conditions.

NMN is a nucleotide and NAD+ precursor in the salvage pathway, feeding into a coenzyme central to energy metabolism, sirtuin activity, and DNA repair. Oral NMN is absorbed and raises blood NAD+ in humans, but evidence for clinical longevity benefits remains limited. Trials report modest improvements on specific endpoints such as the 6-minute walk test, muscle insulin sensitivity, or grip strength; large, long-term outcome studies are lacking. NMN's US dietary supplement status was contested from 2022 to 2025, when the FDA reversed its earlier drug-exclusion ruling and confirmed that NMN may lawfully be marketed as a dietary supplement; regulatory status in the EU and other regions varies.

While advanced glycation end-products (AGEs) are one well-known source of collagen crosslinks, a distinct class of enzyme-mediated crosslinks is introduced by lysyl oxidase (LOX) and its paralogues (LOXL1–4), copper-dependent amine oxidases that oxidise specific lysine and hydroxylysine residues in newly secreted collagen and elastin to reactive aldehydes, which then condense spontaneously to form covalent intramolecular and intermolecular crosslinks — pyridinoline and deoxypyridinoline in collagen, and desmosine and isodesmosine in elastin. LOX-mediated crosslinking is essential for tensile strength and tissue integrity during development, but pathological upregulation — driven by TGF-beta, hypoxia, and PDGF signalling in fibrotic and tumour microenvironments — produces excessive matrix stiffness that drives fibrosis, impairs cellular mechanosensing, and promotes tumour invasion. Unlike AGE crosslinks, LOX-mediated bonds are in principle modifiable by LOX inhibitors such as beta-aminopropionitrile (BAPN), making this pathway a pharmacological target distinct from the AGE/RAGE axis.

Notch signaling is a conserved juxtacrine pathway that governs cell-fate decisions, differentiation, and tissue homeostasis through direct cell-to-cell contact. Binding of Delta-like or Jagged ligands on signal-sending cells to Notch receptors (NOTCH1–4) on receiving cells triggers sequential proteolytic cleavages — first by ADAM metalloproteases (S2 cleavage), then by the γ-secretase complex (S3 cleavage) — releasing the Notch intracellular domain (NICD), which translocates to the nucleus and activates transcription via the CSL/RBPJ complex. Notch is a key regulator of satellite cell quiescence and muscle regeneration, neural progenitor specification, and T-cell development; its activity declines with age in multiple tissue compartments, impairing regenerative responses, and dysregulation in either direction — gain or loss of function — is associated with pathological ageing phenotypes and cancer.

NR is a vitamin B3 form and NAD+ precursor that is metabolized via salvage pathways to increase NAD+, with NMN as a possible intermediate. Human trials reliably show that oral NR raises blood NAD+ and/or related metabolites and is well tolerated. Evidence for downstream clinical benefits, such as improved physical performance, metabolic health, or healthspan, is mixed and largely confined to small, short-duration studies.

NRF2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that orchestrates the cellular antioxidant and cytoprotective response by binding antioxidant response elements (AREs) in the promoters of genes encoding detoxification enzymes, glutathione synthesis components, proteasome subunits, and anti-inflammatory mediators. Under homeostatic conditions, NRF2 is continuously ubiquitinated by KEAP1 (Kelch-like ECH-associated protein 1), an adaptor for CUL3-based E3 ligase, and targeted for proteasomal degradation; oxidative stress or electrophilic compounds modify critical cysteine residues on KEAP1, impairing its ability to present NRF2 for ubiquitination and allowing NRF2 to accumulate and translocate to the nucleus. NRF2 activity declines with age in multiple tissues, contributing to increased oxidative burden and inflammation; natural compounds such as sulforaphane and pharmacological NRF2 activators are studied for their ability to restore cytoprotective capacity, though the distinction between hormetic activation and potentially tumour-promoting chronic activation warrants caution.

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the biologically inactive N-terminal fragment cleaved from proBNP when cardiomyocytes are stretched by elevated ventricular wall stress or volume overload. It has a longer half-life (~60–120 minutes) than BNP itself, making it analytically more stable. NT-proBNP is a central diagnostic and prognostic biomarker for heart failure: in non-acute settings, a value above 125 pg/mL is widely used as a rule-out threshold, while 2023 ESC HFA guidance recommends age-stratified rule-in thresholds for the non-acute / community setting (125 pg/mL for age <50, 250 pg/mL for 50–74 years, and 500 pg/mL for ≥75 years; acute-setting rule-in thresholds — 450/900/1800 pg/mL — are higher). Beyond established heart failure, modestly elevated NT-proBNP in community populations is independently associated with atrial fibrillation, coronary artery disease, chronic kidney disease, and all-cause mortality, so it is increasingly used as a subclinical cardiac stress marker in longevity assessments.

The oldest-old is a demographic and gerontological term for individuals aged 85 and above, the fastest-growing segment of most high-income country populations. This group shows heterogeneous functional and cognitive trajectories; a substantial minority maintains high functional capacity into the late eighties and beyond, a phenomenon sometimes termed successful aging. Compared with younger old adults (65–84), the oldest-old display distinct epidemiology: traditional cardiovascular risk factors such as hypertension and elevated LDL-C lose predictive power, while markers of physical function, nutritional status, and resilience become stronger mortality predictors. Studying this group is methodologically complicated by survival bias — those who reach 85 are a selected population — which may inflate associations between traits observed at that age and longevity.

Eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) are long-chain polyunsaturated fatty acids found principally in fatty fish and fish oil (with algal supplements as the primary source for vegans). Their principal dietary precursor, alpha-linolenic acid (ALA), is found in flaxseed, chia, and walnuts, but conversion to EPA and DHA in humans is inefficient and highly variable. EPA and DHA are incorporated into cell membranes altering fluidity and lipid-raft composition, and serve as substrates for anti-inflammatory specialized pro-resolving mediators (SPMs) including resolvins and protectins, in contrast to the pro-inflammatory eicosanoids generated from omega-6 arachidonic acid. At pharmacological doses (≥2 g/day EPA+DHA), they reduce serum triglycerides by 20–50%; the REDUCE-IT trial showed that 4 g/day icosapent ethyl (a highly purified EPA ethyl ester) reduced major cardiovascular events in statin-treated hypertriglyceridemic patients, though the mineral oil placebo has been questioned. Observational data consistently associate higher oily-fish intake and blood omega-3 index with lower all-cause and cardiovascular mortality; supplementation trials in generally healthy populations show more modest and inconsistent benefits.

One-carbon metabolism is an interconnected network of folate and methionine cycles that transfers single-carbon units for the biosynthesis of nucleotides, the remethylation of homocysteine to methionine, and the production of S-adenosylmethionine (SAM), the universal methyl donor for DNA, RNA, histone, and lipid methylation. Dietary inputs — including folate, choline, betaine, methionine, vitamins B2, B6, and B12 — feed the network at multiple entry points, making its output sensitive to nutritional status. With ageing, dysregulation of one-carbon flux is associated with elevated plasma homocysteine, global DNA hypomethylation, and impaired epigenetic maintenance, linking the pathway mechanistically to two recognised hallmarks of ageing: epigenetic alterations and genomic instability.

The one-repetition maximum (1RM) is the greatest load that can be lifted through a full range of motion for a given exercise in a single maximal effort with proper form, serving as the gold-standard measure of maximal dynamic strength. Percentage-based training zones (e.g., 60–70% 1RM for hypertrophy, ≥85% 1RM for strength) are typically derived from the 1RM. Direct testing carries injury risk in untrained or older individuals; validated prediction equations (e.g., Epley, Brzycki) estimate 1RM from submaximal repetition-to-failure tests, though accuracy decreases above 5–10 reps. Progressive overload is operationalized as periodic 1RM increases over a training cycle; declining 1RM with age reflects both sarcopenia and dynapenia.

Overtraining syndrome (OTS) sits on a continuum with functional overreaching (FOR) and non-functional overreaching (NFOR), per ECSS/ACSM consensus. It is a maladaptive state in which prolonged training load exceeds recovery capacity, causing unexplained performance decline over weeks to months alongside fatigue, mood disturbances, and sleep disruption. Downward HRV trends, rising resting heart rate, and disproportionate RPE for a given workload are commonly observed but non-specific, and parasympathetic indices may paradoxically rise rather than fall in some athletes.

Oxidative stress is an imbalance between reactive oxygen species production and the body's antioxidant defences, leading to oxidative damage of biomolecules. It impairs mitochondrial function, accelerates telomere attrition, and drives chronic low-grade inflammation. Implicated in many hallmarks of ageing, oxidative stress is associated with cardiovascular disease, neurodegeneration, diabetes, and cancer, and is modulated by diet, exercise, sleep, and environmental exposures.

Oxidized LDL (oxLDL) refers to LDL particles in which the polyunsaturated fatty acids and apolipoprotein B-100 have undergone oxidative modification, typically within the subendothelial space where LDL is retained and exposed to reactive oxygen species and lipoxygenases. oxLDL is not recognised by the LDL receptor but is avidly taken up by macrophage scavenger receptors (SR-A, CD36), driving foam cell formation — the hallmark of early atherosclerotic lesions. Circulating oxLDL, measured by immunoassays using antibodies such as 4E6 or E06 that recognise oxidised phosphatidylcholine epitopes, is elevated in subjects with coronary artery disease, metabolic syndrome, and type 2 diabetes. As a direct indicator of lipid oxidation at the vessel wall, oxLDL is conceptually distinct from F2-isoprostanes (a systemic oxidative stress index) and from LDL-C or LDL-P, which do not reflect oxidative modification.

β-oxidation is the principal mitochondrial pathway for catabolizing fatty acids, sequentially cleaving two-carbon acetyl-CoA units from the acyl chain through cycles of oxidation, hydration, further oxidation, and thiolysis. Each cycle of a saturated even-chain fatty acid also yields one FADH2 and one NADH, which feed the electron transport chain, making fat a highly energy-dense fuel per gram. Very-long-chain and branched-chain fatty acids require prior peroxisomal β-oxidation before mitochondrial entry. During fasting, sustained aerobic exercise, or ketogenic conditions, increased β-oxidation delivers acetyl-CoA for hepatic ketogenesis and supports muscle energy supply. Impaired β-oxidation, which occurs in fatty acid oxidation disorders and accumulates with mitochondrial dysfunction in aging, contributes to ectopic lipid deposition, insulin resistance, and metabolic inflexibility.

p16INK4a is a cyclin-dependent kinase inhibitor encoded by the CDKN2A locus that blocks CDK4/6, halting cell cycle progression and enforcing cellular senescence. Its expression rises markedly with chronological age across many tissues, making it a widely used biomarker of senescent cell burden and biological aging. Selective elimination of p16-positive senescent cells (senolysis) extends healthspan in mice, motivating ongoing senolytic drug development for age-related disease.

p21, encoded by CDKN1A (cyclin-dependent kinase inhibitor 1A), is a potent inhibitor of cyclin-CDK complexes — particularly CDK2 — that enforces G1 and S phase cell-cycle arrest in response to p53 activation, DNA damage and other stressors. By halting replication in damaged cells, p21 provides time for repair; if damage is irreparable, sustained p21 expression can stabilise the senescent state. p21 levels rise with age in multiple tissues and its expression is used as one biomarker of the senescent cell burden, though p21 induction is not exclusive to senescence and can be context-dependent. Genetic experiments in mice show that modulating CDKN1A influences both cancer susceptibility and tissue homeostasis in opposing directions, underscoring its context-dependent biology.

p38 MAPK (p38 mitogen-activated protein kinase), comprising four isoforms (α, β, γ, δ) with p38α being the predominant and most studied form, is a stress-activated kinase that is phosphorylated and activated by upstream MAP2Ks (MKK3 and MKK6) in response to inflammatory cytokines, oxidative stress, UV irradiation, and osmotic shock. It phosphorylates a wide range of substrates including the downstream kinase MK2, transcription factors ATF2 and MEF2, and AU-rich element-binding proteins that stabilise pro-inflammatory mRNAs such as TNF-α. In ageing biology, p38α drives the SASP in senescent cells via NF-κB and MK2/tristetraprolin, suppresses satellite cell self-renewal by phosphorylating MyoD and disrupting quiescence, and mediates inflammatory amplification in inflammaging; pharmacological p38α inhibition has been shown to restore muscle regeneration in aged mice.

p53 is a tumour-suppressor protein encoded by the TP53 gene that acts as a central transcription factor in the cellular response to genotoxic stress, hypoxia, oncogene activation and nutrient deprivation. Upon activation, it induces transcriptional programmes that can drive cell-cycle arrest, DNA repair, apoptosis or senescence, with the outcome depending on stress intensity, cell type and co-regulatory context. Because p53-dependent senescence and apoptosis both limit the proliferation of damaged cells, p53 plays a dual role in ageing: it suppresses tumours yet, when chronically active, can deplete stem-cell pools and reinforce senescent-cell accumulation. Germline TP53 variants and somatic TP53 mutations are the most common alterations found in human cancers, and altered p53 activity is implicated in multiple age-related pathologies beyond malignancy.

p62, encoded by the SQSTM1 gene, is a multifunctional scaffold and selective autophagy receptor that recognises ubiquitinated cargo through its UBA domain and delivers it to autophagosomes by simultaneously binding LC3/GABARAP proteins via its LC3-interacting region (LIR). Beyond cargo triage, p62 integrates cellular stress signals: it activates the Nrf2 antioxidant response by sequestering the Keap1 adaptor and promotes mTORC1 activity by recruiting TRAF6 to catalyse K63-ubiquitination of mTOR (facilitating lysosomal translocation) and by amino-acid-dependent scaffolding of Raptor. Because autophagic flux normally degrades p62, its cytoplasmic accumulation — observed in aged tissues, alcoholic liver disease, and many cancers — serves as a practical readout of impaired autophagy and is a histopathological hallmark of ubiquitin-positive inclusion bodies.

Parasympathetic activation refers to engagement of the rest-and-digest branch of the autonomic nervous system, primarily mediated by the vagus nerve to thoracic and upper-abdominal organs, with additional outflow via pelvic splanchnic nerves to lower GI and urogenital organs. It slows heart rate, lowers blood pressure, promotes digestion, and supports recovery while modulating inflammatory tone via the cholinergic anti-inflammatory pathway. Slow paced breathing, meditation, and deep sleep raise parasympathetic tone, reflected in higher RMSSD. Cold-water face immersion engages the vagus via the dive reflex, while whole-body cold is primarily a sympathetic stressor with a parasympathetic rebound.

Partial reprogramming uses transient or low-dose expression of Yamanaka factors to rejuvenate cells without erasing their differentiated identity or inducing pluripotency. Studies in mice show restoration of youthful epigenetic patterns, improved tissue regeneration, and extended healthspan. Because full reprogramming risks teratoma formation, partial protocols aim to capture rejuvenation benefits while preserving cell function. It is an active and contested frontier in longevity research, with safety and durability still under investigation.

PCGrimAge applies the same principal-component denoising framework introduced by Higgins-Chen et al. (2022) to the GrimAge methylation features, producing a more technically stable version of one of the strongest mortality-predictive epigenetic clocks. By regressing out array-platform and batch variance before scoring, PCGrimAge shows markedly better within-individual reproducibility than the original GrimAge algorithm (Lu et al. 2019), an important property when tracking biological-age change in response to interventions such as caloric restriction, exercise, or pharmacological treatments. Like PCPhenoAge, it represents a methodological advance rather than a new biological model.

PCPhenoAge is a technically refined variant of DNAm PhenoAge introduced by Higgins-Chen and colleagues (2022) that applies principal-component (PC) regression to the underlying CpG data before computing the age score. The PC transformation removes technical noise and batch effects that inflate variance in standard methylation arrays, yielding a clock with substantially improved test-retest reliability and reduced sensitivity to sample quality or preprocessing pipeline. In practice, PCPhenoAge retains the mortality-predictive validity of its predecessor while being more suitable for longitudinal studies and intervention trials where within-individual change is the primary outcome.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted by hepatocytes that binds to the LDL receptor on the cell surface and directs it to lysosomal degradation rather than recycling, thereby reducing LDL uptake and raising circulating LDL-cholesterol. Rare gain-of-function PCSK9 mutations cause familial hypercholesterolaemia, while loss-of-function variants — particularly prevalent in African-American cohorts (e.g., Y142X, C679X) — produce lifelong very low LDL levels and markedly reduced coronary heart disease risk without adverse phenotypes, validating the target. Monoclonal antibodies against PCSK9 (alirocumab, evolocumab) reduce LDL by 50–60% on top of statin therapy and lower cardiovascular event rates in high-risk patients; inclisiran, a small-interfering RNA targeting PCSK9 mRNA in hepatocytes, achieves similar LDL lowering with twice-yearly dosing. Oral PCSK9 inhibitors such as MK-0616 (enlicitide; Merck) reached late-stage trials with Phase 3 readouts in 2024–2025.

Peptide therapy uses short amino-acid chains, often injected, intended to modulate growth hormone (e.g., sermorelin, ipamorelin), tissue repair, or metabolism. A few peptides are approved for narrow indications, but most longevity uses are off-label or sourced as research chemicals. Human evidence for anti-aging endpoints is sparse, quality control of compounded products is variable, and regulatory bodies (e.g., FDA) have restricted several popular peptides.

Positron emission tomography with amyloid-targeting tracers — florbetapir, florbetaben and flutemetamol, all FDA-approved — allows in vivo visualisation of fibrillar amyloid-beta plaques, while second-generation tau PET tracers such as flortaucipir map neurofibrillary tangle burden and staging (Braak stages) in living patients. PET amyloid and tau status have become clinically actionable since 2023–2024, following the FDA approvals of lecanemab (Leqembi) and donanemab: both anti-amyloid antibody therapies require confirmed amyloid positivity for treatment eligibility, and tau PET staging increasingly informs prognosis and likely treatment benefit. Centiloid standardisation of amyloid PET allows cross-scanner and cross-tracer comparison, though reimbursement for diagnostic use remains limited in most healthcare systems. Radiation exposure (approximately 5–7 mSv per scan) and cost are relevant constraints for population screening applications.

Per- and polyfluoroalkyl substances (PFAS) are a class of thousands of synthetic chemicals characterised by extremely stable carbon-fluorine bonds, resulting in environmental persistence and, for long-chain variants such as PFOA and PFOS, serum half-lives in humans of several years. Exposure routes include contaminated drinking water, food packaging, non-stick cookware and occupational contact; PFAS have been detected in blood and tissue globally, including in remote Arctic populations. Epidemiological evidence links PFAS exposure to suppressed antibody responses to vaccines, dyslipidaemia, thyroid hormone disruption, reduced birthweight and increased risk of kidney and testicular cancers, with mechanistic pathways involving PPAR-alpha activation and nuclear receptor interference. In April 2024 the US EPA finalised the National Primary Drinking Water Regulation, setting enforceable maximum contaminant levels for PFOA and PFOS at 4 parts per trillion in drinking water; the EU is pursuing a restriction under REACH covering entire PFAS groups.

PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is a transcriptional co-activator and master regulator of mitochondrial biogenesis and oxidative metabolism that lacks intrinsic DNA-binding activity and instead coordinates transcription by interacting with nuclear receptors (PPARα, ERRα) and other transcription factors (NRF1, NRF2, TFAM). Note: the nuclear respiratory factors NRF1/NRF2 are distinct from the antioxidant transcription factor Nrf2/NFE2L2 covered in the nrf2-keap1 entry. It is induced by exercise, cold exposure, fasting, and AMPK or SIRT1 activation, and drives the expression of the mitochondrial genome replication machinery and enzymes of fatty acid oxidation and the tricarboxylic acid cycle. PGC-1α expression and activity decline in aged skeletal muscle and heart, contributing to mitochondrial dysfunction and metabolic inflexibility; its overexpression or pharmacological induction has extended healthspan and delayed age-related muscle wasting in several animal models, making it a prominent target in longevity pharmacology.

Pharmacogenomics studies how genetic variation — primarily in drug-metabolizing enzymes, transporters, and drug targets — influences individual drug response in terms of efficacy and toxicity. CYP2C9 and VKORC1 variants are the canonical example for warfarin dosing: poor metabolizers at CYP2C9 combined with VKORC1 low-expression haplotypes require markedly lower doses to achieve therapeutic anticoagulation, and dosing algorithms incorporating genotype reduce bleeding events. For statins, a non-synonymous variant in SLCO1B1 (rs4149056, Val174Ala) reduces hepatic uptake of simvastatin and atorvastatin, raising plasma drug levels and increasing myopathy risk several-fold in CC homozygotes. Pharmacogenomics is particularly relevant to older adults with polypharmacy because drug-drug-gene interactions compound with age-related changes in kidney and liver function; clinical implementation through pre-emptive panel genotyping is expanding, with CPIC guidelines providing evidence-based dose recommendations for over 40 drug-gene pairs.

PhenoAge is a composite biological-age measure developed by Levine and colleagues in 2018. The original blood-based version combines nine clinical biomarkers including albumin, creatinine, glucose, C-reactive protein and white blood cell count with chronological age, calibrated against mortality. A DNA-methylation version, DNAm PhenoAge, transfers the score to epigenetic data. PhenoAge predicts all-cause mortality and multimorbidity better than chronological age and has been validated in several large cohorts, although clinical use is still emerging.

Serum inorganic phosphate reflects the balance between intestinal absorption, renal tubular reabsorption, and exchange with bone and intracellular stores, regulated principally by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF-23), and calcitriol. Hyperphosphataemia is clinically significant mainly in chronic kidney disease, where impaired renal phosphate excretion drives secondary hyperparathyroidism, vascular calcification, and cardiovascular mortality. Even within the normal reference range, higher serum phosphate in community-dwelling adults has been independently associated with left ventricular hypertrophy, arterial stiffness, and increased all-cause mortality in large prospective studies. Hypophosphataemia can accompany refeeding syndrome, vitamin D deficiency, or overactive FGF-23 signalling, impairing ATP generation, red cell function, and bone mineralisation.

Photobiomodulation, often called red light therapy, applies low-level red and near-infrared light to tissue; most clinical devices use ~600–900 nm, with some PBM literature extending toward ~1100 nm. The proposed mechanism likely involves multiple pathways, including absorption by cytochrome c oxidase in mitochondria, nitric oxide signalling, and broader mitochondrial redox modulation, which together influence ATP production and reactive oxygen species. Clinical evidence supports modest benefits for some skin and musculoskeletal conditions; broader anti-ageing, cognitive, or metabolic claims rest on small or preliminary trials and are not yet established.

The PI3K/AKT pathway is a central intracellular signalling axis activated by receptor tyrosine kinases (including the insulin and IGF-1 receptors), G-protein-coupled receptors, and other stimuli. Phosphoinositide 3-kinase (PI3K) phosphorylates PIP2 to generate PIP3 at the plasma membrane, recruiting AKT (also called protein kinase B) and its activating kinase PDK1; AKT is further activated by mTORC2-mediated phosphorylation at Ser473. Activated AKT phosphorylates a broad set of substrates — including FOXO transcription factors (promoting their nuclear exclusion), GSK-3β (suppressing glycogen synthesis inhibition), BAD (promoting survival), and TSC2 (activating mTORC1) — thereby coordinating cell survival, glucose metabolism, protein synthesis, and proliferation. The tumour suppressor PTEN counteracts PI3K by dephosphorylating PIP3. Reduced PI3K/AKT activity in C. elegans and other organisms extends lifespan through FOXO activation, but in humans the pathway is hyperactivated in many cancers and in insulin-resistant states, representing a complex, context-dependent role in ageing.

Pioglitazone is a thiazolidinedione PPARγ agonist approved for type 2 diabetes mellitus as an insulin sensitizer, acting primarily by promoting the differentiation and lipid uptake of adipocytes, thereby reducing ectopic fat deposition and improving systemic insulin sensitivity. PPARγ activation also modulates inflammatory gene expression and macrophage polarization towards anti-inflammatory phenotypes, which has generated interest in pioglitazone for age-related conditions beyond glycaemic control. The IRIS trial (Kernan et al., 2016, NEJM) demonstrated reduced cardiovascular events in non-diabetic patients with insulin resistance and prior stroke or TIA, providing evidence for cardiovascular benefit in a metabolically compromised but non-diabetic population. Nir Barzilai and colleagues have included pioglitazone in geroscience cohort discussions as a candidate that addresses metabolic and inflammatory hallmarks of aging. Long-term safety concerns include risk of congestive heart failure, bone loss, and a possible association with bladder cancer; France and Germany suspended use in 2011 following safety signals, and the EMA did not withdraw authorisation EU-wide but added contraindications (active or past bladder cancer, uninvestigated haematuria) and strict labelling restrictions, limiting its investigational use as a longevity agent.

Plasma cells are terminally differentiated B cells that have lost expression of B-cell surface markers including BCR-associated CD79 and gained high-level expression of the transcription factors Blimp-1 and IRF4, which drive the factory-like production of secreted antibodies. Long-lived plasma cells occupy specialised survival niches in the bone marrow, sustained by CXCL12/CXCR4 signals, APRIL, and BAFF from stromal cells, and can produce antigen-specific antibodies for decades without re-stimulation. With aging, these bone marrow niches become occupied by long-lived plasma cells from earlier infections and vaccinations, limiting space for newly generated cells — a mechanism contributing to the diminished durability of vaccine responses in elderly individuals, alongside the upstream germinal centre defects of B-cell senescence.

Plasmapheresis is the umbrella term for extracorporeal procedures that separate plasma from cellular blood components; technique varies, with plasma either fractionated or filtered and partially returned, or wholly removed and replaced as in TPE. It is established for autoimmune and hyperviscosity disorders, where its dominant mechanism is removal of pathogenic plasma factors such as antibodies, immune complexes, and inflammatory mediators. In longevity contexts it is proposed to dilute pro-aging plasma factors, but evidence for healthy-aging benefit is preliminary.

Plyometrics are explosive movements — jumps, hops, bounds, throws — that exploit the stretch-shortening cycle, in which a rapid eccentric load primes a powerful concentric contraction. They train rate of force development, neuromuscular coordination, and tendon elasticity. In ageing populations, low-volume jump training improves bone mineral density, balance, and reactive strength, addressing the power deficit that drives falls. Progression and surface choice matter to manage joint load.

PM2.5 refers to airborne particles with an aerodynamic diameter of 2.5 micrometres or less, arising predominantly from combustion sources — vehicle exhaust, power generation, wood burning and industrial processes — as well as secondary formation from gaseous precursors such as sulphur dioxide and nitrogen oxides. Their small size allows deep deposition in the alveolar region and translocation into systemic circulation, where they trigger oxidative stress, endothelial dysfunction and inflammatory cytokine release; carriers of the APOE ε4 allele may face heightened neurological risk through blood-brain barrier penetration. Dose-response analyses by Pope, Burnett and colleagues in large American cohorts have demonstrated continuous associations between long-term PM2.5 exposure and all-cause, cardiovascular and lung-cancer mortality without an apparent safe threshold. The WHO 2021 Air Quality Guidelines tightened the recommended annual mean limit to 5 µg/m³ — a level most European and North American cities still exceed.

A polygenic risk score (PRS) is a weighted sum of an individual's risk-allele dosages across many SNPs associated with a trait, with weights typically derived from GWAS summary statistics using methods such as LD-pruning and thresholding (P+T) or Bayesian shrinkage (LDpred, PRSice). For common complex diseases — including coronary artery disease, type 2 diabetes, and breast cancer — high PRS identifies individuals with lifetime risk comparable to monogenic mutation carriers, suggesting clinical utility for stratified prevention. However, PRS performance degrades substantially when applied across ancestry groups because GWAS discovery cohorts have been disproportionately European, and LD patterns and allele frequencies differ between populations, limiting equitable deployment. Additional challenges include calibration drift over time, limited ability to capture rare variants and gene-environment interactions, and conceptual questions about whether PRS for longevity traits represents a useful clinical endpoint given their composite, late-acting nature.

Polypharmacy is conventionally defined as the concurrent use of five or more medications by one patient, though thresholds vary by definition (some use ≥4, hyperpolypharmacy typically ≥10); it must be distinguished from appropriate polypharmacy, in which multiple drugs are each evidence-based for the individual's conditions. Prevalence increases sharply with age and multimorbidity — over 40% of adults aged 65 and older in many high-income countries take five or more drugs. The clinical risks include drug-drug interactions, additive adverse effects, prescribing cascades (where a drug side effect is treated with another drug), impaired adherence, falls, cognitive impairment and hospitalisation. Deprescribing — the structured reduction of medications that lack net benefit — is an emerging discipline in geriatric and longevity medicine, supported by a growing evidence base for specific drug classes including proton pump inhibitors, benzodiazepines and anticholinergics in older adults.

Polysomnography (PSG) is the gold-standard multi-channel sleep study conducted in a laboratory setting, simultaneously recording electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory airflow, effort, and oxygen saturation. Sleep stages—N1, N2, N3 (slow-wave), and REM—are scored in 30-second epochs according to the AASM manual using EEG, EOG, and EMG channels. PSG is the reference standard for diagnosing obstructive and central sleep apnea (via apnea-hypopnea index), narcolepsy, REM sleep behavior disorder, and periodic limb movement disorder. Consumer wearables and actigraphy are validated against PSG but typically underestimate N3 and N1 and overestimate sleep efficiency.

Polyvagal theory, proposed by Stephen Porges in 1995, posits that distinct vagal branches — a phylogenetically newer ventral-vagal complex and an older dorsal vagal pathway — evolved in mammals to support social engagement versus shutdown/freeze responses. It is widely used in trauma therapy and somatic practice, but its comparative-neuroanatomy and evolutionary claims have been substantively challenged in peer-reviewed work (Grossman & Taylor 2007; Grossman 2023), and mainstream neuroscience does not treat it as established. The well-supported finding that vagal tone (HRV) and breathing influence health does not depend on polyvagal theory and should not be conflated with it.

The ISAPP 2021 consensus definition characterises a postbiotic as a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host. The key distinction from probiotics is that postbiotics contain non-viable organisms or isolated microbial components — including cell wall fragments, teichoic acids, exopolysaccharides, secreted proteins, metabolites and extracellular vesicles — without requiring colonisation or survival through the gastrointestinal tract. This gives postbiotics practical advantages in formulation stability, safety in immunocompromised individuals, and defined composition. Pasteurised Akkermansia muciniphila (discussed separately) is one example that fits the ISAPP postbiotic framework. Evidence for specific health effects varies substantially by preparation; most clinical data come from heat-killed Lactobacillus and Bifidobacterium preparations, primarily in infant colic, allergy and mild gastrointestinal complaints. The field is emerging and regulatory frameworks for postbiotic health claims are still developing in most jurisdictions.

Postprandial glucose refers to blood glucose levels after a meal, often peaking within 30–90 minutes (typically around 60 minutes for mixed meals) before returning toward fasting baseline; conventional clinical measurement at 2 hours post-meal reflects glucose returning toward baseline rather than the peak. The size and duration of the spike reflect carbohydrate quantity and quality, gastric emptying, insulin response, and tissue uptake. Recurrent large excursions (a value rarely exceeded in non-diabetics is roughly 140 mg/dL) are associated, in a graded fashion, with vascular risk and cardiovascular disease, making postprandial control a key target in metabolic and longevity-oriented nutrition.

According to the International Scientific Association for Probiotics and Prebiotics (ISAPP), a prebiotic is defined as a substrate that is selectively utilised by host microorganisms conferring a health benefit. This definition is deliberately broad — encompassing not only fermentable dietary fibres (such as inulin, fructooligosaccharides and galactooligosaccharides) but also non-carbohydrate compounds and applications beyond the gut — and requires evidence of both selective utilisation and a demonstrated health outcome, not merely substrate availability. Well-characterised prebiotics reliably increase populations of Bifidobacterium and Lactobacillus species, enhance SCFA production, and improve stool consistency; effects on harder clinical endpoints such as glycaemic control and immune function have been shown in some trials but are modest and context-dependent. The prebiotic concept should be distinguished from dietary fibre generally: fibre is broadly fermented by many taxa, whereas the selectivity criterion for prebiotics is more stringent and differentiates them from general substrate provision.

The prefrontal cortex (PFC), comprising Brodmann areas 9, 10, 11, 46, and 47 and related regions, is the cortical seat of executive function, working memory, cognitive flexibility, impulse control and prospective planning. It is among the latest brain regions to fully myelinate in adolescence and among the earliest to show measurable structural and functional decline with age: cortical thinning, dendritic retraction, reduced dendritic spine density and diminished dopaminergic and noradrenergic signalling accumulate from the fourth decade onward, even in the absence of overt pathology. Functional MRI studies show that older adults recruit PFC more bilaterally and diffusely than young adults performing equivalent tasks — a pattern interpreted as compensatory in some frameworks and as inefficiency in others. PFC age-related decline is accelerated by chronic stress (via glucocorticoid-mediated dendritic remodelling), hypertension and sleep disruption, and is modifiable through aerobic exercise, cognitively demanding activities and adequate sleep.

ProAge and related proteomic-age clocks estimate biological age from the concentrations of hundreds to thousands of plasma or serum proteins measured by aptamer-based (SomaScan) or proximity-extension assay (Olink) platforms. Landmark studies by Lehallier and colleagues (2019, Nature Medicine) demonstrated that the plasma proteome changes non-linearly with age in three distinct waves, and subsequent work trained predictive models on up to ~3,000 proteins. Proteomic clocks capture post-transcriptional and secreted signals not reflected in DNA methylation, and recent analyses suggest protein-based age acceleration associates with age-related disease risk, though platform-specific protein selection means scores are not directly interchangeable across studies.

Progressive overload is the principle of gradually increasing training demands — load, volume, density, range of motion, or proximity to failure — to keep driving adaptation. Without it, the body settles into a maintenance state and gains plateau. The progression must be small enough to be tolerated and large enough to be meaningful. It is the central mechanism behind sustained gains in strength, hypertrophy, and bone density across a training career.

Prolonged fasting refers to fasting periods of roughly 48 hours up to several days during which only water, electrolytes, and sometimes minimal calories are consumed. After glycogen depletion, the body shifts to fatty acid oxidation and ketogenesis, suppresses IGF-1 and mTOR, and upregulates autophagy. Stem-cell-based regeneration has been demonstrated in rodents; human translation remains limited. Risks include electrolyte disturbances and refeeding syndrome, so prolonged fasting should be medically supervised.

Protein carbonylation is an irreversible, oxidative post-translational modification in which carbonyl groups (aldehydes or ketones) are introduced into protein side chains, most often at proline, arginine, lysine, and threonine residues, either by direct metal-catalysed oxidation or by Michael addition of reactive lipid electrophiles such as 4-HNE. Carbonylated proteins are structurally altered, tend to form aggregates, and are poor proteasomal substrates, making their accumulation a marker of proteostatic stress. Carbonyl content rises progressively with biological age across species and is elevated in tissues affected by Alzheimer's disease, Parkinson's disease, and chronic obstructive pulmonary disease, establishing it as a widely used biomarker of cumulative oxidative damage.

Protein crosslinks are covalent bonds that join two protein molecules or different segments of the same protein. They can form enzymatically, as with collagen maturation, or non-enzymatically through oxidation and glycation by sugars and reactive aldehydes. Pathological crosslinks accumulate in long-lived structural proteins like collagen, elastin, and crystallins, stiffening tissues. This contributes to vascular rigidity, skin ageing, cataracts, and reduced organ elasticity.

Proteostasis, short for protein homeostasis, is the integrated network that controls protein synthesis, folding, trafficking, and degradation to keep the proteome functional. Key players include ribosomes, molecular chaperones, the ubiquitin-proteasome system, and autophagy-lysosome pathways. Maintaining proteostasis is essential for cellular function; its progressive failure with age underlies neurodegenerative diseases such as Alzheimer's and Parkinson's and is recognized as a hallmark of aging.

Prostate-specific antigen (PSA) is a serine protease of the kallikrein family produced almost exclusively by prostatic epithelial cells; it liquefies seminal coagulum but leaks into the bloodstream in proportion to the degree of disruption of prostatic glandular architecture. Elevated serum PSA (commonly flagged above 4 ng/mL, though thresholds vary by age and risk profile) can reflect prostate cancer, benign prostatic hyperplasia, prostatitis, or recent mechanical stimulation, and has a positive predictive value for cancer of roughly 20–30% at levels of 4–10 ng/mL, though this estimate is substantially modified by age, race, DRE findings, and PSA density. Derived metrics — PSA density, PSA velocity, free-to-total PSA ratio, and age-specific ranges — improve specificity and reduce unnecessary biopsy. PSA-based screening has shown a modest reduction in prostate cancer mortality in some randomised trials (notably ERSPC) but not others (PLCO), and detects considerable indolent disease, leading to shared decision-making recommendations (USPSTF Grade C for ages 55–69) about its use as a longevity screening tool.

Pterostilbene is a dimethylated stilbene analogue of resveratrol naturally present in blueberries, grapes, and Pterocarpus marsupium heartwood. The two methoxy groups replacing the hydroxyl groups of resveratrol substantially increase lipophilicity and metabolic stability, conferring approximately two- to fourfold higher oral bioavailability and a longer half-life compared with resveratrol. Like resveratrol, it is studied as a putative SIRT1 activator and AMPK modulator, and additionally activates PPARα, relevant to fat oxidation. In rodent models it improves cognitive function, reduces inflammatory and oxidative markers, and extends lifespan in some strains. Human clinical data are limited to small trials examining lipid profiles, blood pressure, and antioxidant markers, with modest and inconsistent effects; a randomized human trial (Riche et al. 2014, NCT01267227) reported LDL elevation at higher pterostilbene doses in the monotherapy arm — a finding notable enough that ChromaDex subsequently ceased new pterostilbene ingredient orders. No robust evidence supports anti-aging benefit in humans, and long-term safety data are sparse.

Pulse wave velocity (PWV) is the speed at which the pressure wave generated by ventricular ejection travels along the arterial tree, and is the non-invasive gold-standard measure of arterial stiffness. Carotid-femoral PWV (cf-PWV), measured by applanation tonometry or oscillometric devices over the aortic segment, is the most validated modality: the European Society of Hypertension threshold of >10 m/s in the context of hypertension identifies pathological aortic stiffness. Arterial wall composition, cross-linking of structural proteins, elastin fragmentation and vascular smooth-muscle tone all contribute to stiffness, which increases progressively with age and is further accelerated by hypertension, diabetes and chronic kidney disease. Large prospective studies and meta-analyses have demonstrated that cf-PWV independently predicts cardiovascular events and all-cause mortality beyond traditional risk factors, including in populations free of established cardiovascular disease.

Pulsed electromagnetic field therapy delivers low-frequency, low-intensity pulsed magnetic fields to tissue, typically via flat coil applicators at frequencies from 1 to several hundred Hz and field strengths far below therapeutic MRI levels. Proposed mechanisms include voltage-gated ion channel modulation (particularly calcium influx), mitochondrial membrane potential effects, and downstream shifts in reactive oxygen species and inflammatory signaling, though the biophysical mechanisms remain incompletely characterised. Regulatory approval exists for specific indications—bone non-union healing and post-operative pain in some jurisdictions—supported by a moderate body of evidence. Evidence for broader longevity, metabolic, cognitive, or recovery applications is heterogeneous: some small RCTs report reductions in pain and inflammation, but effect sizes are variable, blinding is difficult, device parameters differ widely across studies, and high-quality long-term human trials are lacking.

Pyroptosis is a highly inflammatory form of programmed cell death executed primarily by gasdermin family proteins, especially gasdermin D (GSDMD), which oligomerise to form pores in the plasma membrane after cleavage by inflammatory caspases (caspase-1, -4, -5 in humans; caspase-11 in mice). In the canonical pathway, caspase-1 directly cleaves both GSDMD and pro-IL-1β and pro-IL-18 into their mature secreted forms; in the non-canonical pathway, caspase-4/-5/-11 cleave GSDMD to form pores, while IL-1β and IL-18 maturation requires secondary NLRP3/caspase-1 activation triggered by potassium efflux through the GSDMD pores. Pyroptosis is triggered downstream of inflammasome complexes, including the NLRP3 inflammasome, in response to pathogen-associated molecular patterns, damaged-self signals and sterile stressors. In the context of ageing and age-related disease, dysregulated pyroptosis contributes to tissue inflammation in conditions including atherosclerosis, neurodegeneration and metabolic disease.

Quercetin is a flavonoid abundant in onions, apples, capers, and berries with antioxidant and anti-inflammatory activity. It is investigated as a senolytic, though standalone activity is inconsistent in human cell models; the combination with dasatinib (D+Q) is the regimen actually studied in early human senolytic trials. Standalone supplementation has shown small, inconsistent blood pressure effects mainly in hypertensive populations, and bioavailability is low. Human anti-aging evidence is preliminary.

Rapamycin (sirolimus) is a macrolide mTORC1 inhibitor approved as an immunosuppressant to prevent kidney transplant rejection and to treat lymphangioleiomyomatosis. By inhibiting mTORC1, it slows protein synthesis, enhances autophagy, and extends lifespan in yeast, worms, flies, and mice across multiple labs. Off-label use for human longevity remains investigational; clinical trials are evaluating intermittent low-dose protocols, but efficacy and long-term safety in healthy adults are unproven. The PEARL trial (Moel et al., Aging-US April 2025) reported safety similar across groups; the primary efficacy endpoint of visceral adipose tissue change was not met, but secondary outcomes showed dose-dependent improvements in lean mass and pain in women on 10 mg/week.

Rate of force development (RFD) is the change in muscle force per unit time (N/s), quantifying how rapidly maximal force can be expressed — a key component of muscular power distinct from peak force alone. Early-phase RFD (0–50 ms) reflects neural drive, motor unit synchronization, and Type II fiber recruitment; late-phase RFD (100–200 ms) is more influenced by muscle cross-sectional area and fiber composition. RFD declines with age more rapidly than maximal strength and is closely linked to fall-prevention capacity, functional power, and reactive balance, because most daily protective movements (catching a stumble, rising from a chair) occur within 100–200 ms. Power-focused and plyometric training preferentially improve RFD.

Red cell distribution width (RDW) is a quantitative measure of the variability in erythrocyte volume (anisocytosis), reported as the coefficient of variation of the erythrocyte volume distribution from automated hematology analyzers; the normal range is approximately 11.5–14.5%. Elevated RDW reflects heterogeneous red cell populations and arises from iron, B12, or folate deficiency, hemolysis, blood transfusion, or ineffective erythropoiesis. Independent of its role in anemia workup, higher RDW is a robust, reproducible predictor of all-cause and cardiovascular mortality in community populations, with associations observed even within the reference range. Proposed mechanisms include chronic inflammation, oxidative stress, nutritional deficiency, and impaired bone marrow function, all of which impair erythropoietic homeostasis. RDW is increasingly recognized as a simple, inexpensive marker of biological aging and physiological reserve.

Reactive oxygen species are oxygen-containing molecules such as superoxide, hydrogen peroxide, and hydroxyl radicals produced by multiple cellular sources, including mitochondrial respiration, NADPH oxidases, peroxisomes, and the immune respiratory burst. At low levels they act as signalling molecules regulating immunity and metabolism, but excess ROS damages lipids, proteins, and DNA. Chronic ROS accumulation contributes to mitochondrial decline, cellular senescence, and age-related diseases including cardiovascular and neurodegenerative disorders.

A readiness score is a vendor-defined daily index, popularized by devices like Oura and Garmin (whose analogous metric is branded Training Readiness or Body Battery), that aims to indicate how prepared the body is for physical or cognitive load. Whoop's analogous metric is branded Recovery, not Readiness. It typically blends HRV, resting heart rate, body temperature deviation, sleep quality, and prior strain. Algorithms differ by manufacturer and lack peer-reviewed standardization, so values should be treated as proprietary longitudinal signals rather than clinically validated measures.

Recovery score is a generic category for vendor-defined composite metrics that estimate how well the body has recuperated from prior strain. Branding differs by device: Whoop calls its score Recovery, Garmin uses Body Battery and Training Readiness, and Oura uses Readiness. Inputs commonly include HRV, resting heart rate, respiratory rate, sleep duration, and sleep stages, though exact algorithms are proprietary. There is no scientific consensus on a standardized recovery score; values are not directly comparable across devices and should be interpreted as vendor-specific trends rather than diagnostic measurements.

Regenerative medicine is the field developing therapies to repair, replace, or regenerate damaged cells, tissues, and organs. Approaches include stem cell transplantation, tissue engineering, gene therapy, organoids, biomaterial scaffolds, and cellular reprogramming. By restoring lost function rather than only managing symptoms, it aims to address age-related degeneration, organ failure, and chronic disease. It is closely intertwined with longevity science, where reversing cellular and tissue aging is a central therapeutic objective.

The reliability theory of aging, advanced by Leonid and Natalia Gavrilov in the early 1990s, applies engineering reliability mathematics to biological systems. It models organisms as redundant networks of components that fail stochastically; aging arises as redundancy depletes, producing the observed Gompertz mortality curve. The theory elegantly explains late-life mortality plateaus and provides a quantitative bridge between molecular damage and population-level survival data.

REM (rapid eye movement) sleep is a sleep stage marked by fast eye movements, vivid dreaming, near-waking brain activity, and skeletal muscle atonia. It increases toward the second half of the night and supports memory consolidation, emotional processing, and synaptic plasticity. Reduced REM duration has been associated in epidemiological studies with higher all-cause mortality, cognitive decline, and impaired mood regulation.

Resting heart rate (RHR) is the number of heartbeats per minute at full rest, ideally measured supine after several minutes of quiet rest or upon waking, and is influenced by caffeine, illness, medications, and sleep. Trained individuals typically have lower RHR through a combination of intrinsic sinoatrial node remodeling (notably downregulation of the HCN4 'funny' channel, which persists after autonomic blockade) and elevated vagal/parasympathetic tone, with increased stroke volume as a parallel cardiac adaptation. Epidemiological data (e.g., Aune 2017) link elevated RHR with higher cardiovascular and all-cause mortality, making it a simple biomarker of cardiorespiratory health and recovery.

Resveratrol is a stilbene polyphenol found in grape skins, red wine, and Japanese knotweed. It is studied as a putative sirtuin (SIRT1) activator and AMPK modulator, with effects on inflammation and mitochondrial function in preclinical models. Human trials have produced inconsistent results, and oral bioavailability is poor. There is currently no robust evidence that resveratrol supplementation extends human lifespan or healthspan.

RetinaAge is a biological-age clock derived from fundus photographs of the retina, using deep-learning models trained to predict chronological age from the vascular and neural features of the optic disc, fovea, and retinal vasculature. Published by Zhu and colleagues (2022, British Journal of Ophthalmology), the model was trained on fundus images from healthy UK Biobank participants and applied to the broader UK Biobank cohort (~80,000 images, ~46,000 participants); the gap between predicted retinal age and chronological age independently predicted all-cause mortality and cardiovascular events. Because the retina shares embryological origin with the central nervous system and is the only site where microvasculature can be imaged non-invasively, it offers a clinically practical window onto systemic and neural vascular aging.

Optical coherence tomography (OCT) of the retina generates micrometre-resolution cross-sectional images of retinal layers, enabling quantification of macular thickness, retinal nerve fibre layer (RNFL) thickness and ganglion cell layer volume, while fundus photography documents the retinal vasculature and optic disc. Because the retina shares embryological origin and vascular supply architecture with the brain, retinal parameters serve as proxies for central nervous system and systemic vascular health: RNFL thinning is an established marker of glaucoma and has been associated with Alzheimer's disease, multiple sclerosis and Parkinson's disease. Deep-learning algorithms trained on fundus images can estimate cardiovascular risk factors — including age, sex, blood pressure and HbA1c — directly from the image, and emerging 'retinal age gap' AI clocks predict mortality and morbidity beyond chronological age in large population studies. OCT angiography (OCTA) extends the examination to capillary-level flow mapping without dye injection, enabling assessment of foveal avascular zone geometry as a vascular health marker.

RMSSD (Root Mean Square of Successive Differences) is a time-domain HRV metric defined as the square root of the mean of the squared successive differences between adjacent NN (or RR) intervals, expressed in milliseconds. It is considered the most reliable short-term marker of parasympathetic (vagal) activity and is widely used in wearables and rPPG-based readings. In longevity research, RMSSD is tracked as a daily indicator of recovery, training adaptation, sleep quality, and acute stress load.

Rate of perceived exertion (RPE) is a subjective scale used to quantify how hard physical exercise feels, most commonly on the 6–20 Borg scale or the 0–10 modified scale. It correlates reasonably well with heart rate, lactate, and VO2 in trained individuals. RPE is widely used in longevity and endurance protocols to autoregulate training load, manage fatigue, and complement objective recovery metrics like HRV and resting heart rate.

S6K1 (ribosomal protein S6 kinase 1, encoded by RPS6KB1) is a serine/threonine kinase and a primary downstream effector of mTORC1 that promotes protein synthesis by phosphorylating ribosomal protein S6 and eIF4B, thereby stimulating ribosome biogenesis and translational capacity. It operates within a negative-feedback loop that attenuates insulin receptor substrate signalling, linking anabolic drive to insulin resistance. In model organisms from yeast to mice, genetic reduction of S6K1 activity extends lifespan (in mice the Selman 2009 effect was female-specific, with no significant longevity benefit in males) and confers metabolic benefits, including improved insulin sensitivity and resistance to age-related adiposity; in humans, S6K1 hyperactivity is associated with obesity, type 2 diabetes, and accelerated cellular ageing, though direct longevity evidence in humans remains limited.

Senescence-associated β-galactosidase (SA-β-Gal) is an enzyme activity detectable at pH 6.0 that reflects the increased lysosomal content and elevated expression of lysosomal β-galactosidase (encoded by GLB1) found in senescent cells. First described in 1995 by Dimri and colleagues, it became the most widely used single histochemical marker for senescent cells in tissue sections and cell culture due to its relative ease of detection. SA-β-Gal activity is not exclusive to senescent cells — it can also appear under conditions of quiescence, overconfluence or lysosomal stress — so it is best used alongside complementary markers such as p21, p16^INK4a, SASP components and heterochromatin foci for reliable senescence identification.

S-adenosylmethionine (SAM) is the principal biological methyl-group donor, formed by the condensation of methionine with adenosine triphosphate (ATP) in a reaction catalysed by methionine adenosyltransferase. After donating its methyl group to substrates ranging from DNA and histones to neurotransmitters and phospholipids, SAM is converted to S-adenosylhomocysteine (SAH), which is then hydrolysed to homocysteine — a branch point between remethylation back to methionine and the transsulfuration pathway toward cysteine and glutathione. Intracellular SAM:SAH ratio serves as a cellular indicator of methylation capacity; declining SAM availability with age or methionine restriction is proposed to alter epigenetic programming and modulate longevity in several model organisms, though the net effects in mammals remain context-dependent.

Sarcopenia is the age-related loss of skeletal muscle mass, strength, and function; contributing factors include anabolic resistance, neuromuscular changes, chronic inflammation, and inactivity. Under the EWGSOP2 (2019) consensus, low muscle strength (grip strength or chair-stand) is the primary criterion for probable sarcopenia, confirmed by low muscle quantity or quality (DXA, BIA, CT/MRI), with poor physical performance defining severity. Since October 2016 it has its own ICD-10-CM code (M62.84), recognising it as an independent clinical condition.

Sarcopenic obesity is the concurrent presence of low skeletal muscle mass or function (sarcopenia) and excess adiposity. The combination is more adverse than either condition alone: excess fat amplifies systemic inflammation and lipotoxicity while reduced muscle mass impairs glucose uptake and energy expenditure, creating a self-reinforcing cycle. Risk for cardiometabolic disease, physical disability, and mortality is higher in sarcopenic-obese individuals than in those with only one condition, though exact thresholds vary across diagnostic frameworks. Resistance training combined with sufficient dietary protein (often ≥1.2 g/kg/day) is considered the primary intervention, targeting both muscle preservation and metabolic health.

The senescence-associated secretory phenotype, or SASP, is the complex mixture of cytokines, chemokines, growth factors, proteases and extracellular vesicles released by senescent cells. It is regulated by multiple pathways, prominently including NF-kB, with mTOR, cGAS-STING, p38 MAPK and C/EBPbeta also influencing SASP output in certain contexts. Depending on context, the SASP can recruit immune cells to clear damaged tissue or, when persistent, fuel chronic low-grade inflammation, fibrosis and paracrine senescence in neighbouring cells, making it a key mechanistic link between cellular senescence and age-related disease.

A Finnish sauna is a dry-heat bath, typically 80–100°C with low humidity, used as a passive heat-stress modality. Acute sessions raise core temperature and produce a cardiovascular response (e.g. increased heart rate and peripheral vasodilation) that overlaps with some aspects of exercise, but is not equivalent to aerobic training. Large Finnish cohort studies, often categorising sessions as 1, 2–3, and 4–7 per week, link frequent use with lower cardiovascular and all-cause mortality, with the lowest risk in the 4–7 group; data are observational and causal effects on longevity are not established.

SDNN (Standard Deviation of NN intervals) is a time-domain HRV measure capturing the overall variability of normal heartbeats. Per HRV Task Force standards, SDNN is primarily reported over 24-hour recordings, where it reflects both sympathetic and parasympathetic influences along with circadian rhythms and longer-term low-frequency variability that contributes to 24-h SDNN. Short-term 5-min SDNN is heavily influenced by respiratory/vagal variability, though RMSSD and HF power are more specific markers of vagal modulation. Low 24-hour SDNN is associated with increased cardiovascular and all-cause mortality risk, particularly post-infarction.

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated a 20 percent reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease without diabetes. Longevity-relevant mechanisms include sustained weight loss, improved insulin sensitivity, lower inflammation, and possible cognitive and renal protection. Off-label use solely for lifespan extension in healthy adults is investigational and not endorsed.

A senescent-cell vaccine is an immunological strategy aimed at training the adaptive immune system to recognize and eliminate senescent cells in vivo, analogous to anti-tumour vaccination. The approach was demonstrated preclinically by Suda and colleagues (2021, Nature Aging): mice vaccinated with peptides derived from glycoprotein nonmetastatic melanoma protein B (GPNMB), a surface antigen overexpressed on senescent cells, developed GPNMB-specific cytotoxic T-lymphocyte responses that reduced senescent cell burden, improved physical function, and partially replicated healthspan benefits seen with pharmacological senolytics in progeroid (Ercc1-mutant accelerated-aging) and diet-induced obese mouse models. The concept is in early discovery phase: GPNMB is not exclusively expressed on senescent cells, potential immune tolerance and autoimmunity risks have not been evaluated in humans, no clinical trial has been initiated, and whether a single antigen target can cover the heterogeneous senescent cell landscape across tissues remains unresolved. This is a preclinical proof-of-concept, not an available or approaching clinical product.

Senolytic therapy uses drugs or natural compounds to selectively eliminate senescent cells, which accumulate with age and secrete a multi-component secretome (the SASP) of inflammatory cytokines and chemokines, growth factors, and tissue-remodeling proteases such as MMPs. By targeting senescent-cell anti-apoptotic pathways (SCAPs) and promoting selective apoptosis in these cells, senolytics aim to reduce age-related dysfunction. Evidence is robust in animal models, but human trials remain small and early; clinical efficacy, optimal dosing, and long-term safety are unproven.

Senolytics are compounds that selectively induce cell death in senescent cells by exploiting context-specific survival vulnerabilities, including BCL-2 family proteins and PI3K/AKT signalling; specific compounds such as the FOXO4-DRI peptide additionally target the FOXO4-p53 interaction. The vulnerabilities targeted are heterogeneous and compound-specific. Studied candidates include the dasatinib plus quercetin combination, fisetin and navitoclax. In animal models, intermittent senolytic dosing improves physical function and extends healthspan, but human evidence is still limited to early-phase trials and clinical use outside studies is not established.

Senomorphics, also called senostatics, are compounds that suppress the harmful secretory activity of senescent cells without killing them. They typically target signalling pathways that drive the SASP, including NF-kB, mTOR, JAK/STAT and p38 MAPK. Examples studied preclinically include rapamycin, metformin, ruxolitinib and certain flavonoids. The aim is to reduce chronic inflammation and tissue damage from senescent cells while preserving any beneficial roles they may have in wound healing and tumour suppression.

Sermorelin is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH 1–29) that stimulates pituitary somatotrophs to secrete growth hormone (GH) in a pulsatile, feedback-sensitive manner, in contrast to exogenous GH administration which suppresses endogenous production. It was formerly FDA-approved for paediatric GH deficiency (Geref; the manufacturer notified FDA of discontinuation in 2008, and FDA formally withdrew approval effective June 2009, for commercial rather than safety reasons) and remains approved in some other jurisdictions. In anti-aging medicine, sermorelin is widely prescribed off-label at clinics to raise GH/IGF-1 axis activity, reduce body fat, and improve lean mass and sleep quality in middle-aged and older adults; however, controlled evidence for meaningful longevity or functional outcomes is limited, and the GH secretagogue class broadly lacks Phase III efficacy data for aging indications. Adverse effects include injection-site reactions, fluid retention, and theoretical concern about promotion of occult neoplasia given GH/IGF-1 mitogenic signalling; its use is not endorsed by major endocrinological societies for anti-aging purposes.

SGLT2 inhibitors (gliflozins, e.g. empagliflozin, dapagliflozin) block renal sodium-glucose cotransporter 2, causing urinary glucose excretion. They are approved for type 2 diabetes, heart failure (preserved and reduced ejection fraction), and chronic kidney disease, with robust cardiovascular and renal mortality benefits. Proposed mechanisms include a hypothesized ketone-mediated cardiac fuel shift, mild caloric loss, and reduced glomerular hyperfiltration, though the dominant pathway remains debated. Canagliflozin extended lifespan in male mice. Off-label longevity use in non-indicated adults remains investigational.

Short-chain fatty acids — principally acetate, propionate and butyrate — are produced when anaerobic gut bacteria ferment dietary fibre and resistant starch that reaches the colon undigested. Butyrate is the preferred energy substrate for colonocytes, strengthens tight junctions and maintains mucosal barrier integrity, inhibits histone deacetylases (acting as an HDAC inhibitor) and signals via free fatty acid receptors GPR41, GPR43 and GPR109A to modulate immunity, appetite hormones and insulin secretion. Propionate travels primarily to the liver where it participates in gluconeogenesis and lipid regulation, while acetate enters systemic circulation. Reduced SCFA production — from low dietary fibre intake or loss of key producers such as Faecalibacterium prausnitzii and Roseburia intestinalis — is consistently associated with inflammatory bowel conditions, obesity and impaired glycaemic control, though translating this association into effective dietary or therapeutic interventions remains an active area of research.

Sirtuins are NAD⁺-dependent deacylases and ADP-ribosyltransferases; the three most studied longevity-relevant isoforms differ sharply in subcellular compartment and substrate specificity. SIRT1 is predominantly nuclear and cytosolic, deacetylating transcriptional regulators including p53, NF-κB, PGC-1α, and FOXO proteins to coordinate metabolism, stress response, and genome maintenance. SIRT3 localizes to the mitochondrial matrix, where its best-characterized substrates include SOD2 (K68; activating antioxidant defence) and components of the electron transport chain, directly linking NAD⁺ status to mitochondrial redox homeostasis. SIRT6 is a nuclear chromatin-associated sirtuin that removes H3K9ac and H3K56ac marks at sites of DNA damage and telomeres, and promotes genomic stability; overexpression of SIRT6 extends lifespan in male mice, and it was later shown to modulate IGF signalling and inflammation.

Sirtuins are a family of seven NAD+-dependent enzymes (SIRT1–SIRT7) that deacetylate or otherwise modify proteins involved in metabolism, DNA repair, mitochondrial function, and stress response. Their activity depends on cellular NAD+ availability, linking nutrient status to gene regulation. Sirtuins are implicated in caloric restriction's longevity effects, though direct lifespan extension by sirtuin activators in mammals remains debated. SIRT1, SIRT3, and SIRT6 receive the most aging-related research attention.

The sit-rise test measures the ability to lower oneself to the floor and stand back up using as little support as possible, scored from zero to ten with points deducted for hand, knee, or balance assistance. It captures lower-body strength, flexibility, balance, and body composition in a single movement. In Brito and Araújo's cohort of 2,002 adults aged 51–80 (Eur J Prev Cardiol, 2014), low scores (0–3) carried roughly 5-fold higher all-cause mortality than high scores (8–10) (HR 5.44, 95% CI 3.1–9.5), with each additional point linked to ~21% better survival over a median follow-up of 6.3 years.

Sleep apnea is a disorder of repeated breathing pauses or shallow breathing events (apneas and hypopneas) during sleep, most commonly obstructive sleep apnea from upper-airway collapse, less often central sleep apnea from disrupted respiratory drive. The AASM diagnoses it at an apnea-hypopnea index of at least 5 per hour with symptoms, or at least 15 without. Untreated, it raises the risk of hypertension, atrial fibrillation, stroke, type 2 diabetes, cognitive decline, and all-cause mortality.

Sleep architecture refers to the cyclical organisation of sleep stages across the night, typically comprising four to six 90-minute ultradian cycles each progressing through N1, N2, N3 (slow-wave sleep), and REM, with N3 dominating early cycles and REM expanding in later ones. Healthy young- to middle-aged adult sleep contains roughly 13–23% N3 and 20–25% REM (with N3 declining to <10% by age 70), though normative ranges vary with age, sex, and assessment method. Disruptions to architecture—including suppression of N3 by alcohol, fragmentation of REM by sleep apnea, or the age-related decline of slow-wave sleep—have functional consequences for memory consolidation, hormonal secretion, immune regulation, and cardiovascular recovery, making architectural metrics a key target in longevity-oriented sleep assessment.

Sleep efficiency is the percentage of time spent asleep relative to the total time in bed, calculated as total sleep time divided by time in bed. Values of 85 percent or higher are generally regarded as healthy in adults. Low sleep efficiency reflects fragmented or inefficient sleep and is associated with daytime fatigue, impaired glucose metabolism, elevated cardiovascular risk, and poorer subjective quality of life.

Sleep latency is the time from lights-out to the first epoch of sleep, typically measured in minutes during polysomnography. A latency of about 10 to 20 minutes is considered healthy; very short latencies (under roughly 5 to 8 minutes) can indicate sleep deprivation or excessive daytime sleepiness, while persistently longer values suggest insomnia or circadian misalignment. It is a core metric in polysomnography and consumer sleep trackers used in longevity contexts.

The two-process model, proposed by Alexander Borbély in 1982, describes sleep-wake regulation as the interaction of two independent processes: Process S (homeostatic sleep pressure), which accumulates as adenosine and other somnogens build up during waking and dissipates during sleep, and Process C (the circadian signal), generated by the suprachiasmatic nucleus and imposing a roughly 24-hour oscillation in alerting drive that opposes increasing sleep pressure toward evening to maintain sustained wakefulness. Sleep occurs when Process S exceeds the circadian alerting threshold. The model successfully explains phenomena such as the post-lunch dip, rebound deep sleep after sleep deprivation, and the sharp morning wake boundary, and remains the dominant framework for circadian and sleep medicine research.

Small dense LDL (sdLDL) is a subfraction of LDL particles characterised by reduced diameter (less than approximately 25.5 nm) and higher density compared with large buoyant LDL, arising primarily in states of hypertriglyceridaemia and insulin resistance through CETP-mediated triglyceride-for-cholesterol exchange. sdLDL particles are more atherogenic than large buoyant LDL for several reasons: they have lower affinity for the LDL receptor and therefore a longer plasma half-life, they penetrate the arterial intima more readily, they are more susceptible to oxidative modification, and they bind more avidly to proteoglycans in the subendothelial matrix. Elevated sdLDL concentration is independently associated with coronary artery disease and is a component of atherogenic dyslipidaemia — the lipid triad of elevated triglycerides, low HDL-C, and a predominance of sdLDL.

Spermidine is a naturally occurring polyamine found in wheat germ, aged cheese, soy, and mushrooms, though content varies widely by source and processing. It induces autophagy, the cellular recycling process implicated in aging, and extends lifespan in yeast, worms, flies, and mice. In humans, dietary intake correlates with lower mortality in observational data; limited preliminary trials have explored possible cognitive signals, but results are not definitive. Causal effects on human longevity are not yet established.

Statins (HMG-CoA reductase inhibitors, e.g. atorvastatin, rosuvastatin) lower hepatic cholesterol synthesis and upregulate LDL receptors, reducing circulating LDL cholesterol. They are approved for primary and secondary prevention of atherosclerotic cardiovascular disease, with strong randomized evidence for reduced cardiovascular mortality. Longevity-relevant pleiotropic effects include endothelial improvement, anti-inflammatory action, and possible plaque stabilization. In low-risk individuals, the absolute mortality benefit is small and less certain; benefit is most clearly demonstrated in higher-risk and secondary prevention populations. Off-label use purely for longevity is investigational.

Stem cell exhaustion is the age-related decline in the number, function, and regenerative capacity of tissue-resident stem cells. Drivers include accumulated DNA damage, telomere attrition, epigenetic drift, mitochondrial dysfunction, and a deteriorating niche environment. Consequences include impaired wound healing, anemia, immunosenescence, sarcopenia, and reduced tissue homeostasis. Recognized as a hallmark of aging, it is a key target for regenerative and reprogramming-based interventions.

The stem cell niche is the spatially defined microenvironment — composed of neighbouring stromal cells, vascular elements, extracellular matrix, soluble factors, and biophysical cues such as stiffness and oxygen tension — that locally regulates stem cell quiescence, self-renewal, and differentiation. Landmark niches include the bone marrow endosteal and perivascular niches for haematopoietic stem cells, the intestinal crypt base for Lgr5-positive intestinal stem cells, and the bulge region of hair follicles for epidermal stem cells. With ageing, niche integrity deteriorates through ECM stiffening, loss of supporting stromal cells, inflammatory cytokine accumulation, and SASP from local senescent cells, impairing stem cell function even when the stem cells themselves retain intrinsic self-renewal potential — a distinction with therapeutic implications, since restoring niche signals can partially rejuvenate aged stem cell activity.

Strength training is structured exercise that loads muscles against resistance — free weights, machines, bands, or bodyweight — to drive neural adaptation and muscle protein synthesis. Beyond building muscle and bone, it improves insulin sensitivity, mitochondrial function, and metabolic health. In longevity research, regular resistance training is consistently linked to lower all-cause mortality, preserved independence in later life, and reduced risk of frailty and falls.

Sulforaphane is an isothiocyanate generated when broccoli, broccoli sprouts, and other cruciferous vegetables are chewed or chopped. It activates the Nrf2 pathway, upregulating antioxidant and phase II detoxification enzymes. Human studies report effects on biomarkers of oxidative stress, inflammation, and cardiometabolic risk, with promising but mixed signals in autism and cancer chemoprevention. Long-term clinical outcomes from sulforaphane supplementation are not yet established.

A supercentenarian is a person verified to have reached the age of 110 years or more. The 110+ threshold and term were popularized chiefly by L. Stephen Coles, founder of the Gerontology Research Group, with demographer James Vaupel contributing complementary validation work through MPIDR and the International Database on Longevity. The cohort numbers only a few hundred globally at any time and is studied for genetic resilience, late-life morbidity compression, and as a benchmark against unverified age claims.

Sympathetic dominance describes a chronic shift in autonomic balance toward sustained sympathetic nervous system activation relative to parasympathetic tone, typically reflected in suppressed HRV metrics such as RMSSD and HF power, elevated resting heart rate, and blunted nocturnal vagal withdrawal. Acute sympathetic activation is adaptive, but chronic elevation driven by psychological stress, overtraining, sleep deprivation, or metabolic dysfunction is associated with hypertension, dysregulation of the HPA axis, and accelerated cardiovascular aging. It is not a clinical diagnosis but an operational concept used in longevity and sports science to flag persistently impaired autonomic recovery; interpretation requires ruling out confounders such as dehydration, illness, and measurement artefacts.

SystemsAge is a multi-organ biological-age framework introduced by Tian and colleagues (2023, Nature Medicine) that uses routine clinical laboratory data to generate organ-specific age estimates across 3 brain systems (cerebral cortex, thalamus, cerebellum) and 7 body systems (cardiovascular, respiratory, renal, gastrointestinal, liver, musculoskeletal, immune) — 10 systems total — from blood-based biomarker panels. Rather than a single composite score, it produces a profile of organ biological ages, allowing detection of discordant ageing across systems. In the UK Biobank, organ age gaps predicted organ-specific disease and all-cause mortality; individuals whose organ ages were globally younger than their chronological age showed lower mortality risk. The approach is attractive for scalable population studies because it relies on standard blood tests rather than DNA methylation arrays or imaging. A separate methylation-based 'SystemsAge' clock by Sehgal et al. 2025 Nature Aging (Levine lab) covers 11 physiological systems via a single blood-based assay; the two clocks share a name but use different inputs.

Tau is a microtubule-associated protein that under normal conditions stabilises the axonal cytoskeleton by binding to tubulin; in Alzheimer's disease and other tauopathies it becomes hyperphosphorylated, detaches from microtubules, and aggregates into paired helical filaments that form insoluble neurofibrillary tangles (NFTs) inside neurons. The Braak staging system (stages I–VI) tracks the hierarchical spread of NFTs from the entorhinal cortex through the hippocampus to association neocortex, and this progression correlates more tightly with cognitive severity than amyloid plaque burden does. Tau accumulation is thought to disrupt axonal transport, impair synaptic function, and ultimately trigger neurodegeneration, making tau the primary candidate for the neurotoxic effector of Alzheimer's pathology in current models that position amyloid upstream and tau downstream. Tau biomarkers — particularly phospho-tau 181 and 217 in CSF and plasma — have become key diagnostic targets in the AT(N) biomarker framework.

Taurine is a sulfur-containing non-proteinogenic amino acid synthesized in humans from cysteine via the cysteine sulfinic acid pathway, with dietary intake from animal foods — particularly shellfish, dark poultry meat, and fish — contributing substantially to circulating levels. It is highly concentrated in heart, skeletal muscle, retina, and neurons, where it acts as an osmolyte, modulates intracellular calcium handling, stabilizes mitochondrial membrane potential, and attenuates oxidative and endoplasmic-reticulum stress. A landmark 2023 paper by Singh et al. in Science reported that taurine levels in blood decline markedly with age in mice, monkeys, and humans, and that supplementing physiological amounts of taurine extended median lifespan in both male and female C57BL/6J mice (by approximately 10–12%) and improved several health metrics in middle-aged monkeys; mechanistic studies implicated suppression of cellular senescence, inflammation, DNA damage, and mitochondrial dysfunction. In humans, taurine association with longevity is observational only, and no interventional evidence for lifespan extension exists. A 2025 NIH-led re-analysis (Marcangeli et al., Aging Cell 2025; companion work by Fang et al., Science 2025) found that circulating taurine often increases or remains stable with age in humans, monkeys, and mice, directly challenging the central age-related decline narrative of Singh 2023. Taurine is present in energy drinks and is sold as a supplement; at common doses it appears safe in adults, but long-term high-dose data in humans are limited.

Telomerase is a ribonucleoprotein reverse transcriptase (TERT plus the TERC RNA template) that adds TTAGGG repeats to chromosome ends, counteracting replicative shortening. It is highly active in germline, stem, and most cancer cells but largely silenced in adult somatic tissues. In longevity research, telomerase reactivation has extended healthspan in mice, but it carries oncogenic risk because most human tumors depend on telomerase for unlimited proliferation.

Telomeres are repetitive TTAGGG DNA sequences capping the ends of linear chromosomes, protecting them from degradation, fusion, and erroneous repair. Each somatic cell division shortens telomeres because DNA polymerase cannot fully replicate chromosome ends. Critically short telomeres trigger senescence or apoptosis. Telomere attrition is one of the twelve hallmarks of aging and is associated with cardiovascular disease, immune decline, and reduced regenerative capacity.

Telomere attrition is the progressive shortening of the protective TTAGGG repeat sequences at chromosome ends with each cell division, due to the end-replication problem and oxidative damage. Once telomeres reach a critical length, cells enter replicative senescence or apoptosis via a DNA-damage response. Telomerase, which can extend telomeres, is largely silenced in adult somatic cells. Accelerated attrition is associated with premature ageing syndromes, cardiovascular disease and reduced healthspan.

TERT (telomerase reverse transcriptase) and TERC (telomerase RNA component) together constitute the catalytic core of telomerase; TERT provides reverse-transcriptase activity while TERC is the RNA template used to extend telomeric TTAGGG repeats. Common single-nucleotide variants in both loci are among the strongest GWAS hits for leukocyte telomere length and modestly influence disease risk for cancer, cardiovascular disease, and pulmonary fibrosis in proportion to their effect on telomere length. Rare heterozygous loss-of-function mutations in TERT or TERC cause autosomal dominant telomere biology disorders (TBDs) — a spectrum including dyskeratosis congenita, familial idiopathic pulmonary fibrosis, aplastic anemia, and hepatic cirrhosis — via telomere-mediated replicative failure in high-turnover tissues and anticipation across generations. The contrast between the modest effects of common variants and the severe phenotypes of rare pathogenic mutations illustrates the quantitative sensitivity of telomere homeostasis.

Telomerase reverse transcriptase (TERT) is the catalytic subunit of telomerase; its somatic expression is repressed in most adult human tissues, leading to progressive telomere shortening with each cell division. AAV-delivered TERT transgenes have extended median lifespan, delayed frailty, and improved metabolic and neuromuscular phenotypes in middle-aged and old mice in work from the Blasco laboratory, with a single administration showing lasting effects without elevated cancer incidence in the mouse models studied. Human longevity application remains preclinical; the concern that telomerase activation could promote tumour growth by enabling unlimited replicative capacity in cells harbouring oncogenic mutations is a central safety caveat that has not been resolved in human data. Self-administered TERT gene therapy by individuals outside regulated trials (reported in the context of BioViva/Andrews) lacks peer-reviewed safety or efficacy evaluation and represents an extreme scientific and safety risk.

Testosterone is the principal androgen, produced mainly by Leydig cells in the testes in men and in smaller amounts by the ovaries and adrenals in women. It supports muscle mass, bone density, libido, mood, and erythropoiesis. Laboratories report total testosterone alongside free or bioavailable testosterone, since roughly 98% circulates bound to SHBG and albumin. Levels typically decline with age in men; lower values are observationally associated with sarcopenia, frailty, metabolic syndrome, and higher all-cause mortality and adverse cardiometabolic outcomes, with confounding by obesity, inflammation, and SHBG changes. The TRAVERSE trial (Lincoff et al. 2023 NEJM) found cardiovascular non-inferiority for testosterone therapy in hypogonadal men, with elevated atrial-fibrillation and pulmonary-embolism signals, informing the FDA's 2025 label update that removed the boxed cardiovascular warning while retaining cautions on atrial fibrillation, pulmonary embolism, and blood-pressure elevation.

TRT restores testosterone in men with documented hypogonadism (low serum testosterone plus symptoms), via gels, injections, or pellets. Benefits include improved libido, mood, lean mass, and bone density. Risks include erythrocytosis, fertility suppression, and cardiovascular effects; the recent TRAVERSE trial suggested cardiovascular non-inferiority but not benefit, though TRAVERSE also found increased rates of atrial fibrillation and venous thromboembolism in the testosterone arm. TRT is not validated as a longevity therapy in eugonadal men and remains controversial outside clinical hypogonadism.

Transforming growth factor β (TGF-β) signaling is initiated when TGF-β ligands — including TGF-β1, TGF-β2, and TGF-β3 — bind to heteromeric serine/threonine kinase receptor complexes (TβRII/TβRI) that phosphorylate receptor-regulated SMADs (R-SMADs 2 and 3), which then partner with SMAD4 and translocate to the nucleus to modulate target gene expression. Beyond this canonical SMAD pathway, non-canonical branches engage MAPK, Rho-GTPase, and PI3K effectors. TGF-β is a contextually pleiotropic cytokine with anti-proliferative, immunomodulatory, pro-fibrotic, and pro-apoptotic functions; in the ageing context, elevated TGF-β1 is a component of the aged systemic milieu and has been implicated in suppressing neural progenitor activity and muscle stem cell function, as well as in driving fibrosis across multiple organs, making pathway antagonism an area of active therapeutic exploration.

TPE is a specific form of plasmapheresis in which approximately one to one-and-a-half plasma volumes are removed and replaced per session with albumin, saline, or donor plasma, rather than re-infused. It is standard of care for several neurologic and hematologic diseases. Longevity interest stems from rodent dilution studies suggesting rejuvenation; small human trials (e.g., in Alzheimer's) are early and ongoing, with no proven anti-aging benefit.

Thymic involution is the progressive replacement of thymic epithelial space by adipose tissue that begins in early childhood and accelerates at puberty, reducing the organ's capacity to generate naive T cells from bone-marrow-derived precursors. By the sixth decade, thymic output of T-cell receptor-diverse naive T cells is diminished to a small fraction of peak adolescent output, constraining the repertoire available to respond to new antigens. Several thymic regeneration strategies have been investigated, including the TRIIM trial by Fahy and colleagues in which a growth hormone/DHEA/metformin combination was associated with partial epigenetic age reversal, and interleukin-7 administration to support peripheral naive T-cell homeostasis and survival; both approaches remain early-stage and require replication in larger trials before clinical conclusions can be drawn. Improving thymic function is considered a plausible route to partially reversing age-related immune decline.

Thymosin α-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin α, naturally produced by thymic epithelial cells, that modulates innate and adaptive immunity by activating TLR signalling in dendritic cells and monocytes and promoting Th1-type T-cell responses. The thymus undergoes substantial involution from early adulthood, and declining thymic output with age contributes to T-cell senescence and immune ageing; Tα1 supplementation is proposed to partially compensate for this deficit. Thymalfasin (Zadaxin, SciClone Pharmaceuticals) is approved in over 35 countries — but not the United States — as an adjunct therapy for chronic hepatitis B and C and as an immunostimulant in patients with impaired immunity; it has been used off-label during COVID-19 outbreaks in several countries. Human evidence for anti-aging or longevity benefit is absent; trials in cancer and infection support immunomodulatory activity, but effect sizes and consistency vary. Tα1 is widely marketed by anti-aging clinics; its regulatory classification ranges from approved drug to unregulated peptide depending on jurisdiction. FDA added thymosin α-1 to Category 2 of the interim 503A bulks list on 29 September 2023; the substance was removed from Category 2 effective 27 September 2024 after the nominator withdrew its nomination, and on 4 December 2024 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted against its inclusion on the 503A allowed bulks list, leaving it not eligible for use in 503A compounding in the US.

Time-restricted eating (TRE) confines daily food intake to a consistent window of typically 6–10 hours, leaving 14–18 hours of fasting. The concept emerged from Satchin Panda's circadian biology lab at the Salk Institute. Some trials report improved insulin sensitivity, lipids, and blood pressure independent of calorie reduction; others, including Liu et al. (NEJM 2022), found that time-restricted eating combined with caloric restriction was not superior to caloric restriction alone for weight or metabolic outcomes. Early-window TRE may be preferable, but the evidence remains preliminary.

Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The dual incretin action produces greater weight loss and HbA1c reduction than selective GLP-1 agonists in head-to-head trials; the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, while cardiovascular outcome benefits remain under investigation. Longevity-relevant effects parallel GLP-1 agonists: improved metabolism, weight reduction, and reduced cardiometabolic risk. Off-label use in metabolically healthy adults for lifespan extension remains investigational.

Trimethylamine-N-oxide (TMAO) is a small organic compound produced when gut bacteria convert dietary choline, phosphatidylcholine and L-carnitine — abundant in red meat, eggs and fish — into trimethylamine (TMA), which is then oxidised to TMAO in the liver by flavin-containing monooxygenases (mainly FMO3). Elevated circulating TMAO has been associated with increased risk of major adverse cardiovascular events, atrial fibrillation and all-cause mortality in multiple large prospective studies, and mechanistic work in mice points to inhibition of reverse cholesterol transport and promotion of foam-cell formation. However, the relationship is complicated by the fact that fish consumption, which is generally cardioprotective, also raises TMAO, and that TMAO levels vary markedly with gut microbiota composition, genetics (FMO3 polymorphisms) and renal clearance — making TMAO a biomarker of exposure and microbial metabolism rather than a straightforward causal risk factor.

Tumour Necrosis Factor alpha is a pleiotropic pro-inflammatory cytokine produced predominantly by macrophages and monocytes in response to infection or tissue damage, signalling through two receptors — TNFR1 (widely expressed, mediates inflammation and apoptosis) and TNFR2 (expressed mainly on immune and endothelial cells, implicated in cell survival and immunoregulation). At the cellular level, TNF-α activates NF-κB and MAPK pathways, driving expression of adhesion molecules, other cytokines, and acute-phase proteins. Chronically elevated TNF-α is a recognised component of inflammaging, contributing to insulin resistance, muscle wasting (cachexia/sarcopenia), and neuroinflammation. Anti-TNF biologics such as etanercept, infliximab, and adalimumab are established treatments for rheumatoid arthritis and inflammatory bowel disease, and their potential relevance to age-related inflammatory conditions is an active area of translational interest.

Trained immunity, a concept developed primarily by Mihai Netea and colleagues, refers to the capacity of innate immune cells — principally monocytes, macrophages, and NK cells — to mount enhanced, non-specific responses to secondary stimuli following an initial training event, without invoking classical adaptive immunological memory. The mechanism involves epigenetic reprogramming (histone acetylation and methylation at promoters of inflammatory genes) and metabolic rewiring toward aerobic glycolysis, which together lower the activation threshold of the cell for weeks to months. Well-characterised inducers include β-glucan (a fungal cell-wall component) and the BCG tuberculosis vaccine, which have been shown to reduce heterologous infections and all-cause mortality in some controlled trials. Trained immunity is distinct from the somatic hypermutation and clonal selection that define B- and T-cell memory, and it represents an epigenetic memory in the innate arm of immunity.

T regulatory cells are a specialised CD4+ T-cell subset defined by expression of the transcription factor FOXP3 that suppresses excessive immune responses and maintains self-tolerance. They act through multiple mechanisms including secretion of the anti-inflammatory cytokines IL-10 and TGF-β, competitive consumption of IL-2 via high-affinity CD25 expression, expression of inhibitory co-receptors such as CTLA-4, and direct cytotoxicity toward activated effector cells. In the context of aging, Treg numbers in peripheral blood generally increase or are maintained, but their suppressive function may be impaired; paradoxically, elevated Treg activity has been proposed both to contribute to immunodeficiency by dampening anti-tumour immunity and, in some tissues, to limit chronic inflammation. In the tumour microenvironment, high Treg infiltration is associated with immune evasion and worse prognosis.

Triglycerides are the main storage form of dietary and endogenous fat, transported in the blood by triglyceride-rich lipoproteins, mainly VLDL, chylomicrons, IDL, and their remnants. Fasting triglyceride levels rise with insulin resistance, excess refined carbohydrates, alcohol intake, and metabolic syndrome. Elevated values reflect higher concentrations of triglyceride-rich remnant lipoproteins, and remnant cholesterol carried by these particles is causally linked to atherosclerotic cardiovascular disease (Mendelian randomization). Lower fasting triglycerides are associated with better insulin sensitivity and reduced cardiovascular risk.

Thyroid-stimulating hormone (TSH) is released by anterior pituitary thyrotrophs and regulates thyroid hormone production via negative feedback from circulating T3 and T4. In primary thyroid disease it is the most sensitive single marker of thyroid status: higher values typically indicate hypothyroidism, while suppressed values suggest hyperthyroidism or exogenous hormone excess. In central (pituitary or hypothalamic) hypothyroidism, TSH may be inappropriately normal or low alongside low fT4, so combined interpretation with free T4 is required. Reference ranges shift slightly upward with age, and subclinical dysfunction is common in older adults.

Type I interferons — primarily IFN-α (multiple subtypes) and IFN-β — are cytokines secreted by virtually all nucleated cells in response to viral nucleic acids detected by innate pattern recognition receptors, most prominently the cGAS-STING pathway for cytosolic DNA, and TLR7/TLR9 for endosomal RNA/DNA. They signal through the IFNAR1/IFNAR2 receptor complex to induce hundreds of interferon-stimulated genes that establish an antiviral cellular state, activate NK cells, and bridge innate to adaptive immunity. Chronic, low-level type I IFN signalling — driven in aging by accumulated cytosolic DNA fragments, mitochondrial DNA leakage, and retrotransposon activity that activates cGAS-STING — is an important contributor to inflammaging. Pathological extremes of constitutive type I IFN activation are exemplified by SAVI (STING-associated vasculopathy with onset in infancy) and Singleton-Merten syndrome, monogenic interferonopathies that illustrate the tissue-damaging potential of uncontrolled type I IFN signalling.

Skeletal muscle fibers are broadly classified into Type I (slow-oxidative) and Type II (fast-glycolytic and fast-oxidative-glycolytic) on the basis of myosin heavy chain isoform expression, metabolic profile, and contractile speed. Type I fibers are fatigue-resistant, mitochondria-dense, and reliant on oxidative metabolism; they dominate endurance activity and Zone 2 training stimulus. Type II fibers — subdivided into IIa (intermediate) and IIx (fast-glycolytic; humans lack the rodent IIb fiber type) — generate higher force and power but fatigue more rapidly and are preferentially recruited during heavy resistance exercise and sprinting. With aging, Type II fibers show selective atrophy and denervation before Type I, contributing to dynapenia and fall risk; resistance and power training selectively preserve and hypertrophy these fast fibers.

The ubiquitin-proteasome system (UPS) is a major route for selective degradation of short-lived, misfolded, or regulatory proteins, complementary to autophagy-lysosomal degradation. Target proteins are tagged with ubiquitin chains via E1 activating, E2 conjugating, and E3 ligase enzymes, with the E3 ligase providing substrate specificity; K48-linked polyubiquitin chains are the canonical proteasome-targeting signal, while other linkages have non-degradative roles. Tagged proteins are then unfolded and degraded into short peptides inside the 26S proteasome. UPS activity declines with age, contributing to loss of proteostasis and neurodegeneration.

The unfolded protein response (UPR) is an adaptive signalling programme activated when misfolded or unfolded proteins accumulate in the endoplasmic reticulum (ER), engaging three parallel branches initiated by the sensors IRE1alpha, PERK, and ATF6. Collectively, these branches attenuate global cap-dependent translation via eIF2alpha phosphorylation, transcriptionally upregulate ER-resident chaperones and folding enzymes, and expand ER-associated protein degradation (ERAD) to clear aberrant proteins. When ER stress is resolved, the UPR is switched off and homeostasis is restored; when stress is chronic and irresolvable — a condition increasingly common with ageing — the UPR shifts its output to activate NF-kB-driven inflammation and CHOP-dependent apoptosis, coupling proteostatic failure to tissue degeneration.

Uric acid is the final catabolic product of purine metabolism in humans, produced mainly in the liver by xanthine oxidase and excreted predominantly by the kidney (~70%) with the remainder through the gut. Hyperuricemia (typically defined as serum uric acid >6.8 mg/dL or >404 µmol/L — the saturation threshold above which monosodium urate crystals can form; some guidelines use sex-specific cut-offs of >6 mg/dL in women and >7 mg/dL in men, while <6 mg/dL / <360 µmol/L is the urate-lowering treat-to-target ceiling for established gout per ACR 2020 / EULAR 2016) is the prerequisite for monosodium urate crystal deposition, which causes gout arthritis and urate nephropathy. Beyond gout, persistently elevated uric acid is epidemiologically associated with hypertension, insulin resistance, metabolic syndrome, chronic kidney disease, and cardiovascular events; whether these associations are causal or confounded is debated, as Mendelian randomization results have been inconsistent. Uricosuria and renal tubular handling are strongly influenced by dietary purines (red meat, organ meat, beer, fructose) and medications (thiazides, low-dose aspirin, cyclosporine), and lower serum levels are associated with better metabolic health in most population studies.

Urolithin A is a gut-derived metabolite produced when colonic bacteria transform ellagitannins and ellagic acid — polyphenols found in pomegranates, walnuts, and berries — via species such as Gordonibacter urolithinfaciens; because the requisite microbiome varies between individuals, dietary ellagitannin intake does not reliably raise urolithin A levels in all people. The compound activates mitophagy through mechanisms including inhibition of prohibitin-2 and indirect PINK1/Parkin pathway engagement, and improves mitochondrial respiration in preclinical models. In human randomized trials, a phase I safety and biomarker study (Andreux et al., 2019) established tolerability in older adults, while the ATLAS trial (Singh et al., 2022) in overweight middle-aged adults showed improvements in skeletal muscle mitophagy markers, aerobic endurance, and muscle strength as secondary endpoints; the primary endpoint (peak power output) was not met, and both trials were conducted by Amazentis, the commercial developer. Regulatory status: sold as a dietary supplement in many countries; not approved as a drug; longer-term safety and efficacy trials are ongoing.

The vaccine response deteriorates with aging due to multiple converging immunological deficits: reduced naive T- and B-cell diversity, impaired germinal centre reactions, diminished plasma cell longevity, and dysregulated innate sensing all lower the magnitude, affinity, and durability of vaccine-induced immunity. These deficits necessitate formulation adaptations in vaccines targeted at older adults — high-dose or adjuvanted influenza vaccines (e.g., Fluzone High-Dose, Fluad with MF59 adjuvant) elicit substantially stronger seroprotection rates than standard formulations in persons over 65. The recombinant subunit zoster vaccine Shingrix, which uses the AS01B adjuvant system to drive a strong CD4+ T-cell and antibody response, demonstrates approximately 90–97% efficacy against herpes zoster depending on age group (approximately 90% in adults aged 70+) compared with roughly 50% for the earlier live-attenuated Zostavax, which was discontinued in the US in 2020, illustrating how adjuvant engineering can partly compensate for age-related immunosenescence.

Vagal tone describes the baseline activity of the vagus nerve, the primary parasympathetic pathway connecting the brainstem to organs including the heart, lungs, and gut. Higher vagal tone is associated with efficient heart-rate slowing during exhalation, faster post-stress recovery, and lower systemic inflammation. It is commonly estimated from RMSSD or high-frequency HRV. In longevity contexts, strengthening vagal tone through breathwork, exercise, and sleep is considered a modifiable resilience factor.

Visceral adipose tissue (VAT) is the metabolically active fat depot surrounding the intra-abdominal organs, distinct from subcutaneous adipose tissue. VAT adipocytes drain into the portal circulation and secrete pro-inflammatory adipokines including TNF-α, IL-6, and resistin while producing less adiponectin than subcutaneous fat, creating a systemic inflammatory and insulin-resistant milieu. High VAT is associated with increased risk of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and all-cause mortality independently of total body fat or BMI. Gold-standard quantification uses abdominal CT or MRI; DEXA and waist circumference are practical surrogates. Aerobic exercise and weight loss preferentially reduce VAT relative to subcutaneous depots.

Vitamin B12 (cobalamin) and folate (vitamin B9) are essential coenzymes in one-carbon metabolism: B12 is required for methionine synthase (which regenerates methionine from homocysteine) and methylmalonyl-CoA mutase, while folate supplies methyl groups via the folate cycle. Deficiency of either causes megaloblastic anemia by impairing DNA synthesis; B12 deficiency additionally produces neurological damage — including subacute combined degeneration of the spinal cord — through mechanisms not fully replicated by folate. Low B12 is prevalent in older adults, strict vegans, and those taking metformin or proton pump inhibitors. Functional B12 status is more accurately reflected by elevated methylmalonic acid and holotranscobalamin (active-B12) than by total serum B12 alone, which can be misleadingly normal. Both markers are clinically used to investigate elevated homocysteine and associated cardiovascular and cognitive risk.

25-hydroxyvitamin D (25-OH-D, calcidiol) is the major circulating form of vitamin D and the standard clinical biomarker for assessing vitamin D status, produced in the liver by hydroxylation of cholecalciferol (D3) or ergocalciferol (D2). It reflects both dietary intake and skin synthesis from UVB exposure; its half-life of roughly 2–3 weeks makes it a reliable index of longer-term status compared with the active hormonal form 1,25-(OH)₂D. Deficiency (commonly defined as <50 nmol/L or <20 ng/mL) is associated with impaired bone mineralization, falls, increased susceptibility to respiratory infection, and observationally with higher all-cause and cardiovascular mortality, although randomized trials have shown mixed results for supplementation on hard outcomes. Sufficiency thresholds remain debated, but most guidelines recommend >50 nmol/L and many longevity-oriented practitioners target 75–100 nmol/L.

VO2max is the maximum rate of oxygen consumption during intense exercise, typically expressed in mL/kg/min. Per the Fick principle, it reflects oxygen delivery (cardiac output, hemoglobin) multiplied by muscle extraction at the mitochondria. VO2max is among the strongest predictors of all-cause mortality: higher VO2max is robustly associated with lower long-term risk across cohort studies (e.g., Mandsager 2018), making it a central marker of cardiorespiratory fitness in longevity research.

White matter hyperintensities (WMH) are regions of abnormally high signal intensity on T2-weighted and FLAIR MRI sequences within the cerebral white matter, reflecting focal demyelination, axonal loss, gliosis and small-vessel ischaemia rather than a single pathological entity. Their prevalence rises steeply with age — present in roughly 10–20% of individuals in their 60s and in the majority of those over 80 — and their volume is strongly associated with hypertension, diabetes, and smoking as modifiable risk drivers. WMH predict cognitive decline (particularly processing speed and executive function), incident dementia, stroke and mortality; large or rapidly progressing confluent WMH carry greater clinical weight than small punctate lesions. They are a key imaging marker in the diagnosis of cerebral small vessel disease and in vascular contributions to cognitive impairment and dementia (VCID).

Whole-body cryotherapy (WBC) exposes the body to extreme cold air, typically −100 to −140°C, for 2–4 minutes inside a nitrogen-vapour or electric cryo-chamber, in contrast to cold-water immersion (CWI) at approximately 10–15°C for 10–15 minutes; the two modalities differ substantially in cooling rate, depth of tissue cooling, and physiological response. Proposed mechanisms include acute noradrenaline and endorphin release, transient anti-inflammatory cytokine shifts, and sympathoadrenal activation followed by a parasympathetic rebound. A 2015 Cochrane review (Costello et al., CD010789) found insufficient evidence to determine whether WBC reduces muscle soreness or improves recovery compared with passive rest, rating evidence quality as low to very low; evidence for immune, metabolic, or longevity-specific effects in healthy adults is preliminary. WBC carries risks of frostbite, hypoxia from nitrogen vapour, and cardiovascular stress, and is contraindicated in cold urticaria, Raynaud's phenomenon, and severe cardiovascular disease.

Whole-body MRI (WB-MRI) acquires multi-station images covering the brain, neck, thorax, abdomen and pelvis without ionising radiation, enabling simultaneous assessment of soft tissue, organs and bone marrow in a single session lasting approximately 45–90 minutes. Its clinical utility is established in specific contexts — surveillance of hereditary cancer syndromes (Li-Fraumeni, BRCA2) and staging of multiple myeloma — but evidence for benefit in asymptomatic general-population screening is lacking; randomised trial data demonstrating reduced morbidity or mortality from commercial longevity-screening offerings are not available. Incidentaloma rates are high, with studies reporting clinically significant and minor incidental findings in 30–50% of asymptomatic subjects, creating a risk of diagnostic cascades involving further imaging, biopsy and unnecessary intervention. Major radiology and oncology societies have not endorsed WB-MRI for routine preventive screening outside of defined high-risk genetic populations.

Whole-genome sequencing (WGS) generates complete base-pair-resolution data across nuclear and mitochondrial DNA, enabling discovery of rare coding and non-coding variants, structural variants, and copy-number changes that are invisible to SNP arrays. In aging research, WGS has several distinct applications: it identifies rare longevity-associated variants in centenarian families and cohorts (e.g., protective mutations in PCSK9, APOC3, or DNA repair genes) that require deep sequencing to detect; it quantifies somatic mutation burden and clonal hematopoiesis of indeterminate potential (CHIP) in aging tissues, linking somatic evolution to cardiovascular and cancer risk; and it maps mitochondrial heteroplasmy dynamics that accumulate with age. Sequencing costs have fallen from ~$3,000/Gb in 2008 toward approximately $1–5/Gb by the mid-2020s depending on platform and throughput, making population-scale WGS studies feasible; however, interpreting variants of uncertain significance (VUS) and managing incidental findings remain major clinical and ethical challenges, especially as WGS enters preventive medicine for healthy aging populations.

The Wim Hof method combines cyclic hyperventilation-style breathing, breath holds, and gradual cold exposure, popularised by Dutch athlete Wim Hof. Small studies report transient effects on sympathetic activation, catecholamine release, and short-term immune markers after lipopolysaccharide challenge. Long-term and clinical benefits, including for chronic disease or longevity, remain unproven, and the breath-hold component carries risks of fainting, especially in or near water.

Wnt signaling is a family of evolutionarily conserved intercellular communication pathways initiated by secreted Wnt glycolipoproteins binding to Frizzled receptors, with the canonical (β-catenin-dependent) branch being the most studied. In the absence of Wnt ligands, a destruction complex containing APC, Axin, GSK-3β and CK1 phosphorylates β-catenin, targeting it for proteasomal degradation; Wnt binding stabilises β-catenin, which then translocates to the nucleus to drive TCF/LEF target gene transcription. Wnt signaling is essential for stem cell self-renewal, tissue regeneration, and bone homeostasis, but its activity declines in aged tissues such as skeletal muscle, intestinal crypts, and the bone marrow niche, contributing to stem cell exhaustion; conversely, dysregulated Wnt activity is a driver of cancer and tissue fibrosis in other contexts.

WRN encodes a member of the RecQ DNA helicase family with both helicase and exonuclease activities, involved in multiple DNA repair pathways including base excision repair, non-homologous end joining, and replication fork restart at sites of stalled polymerases. Biallelic loss-of-function mutations cause Werner syndrome, a segmental progeroid syndrome in which features of aging — including cataracts, atherosclerosis, type 2 diabetes, osteoporosis, and malignancies — appear in the third and fourth decades; median survival historically was reported as approximately 54 years (Goto and colleagues' Japanese Werner registry analyses around 2000), and a 2022 retrospective study by Oshima and colleagues found mean age at death for patients dying between 2011 and 2020 had risen to approximately 59 years, likely reflecting improved management of malignancy and vascular disease. At the cellular level, WRN-deficient cells accumulate replication stress, telomere dysfunction, and genomic instability disproportionately rapidly. Werner syndrome is extensively studied as a model of accelerated aging, particularly to distinguish aging-driver from aging-bystander mechanisms, though the segmental nature of the phenotype means it does not recapitulate normal aging comprehensively.

Xenohormesis is the hypothesis that animals benefit from stress-response molecules produced by stressed plants and microbes, sensing them as cues of environmental adversity. Polyphenols such as resveratrol, quercetin, and curcumin are typical examples, proposed to activate sirtuins, AMPK, and other stress-defence pathways, although direct sirtuin activation by resveratrol has been disputed, with much of the in-vivo effect now attributed to AMPK and indirect pathways. Direct evidence that dietary xenohormetic compounds extend human healthspan is still limited.

The Yamanaka factors are four transcription factors, OCT4, SOX2, KLF4, and c-MYC (OSKM), identified by Shinya Yamanaka in 2006 as sufficient to reprogram differentiated somatic cells back into a pluripotent embryonic-like state. This work, recognized by the 2012 Nobel Prize in Physiology or Medicine (shared with John B. Gurdon for the discovery that mature cells can be reprogrammed to become pluripotent), demonstrated that cellular identity and aging are reversible. They are now central tools in regenerative medicine, disease modeling, and longevity research focused on epigenetic rejuvenation.

Zone 2 training is sustained aerobic exercise at or just below the first lactate threshold (LT1, ~1.5–2.0 mmol/L), often roughly 60–70% of max heart rate, though the precise percentage varies; lactate testing or the talk-test is more accurate. At this intensity, fat oxidation supplies most energy in slow-twitch fibers, with rising carbohydrate use near the upper end. Regular Zone 2 work increases mitochondrial density, capillarization, and metabolic flexibility.